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ABSTRACT
Defects in articular cartilage exhibit little spontaneous healing response, in part
due to the limited number of chondrocytes available to infiltrate the defect and the
absence of a provisional fibrin scaffold to accommodate cell migration into the lesion.
One variable related to tissue engineering strategies employing cell-seeded scaffolds to
treat such defects is the amount of cartilage formed in the construct prior to implantation.
The objectives of this thesis were to evaluate effects of scaffold cross-link density and
bioreactor culture environment on chondrogenesis in cell-seeded type II collagen
scaffolds in vitro, and to begin to test effects of implant compositional maturity (viz.
glycosaminoglycan, GAG, content) on chondral defect repair.
Scaffold cross-link density, a determinant of cell-mediated scaffold contraction
and degradation, affected chondrogenesis; scaffolds of low cross-link density that
experienced contraction exhibited greater cartilaginous tissue formation compared to
highly cross-linked scaffolds that resisted contraction. In addition to tissue-level effects
on histogenesis, cross-link density was found to direct phenotypic differentiation at the
cellular level. When employing marrow-derived stem cells as an alternative to
chondrocytes, scaffolds with lower cross-link densities (and thus less resistance to
contraction and degradation) favored chondrocytic differentiation. In comparison to
these findings, bioreactor culture of chondrocyte-seeded scaffolds demonstrated little
benefit over static culture with respect to histogenesis within the first 2 weeks of culture.
To begin to investigate effects of implant maturity on in vivo repair outcome,
chondrocyte-seeded type II collagen scaffolds achieving 30% of the GAG content in
native cartilage were implanted in chondral defects in a caprine model. Repair tissue
evaluated at 15 weeks consisted primarily of fibrocartilage and small amounts of hyaline
tissue. Implantation of the construct reduced fibrous tissue formation compared to
controls, but did not significantly affect other outcome variables. Future animal
investigations will evaluate effects of implanting constructs with GAG contents 50% and
75% of that in normal cartilage.
An additional study evaluated a construct comprised of a non-cell-seeded type II
collagen scaffold and a bone graft substitute for treating osteochondral defects in a goat
model. These implants qualitatively improved bone formation, but did not significantly
improve repair of cartilage compared to controls.
Thesis Supervisor: Myron Spector
Title: Professor of Orthopaedic Surgery (Biomaterials), Harvard Medical School
Senior Lecturer, Department of Mechanical Engineering, MIT
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1.1 General introduction
The limited healing potential of articular cartilage remains a difficult orthopedic
problem. Defects in the tissue arising from traumatic injury or chronic disease exhibit
very little spontaneous healing response. Instead, degradative changes in the damaged
tissue often predispose the joint to widespread degeneration, ultimately leading to the
painful and often debilitating condition of osteoarthritis and eventually necessitating total
joint replacement. While a number of clinical approaches to treating defects in the
articular surface have shown promise with respect to promoting synthesis of reparative
tissue, relieving pain, and restoring joint function in the near term, none result in
regeneration of the tissue, and the persistence of the reparative tissue in the load-bearing
environment of the joint over the long term remains uncertain.
Tissue engineering strategies employing cell-seeded scaffolds hold much promise
for improving cartilage repair. One important variable in such approaches is the amount
of cartilage that should be formed within the construct prior to its implantation. It has
been suggested that the limited mechanical properties of constructs at the early stages of
maturation may not be sufficient to withstand the loading environment, while scaffolds
containing more mature cartilaginous tissues may suffer inadequate integration with host
tissue.' In order to begin to identify potential relationships between implant maturation
and repair outcome, methods for fabricating in vitro engineered cartilaginous tissues with
various degrees of compositional maturity must be identified. In light of this, Chapters 2-
4 of this thesis explore the effects of scaffold cross-link density and bioreactor culture
environment on chondrogenesis in cell-seeded type II collagen scaffolds in vitro. In
Chapter 5, the potential benefit of chondrocyte-seeded type II collagen scaffolds with a
GAG content approximately 30% of that in native cartilage is evaluated in a caprine
model. Finally, an additional in vivo study conducted to evaluate the benefits of a
composite construct comprised of a non-cell-seeded type II collagen scaffold and a bone
graft substitute material for treating osteochondral defects in a goat model is reported in
Chapter 6.
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1.2 Articular Cartilage
Articular cartilage is a specialized connective tissue that provides a remarkable
load-bearing surface in synovial joints such as the knee, hip, and elbow. The molecular
composition of the tissue, combined with its particular structural arrangement, gives rise
to the mechanical properties that serve to distribute a wide range of loads across the joint
surfaces. Together with the synovial fluid, articular cartilage enables very low-friction,
wear-resistant motion that functions sufficiently pain-free in most individuals over the
course of their lifetimes.
1.2.1 Anatomy andfunction, mechanical properties
Articular cartilage forms a thin layer of tissue lining the ends of all diarthrodial
joints in the body. Macroscopically, the tissue has a white, glossy appearance, and varies
in thickness depending on location. As a subset of hyaline cartilage, articular cartilage
differs from elastic cartilage and fibrocartilage in composition, structure, and mechanical
properties.
A primary function of articular cartilage relates to its capacity for supporting
mechanical loads. In joints such as the hip and knee, the tissue distributes loads that can
reach stresses of up to 18 MPa, 2 deforming to increase the contact area and thus minimize
the peak stress experienced by the underlying bone. This response to loading is time-
dependent, and the viscoelastic behaviors of the tissue, such as creep and stress-
relaxation, are well documented. 12 Much of this viscoelastic response to loading is
attributed to frictional forces arising from the flow of interstitial fluid within the porous
extracellular matrix (ECM).10 The low hydraulic permeability of the tissue results in
pressurization of the interstitial fluid upon compression such that greater than 95% of the
load is carried by the fluid.' 3" 4 The inherent Young's modulus of the solid matrix
component of articular cartilage, measured in compression at equilibrium after effects of
fluid flow and pressurization have dissipated, ranges from 0.41 to 0.85 MPa, while the
Poisson's ratio ranges from 0.06 to 0.18.14
In addition to supporting loads, another key function of articular cartilage is its
contribution to the lubricating mechanism of synovial joints. With a coefficient of
friction less than 0.01,15 the articular cartilage, in combination with the synovial fluid,
16
allows for extremely low-friction, wear-resistant motion of articulating surfaces within
the joint.
1.2.2 Composition and structure
The mechanical properties that provide the function of articular cartilage are
derived from its complex composition and structure. The tissue is comprised of cells and
water within a framework of collagens (principally type II collagen), proteoglycans, and
non-collagenous proteins. Chondrocytes, the cells responsible for synthesizing and
maintaining cartilage, are the only cell type present in cartilage and are found at a
relatively low cell number density (~10,000 cells/mm 3)16- 18 compared to other tissues,
making up approximately 1% of the total volume of the tissue.' 8 This cellular phenotype
is characterized by a generally spherical morphology and synthesis of type II collagen
and large proteoglycans that form the major components of the cartilage ECM. When
isolated from the tissue and transferred to a two-dimensional in vitro culture
environment, these cells are known to dedifferentiate, synthesizing primarily type I
collagen and small proteoglycans.19-23 The chondrocytic phenotype can be partially
recovered by returning the cells to a three-dimensional environment 4-26 and by
supplementing culture medium with certain growth factors,27-30 though the extent of this
redifferentiation is uncertain.
The network of macromolecules synthesized by the chondrocytes accounts for
20%-40% of the wet weight of the tissue. 3 1 The principle architectural components of
this network are large diameter type II collagen fibrils that provide tensile stiffness and
strength and resistance to shear deformation. Other collagens found in the tissue in
smaller quantities include types VI, IX, and XI; these are thought to play a role in linking
the type II collagen fibrils and in cell attachment.3 '
Large, aggregating proteoglycans and associated water molecules provide the
resistance to compression critical to proper function of load-bearing joints. These
proteoglycans consist of a protein core and negatively charged glycosaminoglycan
(GAG) side chains. The negatively charged GAGs repel each other and attract positively
charged ions in the interstitial fluid, increasing the osmolarity of the tissue and resulting
in an osmotic pressure that is resisted by the collagen network. Most of the large
17
proteoglycans in cartilage are linked to hyaluronan molecules, forming large
proteoglycan aggregates that fill the interfibrillar space.
Articular cartilage possesses a unique structural organization that distinguishes it
from other hyaline cartilages. Four zones have been identified, based on morphological
changes in the cells and matrix with depth from the surface: a superficial zone, an
intermediate zone, a middle zone, and a calcified zone. Cells in the thin superficial
zone at the articular surface appear flattened and elongated parallel to the surface. The
ECM in this zone contains very little proteoglycan, consisting principally of small
collagen fibrils aligned parallel to the surface. Lubricin (also referred to as superficial
zone protein, proteoglycan 4, or PRG4), a glycoprotein synthesized by the chondrocytes
within this layer, is thought to play a role in the lubrication of the joint.35-38 The
intermediate zone contains cells with a more spherical shape, increased proteoglycan
content, and larger diameter collagen fibrils oriented oblique to the surface. Collagen
fibrils in the middle zone are aligned perpendicular to the articular surface. Cells in this
region are found in a similar manner, arranged in a columnar fashion perpendicular to the
surface. A thin transitional region of calcified cartilage separates the middle zone from
the subchondral bone. Collagen fibers that span the calcified cartilage zone firmly anchor
the articular cartilage to the underlying bone.
1.3 Articular Cartilage Defects and Spontaneous Healing Response
Damage to articular cartilage can result from traumatic injury, disease, or chronic
mechanical loading. Defects in the articular surface are often categorized as either
chondral or osteochondral, as the spontaneous healing response of the tissue largely
depends on whether the defect is contained in the cartilage layer or extends into the
subchondral bone. Neither type of defect heals by regeneration (i.e. replacement of the
damaged tissue by tissue that is compositionally, structurally, and functionally identical
to the native tissue), but generally result in progressive degenerative changes throughout
the joint that lead to osteoarthritis, a condition characterized by loss of cartilage, causing
pain, loss of motion, and instability.
18
1.3.1 Chondral defects
Defects in articular cartilage that are confined to the chondral region (viz. not
penetrating the subchondral bone plate) generally exhibit very little, if any, healing
response due to a number of factors. The avascularity of the tissue precludes the
formation of a fibrin clot that could act as a provisional scaffold into which cells can
migrate and begin synthesizing reparative tissue. Additionally, cartilage lacks access to
the endogenous supply of cells and soluble regulators that stimulate the healing response
in vascularized tissues. The relatively low cell number density of cartilage and limited
mitotic activity of the chondrocytes results in few native cells available to contribute to
repair. The cells near the vicinity of a defect are encapsulated within a very dense ECM
which must be degraded prior to their migration to the defect site. Finally, any reparative
tissue that forms may not withstand the high load-bearing environment long enough to
develop into fully matured articular cartilage.
1.3.2 Osteochondral defects
While chondral defects exhibit very little spontaneous repair response, defects
that penetrate the subchondral bone plate gain access to blood, cells, and soluble
regulators from the bone and the marrow space that stimulate formation of a fibrin clot
and subsequent synthesis of reparative tissue. The tissue that forms, however, is primarily
fibrous tissue or fibrocartilage, as opposed to regenerated articular cartilage.39 The extent
to which the formation of such tissue may relieve pain remains uncertain and the
discrepancies in the mechanical properties between this reparative tissue and native
articular cartilage raise the question of its functional capabilities and persistence in the
long term.
1.4 Clinical Treatment Strategies
1.4.1 Lavage and Debridement
Irrigation of the joint during exploratory arthroscopy or using a closed-needle
lavage technique has been reported to relieve pain in patients with early-stage
osteoarthritis, possibly resulting from the removal of loose pieces of cartilage or pain-
signaling molecules from the intra-articular space. 39 These effects are short-lived,
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however, with improvement compared to placebo persisting for only 4 to 24 weeks, and
no demonstrated improvement in joint function.40'4' During arthroscopic examination
and lavage, damaged or diseased chondral tissue is often removed by mechanical
debridement or laser abrasion. Studies conducted in rabbits, however, have indicated that
such surgical removal of tissue results in cell death in tissue bordering the wound edge
and further degeneration of the surrounding cartilage.42
1.4.2 Marrow Stimulation
While chondral defects exhibit very little spontaneous repair response, defects
that penetrate the subchondral bone plate gain access to blood, cells, and soluble
regulators from the bone and the marrow space that stimulate formation of a fibrin clot
and subsequent synthesis of reparative tissue. The microfracture technique attempts to
induce this spontaneous response by extending chondral defects into the sub-chondral
space. In this procedure, degraded cartilage is debrided and an awl is used to make small
perforations, or "microfractures," in the subchondral bone plate, introducing blood and
marrow into the cartilage defect. The holes are placed approximately 3-4 mm apart, with
care taken not to compromise the integrity of the subchondral plate.43
The microfracture procedure has many advantages compared to other cartilage
repair procedures. In most cases it can be performed arthroscopically, involves only a
single operation, does not require costly instrumentation or facilities, and is not
considered technically challenging.
Animal models employed for evaluating microfracture procedures have included
dogs,44 sheep,45 horses, 46 and non-human primates. 4 7 In these studies, microfracture
stimulated greater filling of the defects with reparative tissue compared to untreated
controls. In the sheep, much of this tissue was classified as hyaline or articular
cartilage.48 In contrast, Breinan et al. found microfracture in a canine model resulted in
formation of predominantly fibrocartilage and fibrous tissue, with very little hyaline
cartilage observed. 4 Similarly, Knutsen et al. have reported tissue formed following
microfracture in humans to be primarily fibrocartilaginous.49 While it has been
questioned whether such tissue can withstand the loading environment of the joint over
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the long term, clinical outcomes have been encouraging. Steadman reported improved
function and pain relief in 80% of the patients at an average follow-up of 11 years.50
1.4.3 Tissue Transplantation
An alternative approach to stimulating synthesis of reparative tissue is direct
transplantation of healthy cartilage to the defect site. Due to the difficulty of securing a
purely chondral graft within a cartilage defect, single or multiple cylindrical
osteochondral plugs taken from low weight bearing regions of the joint are transplanted
into holes created at the defect site in a procedure referred to as osteochondral
autografting or mosaicplasty. Clinical and experimental studies of the mosaicplasty
procedure have indicated several inherent difficulties encountered in this approach,
including: donor site morbidity,5 1 chondrocyte death due to the harvest procedure5 2 and
impact loading during placement of the graft,53 mismatch of stiffness between
transplanted and recipient tissues,54 increase in subchondral bone density at the recipient
site,54 and incomplete integration with host cartilage. Reports of clinical outcomes of
have been mixed: good or excellent results have been reported by Scranton (90%),56
Ozturk (85%),57 Szerb (79-94%) 58 and Marcacci (78%)59 at a minimum follow-up of 2
years. Bentley, on the other hand, reported only 34% good or excellent repairs evaluated
arthroscopically at 1 year follow-up. 60
1.4.4 Cell Transplantation
Described by Brittberg et al.,61 the autologous chondrocyte implantation (ACI)
procedure attempts to stimulate healing of cartilage defects by implantation of autologous
articular chondrocytes expanded in number in vitro. Cartilage biopsies from minor load-
bearing regions of the same or other joint are obtained during an initial arthroscopy and
enzymatically digested to isolate the cells. Due to the low cell number density of the
tissue, the chondrocytes are expanded in vitro in order to obtain a sufficient number to
populate the defect space once re-implanted. Following expansion, the cells are injected
into the defect and covered with a periosteal flap that is sutured in place and sealed with
fibrin glue to enhance the retention of the cells in the defect space.
Several animal models have been employed in investigations of ACI, with mixed
results. In one of the first reported studies of ACI, cartilage defects in rabbits treated with
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transplanted chondrocytes exhibited substantial improvement in cartilage formation (82%
of the defect area) compared with untreated controls (18%).62 In a recent investigation of
the repair of defects in the tibiotarsal joints of horses, ACI resulted in greater filling of
the defects with reparative tissue and better histological scores at 1 and 2 years compared
with untreated controls.63 In work by Breinan et al. employing a canine model, however,
no significant differences could be found in the amount of reparative tissue formed, nor
integration of reparative tissue with host tissue, when comparing ACI to implantation of
periosteal flap alone or untreated controls following 12 and 18 months. 64 Similarly,
Russlies et al. found that defects in the femoral condyle or trochlea of sheep treated with
ACI filled primarily with fibrocartilage and showed no histological differences compared
to untreated controls after 1 year. 5
Clinical results of ACI have been somewhat better than findings from animal
studies. Since the first human procedure in 1987, ACI has been conducted in thousands
of patients worldwide, with generally good reported outcomes. In a retrospective study
of 94 patients with 2-9 year follow-up, good or excellent results were reported for 65%-
92% of the cases, depending on the type and location of the cartilage defect. 66
Histological analysis indicated a correlation between formation of hyaline-like reparative
tissue and assessed symptomatic outcome. Similar results have been reported by
others. 49'60'67-70 While these results are promising, indicating relief of pain and improved
function in many cases, histological analyses have indicated that the reparative tissue
formed is primarily composed of fibrocartilage, 69 not regenerated hyaline cartilage.
While this tissue may act as a functional replacement for several years, it is unclear
whether its limited mechanical properties are sufficient to withstand physiological loads
over the long term.
Much progress has been made in developing treatment strategies for damaged
articular cartilage that often provide relief of pain and postpone the need for total joint
replacement, the benefits of which must not be underestimated. However, it remains
clear that no procedure demonstrated to be a consistently reliable and effective treatment
yet exists.
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1.5 Tissue Engineering and Regenerative Medicine
The emerging fields of tissue engineering and regenerative medicine may hold
much promise for cartilage repair. Tissue engineering has been described as "an
interdisciplinary field that applies the principles of engineering and the life sciences
toward the development of biological substitutes that restore, maintain, or improve tissue
function." 7' Three categories of technologies - often referred to as the "pillars" of tissue
engineering - are generally employed, alone or in combination, for the development of
such biological substitutes: cells, biomaterial scaffolds, and environmental regulators.
While the terms have often been used interchangeably, tissue engineering is generally
considered to involve the synthesis of a tissue in vitro for subsequent implantation or ex
vivo use, whereas regenerative medicine involves implantation of cells and scaffolds or
delivery of environmental regulators such that the formation of tissue occurs in vivo, in
situ. The following sections provide a brief description of tissue engineering and
regenerative medicine technologies in the context of cartilage repair, along with rationale
for the selection of cells, scaffolds, and environmental regulators employed in this thesis.
1.5.1 Cells
Numerous tissues have been identified recently as sources of cells that exhibit
chondrogenic potential in vitro, including periosteum,7 2-77 bone marrow,78-83 synovium, 84-
89 and adipose tissue.90 -97 To date, however, only chondrocytes isolated from autologous
cartilage have been employed clinically. The primary advantage of using native
chondrocytes is that the cells already possess the desired differentiated phenotype, though
the cells may undergo some dedifferentiation during in vitro expansion. As such, the
supposition is that these cells are more likely to synthesize a cartilaginous tissue, and may
due so in a shorter time frame, compared to other cell types that must first differentiate to
the chondrocytic phenotype. Based on this rationale, chondrocytes were chosen for use
in the in vitro studies presented in Chapters 2-3 and the in vivo cartilage repair study
presented in Chapter 5 of this thesis.
While the differentiated phenotype of the cells makes native chondrocytes an
appealing option for cartilage repair, several difficulties are encountered with their use.
The low cell number density of the tissue limits the number of chondrocytes that can be
obtained from a small biopsy. Additionally, chondrocytes generally display limited
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mitotic and migratory activity. 66'98 These difficulties can be partially overcome by use of
certain supplements that stimulate proliferation of the cells during expansion (e.g.
fibroblast growth factor 2).28 Possibly the most significant disadvantage to using native
chondrocytes is donor site morbidity. Defects created in the healthy cartilage during the
biopsy are not expected to heal and may further degenerate, compromising the integrity
of the surrounding joint surface. Indeed, animal studies have indicated that the harvest
procedure required to obtain the cells has potentially deleterious effects on certain
properties of surrounding tissue (e.g. up to 3-fold increases in dynamic stiffness and
streaming potential measured 18 weeks after the surgical procedure.)9 9 In light of this,
the potential use of mesenchymal stem cells derived from bone marrow as an alternative
to native chondrocytes is examined in Chapter 4.
As discussed earlier, delivery of cells alone has yet to succeed in producing the
desired regeneration of articular cartilage. Methods employing a combination of cells
and biomaterial scaffolds, however, have induced partial regeneration of other tissues
such as skin and peripheral nerves (see Yannas' 00 for review), and have shown promise
for improving repair of articular cartilage.' 0 1
1.5.2 Scaffolds
Porous biomaterials can provide three-dimensional scaffolding into which cells
can migrate, attach, and begin synthesizing new tissue. When implanted in a cartilage
defect, such scaffolds may serve several functions, such as 1) structurally reinforcing the
defect, 2) preventing ingress of surrounding tissue, and 3) acting as a delivery vehicle for
cells, growth factors, or genes. The chemical, structural, and mechanical properties of
scaffolds can each influence cellular behavior and resulting histogenesis.
A wide variety of materials has been investigated for use in cartilage repair
applications, and can be generally categorized as naturally occurring (e.g. collagen,
gelatin, hyaluronan, fibrin, chitosan, and alginate) or synthetic (e.g. polylactic acid,
polyglycolic acid). Chemical composition of the scaffold can regulate cell attachment,
migration, and biosynthetic activity via integrin-ligand interactions (for naturally
occurring materials), and also determines the degradation mechanism (e.g. hydrolysis or
enzymatic digestion), degradation rate, and degradation products.
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Prior cartilage tissue engineering studies in our laboratory have focused on the use
of collagen-based scaffolds. As the most abundant protein in the human body, collagen
provides a natural adhesion surface for cells, contains biological information that can
direct cellular activity, and has physiologic degradation products, making it an appealing
choice of scaffold material. Type II collagen may be of particular interest as a scaffold
material for cartilage tissue engineering and repair applications, as this collagen type is
specific to cartilaginous tissues. Indeed, several studies have indicated benefits of type II
collagen-based scaffolds compared to type I collagen scaffolds, including higher rates of
proliferation'0 2 and protein and GAG synthesis'0 3 by chondrocytes grown in the scaffolds
in vitro, as well as greater amounts of reparative tissue filling chondral defects treated
with the scaffolds in a canine model, 04 though it should be noted that variation in other
scaffold characteristics (e.g. pore size and porosity) in addition to collagen type may have
contributed to these results. Based on these data, type II collagen was chosen as the
material for fabrication of scaffolds used throughout this thesis. The type II collagen
material used was derived from porcine cartilage, and was kindly provided by Geistlich
Biomaterials (Wolhusen, Switzerland). While the exact composition and processing
protocol of this material are proprietary information and were not revealed to the author,
a prior gel electrophoresis analysis performed by our group confirmed the type II
collagen content of the material. 105
1.5.3 Environmental regulators
The third pillar of tissue engineering is environmental regulators that direct
cellular behavior and histogenesis. Investigations of soluble regulators, such as growth
factors and cytokines, comprise the majority of the work reported in this category, but
other environmental factors such as mechanical loading and mass transport may also be
included.
Due to the limited mitotic and biosynthetic activity of chondrocytes, numerous
growth factors have been investigated for their potential in enhancing proliferation and
promoting maintenance of the chondrocytic phenotype in vitro. Of those reported,
fibroblast growth factor 2 (FGF-2) appears to be the most potent mitogen, 29,106-112 while
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transforming growth factor-P 1 (TGF-@ 1) is the growth factor most frequently employed
for stimulating chondrogenic differentiation and biosynthetic activity. "3-"9 One finding
of interest is that growth factors employed during monolayer expansion of the cells
affects the subsequent behavior of the cells when they are transferred to a 3D
environment. In particular, cells expanded in the presence of FGF-2 demonstrate greater
capacity for chondrogenesis when transferred to micromass or scaffold culture
environments compared to cells grown in the absence of FGF-2.28,29,112 Another finding
of interest is the enhanced redifferentiation of chondrocytes cultured in 3D in defined,
serum-free media compared to serum-supplemented media, suggesting the possibility of
factors present in the serum that inhibit chondrocytic differentiation.28 Based on these
findings and pilot studies performed in our laboratory, the combination of expansion
medium (serum-supplemented medium containing FGF-2, TGF-@ 1, and platelet-derived
growth factor-DO) and 3D differentiation medium (serum-free medium supplemented
with TGF-$ land dexamethasone) reported to result in the greatest amount of
chondrogenesis 2 8,112,1 2 0 was chosen for use in studies involving chondrocytes presented in
Chapters 2, 3, and 5 of this thesis.
In addition to soluble regulators, other environmental factors can regulate
histogenesis in cell-scaffold constructs, such as application of mechanical loading or
convective mass transport. Several bioreactor systems have been developed in which
tissue constructs are cultured under laminar flow conditions that enhance delivery of
nutrients and removal of wastes from the developing tissue, and provide mechanical
stimuli that may promote tissue growth (see Martin'2 1 and Bilodeau12 2 for reviews). The
potential of one such system - a rotating-wall culture vessel - for accelerating
chondrogenesis within chondrocyte-seeded type 1I collagen scaffolds is examined in
Chapter 2 of this thesis.
1.6 Animal models for cartilage repair
Animal models have played a significant role in evaluating the potential of tissue
engineering and regenerative medicine approaches to cartilage repair. While no
experimental animal model exists that is directly applicable to humans, much can be
learned from pre-clinical evaluation of techniques for restoring damaged articular
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surfaces in animals that may inform future clinical practices. Such pre-clinical animal
experiments must be carefully designed in order to maximize the understanding of the
repair strategy being evaluated.
1.6.1 Species and age
Numerous species have been employed in assessing techniques for repairing
articular defects. The majority of cartilage repair studies reported in the literature have
been conducted in rabbits, at least partially influenced by practical advantages of cost and
space requirements. Larger animals, such as pigs, 5"23"24 dogs,44 64 ,10 4 sheep,65"25"26 and
goats' 2 7 -129 are increasingly being employed, as the cartilage in these animals more
closely resembles that found in humans, particularly with respect to tissue thickness. As
there tends to be a decrease in repair potential of cartilage with increased age of the
animal, 3 0 and the large majority of clinical cartilage repair procedures are conducted in
adult patients, it is generally accepted that cartilage repair techniques should be evaluated
in skeletally mature animals in order to demonstrate potential clinical relevance.
1.6.2 Defect
Another issue that must be addressed in designing an animal model for cartilage
repair is the type and location of the defect to be created in the articular surface. While a
long-term goal may be regeneration of large regions of cartilage within a joint that has
experienced widespread degenerative changes as a result of chronic osteoarthritis,
treatments that would lead to effective repair of small, focal defects such as might be
generated by traumatic injury could provide meaningful clinical benefits in pain relief
and preventing or postponing continued degeneration of the joint. Location of the defect
is also important, as damage to cartilage occurs most frequently in high load-bearing
regions ofjoint surfaces. In light of these, most animal models employed for cartilage
repair studies involve creation of defects in the condyle or trochlea of normal knee joints.
The age of the defect at time of treatment must also be taken into consideration.
While the vast majority of animal studies have involved acute defects in which the defect
is created and treated during the same surgical procedure, most patients are not treated
until a considerable amount of time after the original damage to the cartilage occurred.
There is experimental evidence that the age of the defect and associated changes in joint
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homeostasis can influence the success of the repair, with immediate treatment of fresh
defects leading to improved results compared to delayed treatment.13 '
Unlike many other tissues, there exists no critical size for defects in cartilage
below which the tissue will spontaneously heal, as even the smallest macroscopic
chondral defect (e.g. an incision) generally exhibits little or no reparative response. As
such, the appropriate size of an experimental defect is often a difficult decision, and
generally is designed relative to the size of the animal and the targeted clinical indication.
The depth of the defect is of particular concern, as the spontaneous healing response
increases with penetration of the subchondral plate, and would thus be expected to
significantly affect the outcome of any treatment strategy. Due to the limited thickness of
the cartilage in rabbits (< 0.5 mm), most studies in these animals have involved treatment
of osteochondral defects. The increased thickness of cartilage in larger animals such as
dogs, goats, and sheep supports their use in studies involving defects confined to the
chondral region of the joint surface.
1.6.3 Outcome assessment
1.6.3.1 Methodology
Histology, biochemistry, and mechanical testing are the three primary methods of
assessing the outcome of cartilage repair procedures in animals. These methods are
mutually exclusive, as each generally results in destruction of the specimen. Histology is
the most frequently employed method due to the breadth of information regarding the
reparative tissue that can be obtained, including the amount and type of tissue formed,
morphological characteristics of cells and ECM, degree of integration with host tissue,
and changes in cells or ECM of host tissue. While biochemical and mechanical analysis
provide quantitative measures of the composition and function of the reparative tissue,
histological evaluation can provide qualitative insight into tissue composition and
function by means of immunohistochemical staining and analysis of tissue architecture.
It is important to note that none of these methods of evaluation can be directly related to
measures pain relief and joint function used to evaluate success clinically.' 32
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1.6.3.2 Assessment time points
The time point at which repair outcome is assessed is also of critical importance.
Most cartilage repair studies reported in the literature have evaluated outcomes at time
points ranging from 2-6 months, allowing time for synthesis of new tissue and early
stages of remodeling to be initiated. A few studies have evaluated outcomes at longer
time points up to 18 months.5' 124 133"34 In some of these cases, promising results
obtained at short time points were not seen to persist at 12 or 18 months, 133,134
emphasizing the importance of evaluating treatment strategies in long-term animal
studies prior to clinical implementation.
1.7 Review of cartilage repair strategies evaluated in a canine model
Several studies evaluating the potential of various tissue engineering and
regenerative medicine techniques for cartilage repair in a canine model have been
performed in our laboratory over the past decade. 4 4 ,64 ,10 1,104,1 3 3 Chondral defects, 4mm in
diameter, were created in the trochlea of adult canine knee joints by removing the tissue
down to the calcified cartilage layer. Histomorphometric analyses of center-cut cross-
sections through the defects were performed to determine the amount and type of repair
tissue formed at various time points. Untreated defects demonstrated 34% of the cross-
sectional area filled with reparative tissue at 3 months. Approximately half of this tissue
was classified as hyaline cartilage, and the other half as fibrocartilage. 3 3 Introducing
autologous chondrocytes into the defects, as in the ACI procedure, increased the amount
of hyaline cartilage that formed, bringing the total amount of repair tissue to 48% of the
original defect cross-sectional area.' 3 3 The hyaline tissue formed in both the untreated
defects and defects treated with chondrocytes, however, did not persist over the long
term, but was replaced by fibrocartilage and fibrous tissue as the tissue was remodeled
until at 18 months hyaline cartilage comprised only 10% of the original defect cross-
sectional area. It was hypothesized that long-term success of the repair may be improved
by increasing the initial degree of defect filling and the percentage of the reparative tissue
comprised of hyaline cartilage. 33
Two subsequent studies evaluated the potential of delivering cells in collagen-
based scaffolds for improving the amount and composition of the tissue that initially
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formed. In the first study, seeding the chondrocytes in a type II collagen scaffold within
12 hours prior to implantation resulted in further increase in the amount of tissue filling
the defects to 58% at 15 weeks, but very little of this was hyaline cartilage, with
fibrocartilage and fibrous tissue accounting for 40% and 16% of the original defect area
respectively. 104 Finally, pre-conditioning the chondrocyte-seeded scaffolds through in
vitro culture for 4 weeks to allow deposition of ECM within the scaffold and
enhancement of the mechanical properties of the construct prior to implantation resulted
in reparative tissue filling 88% of the original defect area, approximately half of which
was classified as hyaline cartilage and half as fibrocartilage. 01 The use of type II
collagen scaffolds was thus demonstrated to result in substantial improvement in the
amount and type of reparative tissue formed within the chondral defects at 15 weeks.
Whether such improvements lead to improved long-term performance remains to be
determined. Further, these studies demonstrated the benefit of employing cell-seeded
scaffolds that had achieved some degree of histogenesis in vitro prior to implantation in
improving in vivo cartilage repair.
While tissue formation occurred within the cell-seeded scaffolds during the 4-
week in vitro culture period prior to implantation, histological analysis of constructs
similar to those employed in the study described above indicated that the majority of the
cells had a fibroblastic morphology rather than the rounded morphology typical of native
chondrocytes.' 0 1 Additionally, biochemical and immunohistochemical analyses
demonstrated that such constructs contained very little GAG and type II collagen
compared to normal cartilage.'03
1.8 Objectives, Hypotheses, and Specific Aims
Stemming from the studies described above, our thesis is that cell-seeded type II
collagen scaffolds exhibiting a degree of chondrogenesis achieved in vitro can facilitate
reparative processes when implanted into defects in articular cartilage. In order to further
improve cartilage repair resulting from implantation of cell-seeded scaffolds, techniques
for enhancing chondrogenesis within the constructs prior to implantation may be
required. In light of this, the objectives of the work described in the following chapters
were to evaluate the effects of scaffold cross-link density and bioreactor culture
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environment on chondrogenesis in cell-seeded type II collagen scaffolds in vitro, and to
begin to test the effects of implant compositional maturity (as indicated by GAG content)
on the reparative process in chondral defects in a goat model. An additional objective
was to evaluate the benefits of a composite construct comprised of a non-cell-seeded type
II collagen scaffold and a bone graft substitute material for treating osteochondral defects
in a goat model. The working hypotheses were as follows:
1. The dynamic culture environment provided by a rotating-wall bioreactor system
accelerates chondrogenesis within chondrocyte-seeded type II collagen scaffolds
compared to static culture conditions during the first 2 weeks of culture.
2. Decreasing scaffold cross-link density increases cartilaginous tissue formation
within chondrocyte-seeded type II collagen scaffolds in vitro.
3. Decreasing scaffold cross-link density increases chondrocytic differentiation of
bone marrow-derived mesenchymal stem cells seeded within type II collagen
scaffolds and increases cartilaginous tissue formation by these cells in vitro.
4. Implantation of chondrocyte-seeded type II collagen scaffolds achieving a degree
of chondrogenesis in vitro such that the GAG content of the implant is 30% of
that in native cartilage improves repair of chondral defects in a caprine model.
5. Implantation of a non-cell-seeded composite collagen scaffold improves repair of
osteochondral defects in a caprine model.
In order to test these hypotheses, in vitro and in vivo studies were conducted with
the following specific aims:
1. Compare biosynthesis rates, GAG and type II collagen content, and cell
morphology of chondrocyte-seeded type II collagen scaffolds cultured in a
rotating-wall bioreactor or in static culture conditions for 2 weeks.
2. a) Quantify the effects of carbodiimide concentration on type II collagen scaffold
cross-link density (as indicated by measurement of swelling ratios) and
compressive stiffness.
b) Evaluate the effects of scaffold cross-link density on cell-mediated scaffold
contraction and degradation, GAG and type II collagen content, and morphology
of cells in chondrocyte-seeded type II collagen scaffolds in vitro.
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3. Evaluate the effects of scaffold cross-link density on cell-mediated scaffold
contraction, GAG and type 1I collagen content, and morphology of cells in type I
collagen scaffolds seeded with bone marrow-derived mesenchymal stem cells.
4. Evaluate the histological make-up of reparative tissue formed in chondral defects
16 weeks after implantation of a chondrocyte-seeded type 1I collagen scaffold
with 30% of the GAG content of normal cartilage for comparison with reparative
tissue formed in untreated defects.
5. Evaluate the histological make-up of reparative tissue formed in osteochondral
defects in a caprine model 16 weeks after implantation of a composite collagen
scaffold for comparison with reparative tissue formed in untreated defects.
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Chapter 2
Effects of a Bioreactor Culture System on
Chondrogenesis within
Chondrocyte-Seeded Type II Collagen
Scaffolds at Short Time Points.
33
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2.1 Introduction
Bioreactors that provide a dynamic environment for culturing cells and tissues are
increasingly being employed for in vitro development of engineered constructs to serve
as grafts for in vivo repair or replacement of damaged tissues. Hydrodynamic conditions
created by these bioreactors can increase nutrient supply to cells by convective mass
transport and provide mechanical stimuli to tissue constructs that regulate cellular
differentiation and biosynthetic activity. Several reports have indicated the potential of
bioreactor culture for formation of cartilaginous tissues within chondrocyte-seeded
constructs when cultured for extended time periods. The objective of the work presented
in this chapter was to evaluate the potential of bioreactor culture to accelerate
chondrogenesis with chondrocyte-seeded type II collagen scaffolds within the first two
weeks of culture.
2.2 Background
Martin, et al., have suggested a general definition of bioreactors to be "devices in
which biological and/or biochemical processes develop under closely monitored and
tightly controlled environmental and operating conditions (e.g. pH, temperature, pressure,
nutrient supply and waste removal)."12 Several types of bioreactors that provide a
dynamic flow environment have been employed in tissue engineering studies, including
stirred flasks, 135-139 rotating-wall vessels, 136-1'0 hollow fiber chambers,' 5' and direct
perfusion systems 12-154 among others (see Freed and Vunjak-Novakovic15 or Martin and
Vermettel5 6 for reviews.) Of these bioreactors, the rotating-wall vessel, in which tissue
constructs are suspended between concentric cylinders rotating about a central horizontal
axis, has been most frequently reported for use in synthesizing cartilaginous tissues in
vitro. Developed by NASA, 5 7 and based on the viscous pump bioreactor from the
University of Houston,' 58 rotating-wall bioreactors provide a laminar flow, low-shear
culture environment that simulates microgravity, providing dynamic equilibrium by
balancing the gravitational, centrifugal, and drag force vectors acting on a tissue
construct.155
Investigations involving chondrocytes grown in porous polymer scaffolds in
rotating-wall bioreactors have reported varied results. Cultures of bovine chondrocyte-
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seeded polyglycolic acid (PGA) scaffolds grown in rotating-wall bioreactors for 6 weeks
resulted in constructs with larger size, greater cell numbers, increased collagen and
glycosaminoglycan (GAG) contents, and improved mechanical properties (e.g.
equilibrium modulus, dynamic stiffness, and hydraulic permeability) when compared to
constructs cultured under static conditions.' 36,139,14 4 Data from a similar study by Gooch,
et al., however, revealed no significant differences between static and bioreactor culture
environments with regard to construct wet weight and cell and GAG contents.' 38
Additionally, Hu and Athanasiou reported greater volume, mass, and GAG and collagen
content at 4 and 8 weeks in statically cultured constructs compared to rotating-wall
bioreactor cultures of chondrocytes seeded at low densities in PGA scaffolds and agarose
gels.148
2.3 Objective, Hypothesis, and Rationale
The objective of the current study was to compare the effects of dynamic and static
culture environments on tissue development in chondrocyte-seeded type II collagen
scaffolds at short time points. Most studies employing rotating-wall bioreactors for
development of tissue-engineered cartilage have focused on evaluation of specimens
following extended culture periods. Cell-seeded scaffolds are generally cultured for 4-12
weeks prior to analyses, 136-138,142,144,146,147 with one report of constructs remaining in the
bioreactor for up to 7 months.137 Little has been reported concerning the effects of
bioreactor culture conditions at shorter time points. Recent investigations of
chondrocytes cultured under static conditions in type II collagen scaffolds have produced
cartilaginous tissues in only 2 weeks.' 59 In the clinical context of developing implants for
cartilage repair, such short culture times provide benefits of lower costs, reduced the risk
of contamination, and less time between biopsy and implantation procedures. In light of
this, a 2-week time point was selected as a target for producing an implantable
cartilaginous construct. Based on prior work with rotating-wall bioreactors in our
laboratory,160 the hypothesis was that the dynamic culture environment provided by a
rotating-wall bioreactor would accelerate chondrogenesis (specifically, synthesis of GAG
and type II collagen content, and adoption of a chondrocytic morphology of the cells)
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within chondrocyte-seeded type II collagen scaffolds compared to static culture
conditions during the first 2 weeks of in vitro culture.
2.4 Materials and Methods
2.4.1 Scaffold Fabrication and Cross-linking
Porous scaffolds were fabricated by freeze-drying a porcine-derived type II
collagen slurry (Geistlich Biomaterials, Wolhusen, Switzerland) to form sheets
approximately 2.5 mm thick. Morphometric analysis of the pore structure performed as
previously reported 6 1 resulted in a pore diameter of 190 ± 25pm and porosity of 88 ±
1%. Disks 8 mm in diameter cut from the porous sheets were sterilized and cross-linked
by dehydrothermal treatment162,163 under a vacuum (50 mTorr) and temperature of 105 0C
for 24 hours. Further cross-linking was achieved by treatment with a water-soluble
carbodiimide. 64'165 Matrices were immersed in a solution containing l-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC, Sigma Chemical Co., St.
Louis, MO; 6mmol EDAC per gram of collagen scaffold) and N-hydroxysuccinimide
(NHS; Sigma, 5:2 molar ratio of EDAC:NHS) for 2 hours. Scaffolds were then washed
extensively in phosphate-buffered saline and stored in water for 12 hours prior to use.
2.4.2 Cell Isolation and Monolayer Culture
Articular cartilage was harvested from the knee (stifle) joints of 6 adult mongrel
dogs immediately postmortem. Chondrocytes were isolated from the tissue by digestion
in pronase (20 U/ml, Sigma) for 1 hour, followed by type II collagenase (200 U/ml,
Worthington Biochemical, Lakewood, NJ) overnight. The resulting cell suspension was
filtered through a 40 pm cell strainer, re-suspended in Dulbecco's modified Eagle's
medium (DMEM, Gibco Life Technologies, Carlsbad, CA) with 10% fetal bovine serum
(FBS, Hyclone Technologies, Logan, UT) and 10% dimethylsulfoxide (DMSO, Sigma),
and frozen in liquid nitrogen. Upon thawing, cells were plated in 75 cm 2 culture flasks at
2x106 cells/flask in basal media [DMEM, 0.1 mM nonessential amino acids, 100 mM
HEPES buffer , 100 U/ml penicillin, 100 gg/ml streptomycin, and 0.29 mg/ml L-
glutamine, all from Gibco] supplemented with 10% FBS, 1 ng/ml transforming growth
factor-P I(TGF- 1; R&D Systems, Minneapolis, MN), 5 ng/ml fibroblast growth factor-2
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(FGF-2; R&D Systems), and 10 ng/ml platelet-derived growth factor-p (PDGF-pp;
R&D Systems). Cells from the six animals were cultured separately. Cultures were
incubated at 37*C in 5% CO2, with medium changed every 2-3 days. Upon reaching
confluence, primary culture (PO) cells were released from the flasks by trypsinization,
counted and assessed for viability by Trypan Blue exclusion, and re-plated in 75 cm 2
flasks at 2x10 6 cells/flask (2.67x 104 cells/cm 2). Cells from the first sub-culture (P1) were
collected just prior to confluence and seeded in type II collagen scaffolds as described
below.
2.4.3 Three-Dimensional Culture in Type II Collagen Matrices
Type II collagen matrices were soaked in PBS for 1 hour, transferred to complete
medium for 10 minutes, and then briefly blotted on sterile filter paper to remove excess
liquid. Each matrix sample was seeded with P1 chondrocytes by pipetting a suspension
of 4x10 6 cells in 80 gl medium onto the surfaces of the matrix (40 gl per side.) Cell-
seeded matrices and non-seeded controls were cultured in 24-well plates coated with 1 ml
of 2% agarose to prevent the cells from attaching to the bottom of the culture dish.
Chondrogenic medium [basal medium supplemented with 1% insulin-transferrin-
selenium (ITS)-' Premix (Sigma), 10 ng/ml TGF-p1, 10-7 M dexamethasone (Sigma), 0.1
mM ascorbic acid 2-phosphate, and 1.25 mg/ml bovine serum albumin] was added to
each sample (0.5 ml/well) 2 hours post-seeding, followed by another 1.0 ml 16 hours
later.
All scaffolds were cultured under static conditions for 4 days in order to allow
cells to attach to the scaffolds. The end of this attachment period was defined as time
zero (t = 0), at which point constructs allocated for dynamic culture were transferred to a
250 ml volume rotating wall bioreactor (model STLV, 250mL, SYNTHECON, Inc.,
Houston, TX). The bioreactor was filled with chondrogenic medium and rotated at a rate
that allowed the constructs to remain in a free-floating state between the inner and outer
cylinders. Culture medium in the bioreactor vessel was replaced at a rate of 50% every
2-3 days. The entire volume of culture medium was replaced on day 7, at which point
50% of the constructs were removed for analysis. The remaining constructs were
cultured an additional week prior to removal for analysis.
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Cell-seeded constructs allocated for static culture were incubated in chondrogenic
medium (1.5 ml per well) in agarose-coated 24-well plates, with medium replaced every
2-3 days. Non-cell-seeded scaffolds were cultured under identical conditions as controls.
All specimens were maintained in an incubator environment at 37"C with 5% CO2 and
95% humidity.
2.4.4 Cellular biosynthesis of ECM macromolecules
Following removal from bioreactor or static cultures, scaffolds (n=6) were
incubated for 24 hours in medium containing 3H-proline (10 pCi/ml) and 3 5S-sulfate (10
pCi/ml) in order to determine rates of total protein and sulfated GAG synthesis,
respectively. At the end of the 24-hour radiolabeling period, unincorporated isotopes
were removed by washing the scaffolds (8 washes, 15 minutes per wash at 4*C) in PBS
supplemented with unlabeled proline (1.0 mM) and sulfate (0.8 mM). Constructs were
frozen at -20'C, lyophilized, and digested in a papain solution (0.125 mg papain per 6.25
mg of sample) at 60'C overnight.
The radioactivity content of the solubilized samples was determined by
combining 100 p1 of the digested scaffold sample with 4 ml scintillation fluid (CytoScint
ES; ICN Biomedicals Irvine, CA) and counted for 3 minutes in a liquid scintillation
counter (Packard 1600 TR; Packard Instrument, Downers Grove, IL). Total amounts of
proline and sulfate incorporated into the constructs were extrapolated from counts per
minute using known amounts of radiolabeled medium.
2.4.5 DNA and GAG Content
Cell-seeded scaffolds and non-seeded control matrices allocated for analysis of
DNA and sulfated-GAG content (n=6) were washed in PBS and stored at -20*C until
assayed. After lyophilization, the matrices were weighed and dry masses recorded.
Scaffolds were then digested overnight in a papain buffer at 600C.
Fluorometric quantification of DNA content in the digests was performed using a
PicoGreen Reagent Kit (Invitrogen, Carlsbad, CA). The background fluorescence of the
matrix was accounted for by subtracting the mean value obtained for non-seeded controls
from the value of each cell-seeded construct.
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The GAG content of the matrices was determined by the dimethylmethylene blue
(DMMB) dye assay.166 A 5 g1 aliquot of the papain digest was mixed with 195 pl of the
DMMB dye and the absorbance at 530 nm was measured with a spectrophotometer
(Victor2, Perkin Elmer, Wellesley, MA). GAG content was derived by comparison of the
absorbance measurements with a standard curve obtained using chondroitin-6-sulfate
from shark cartilage (Sigma).
2.4.6 Histological and Immunohistochemical Evaluation
Chondrocyte-seeded matrices (n=3) were fixed in 10% formalin for a minimum of
3 days prior to processing and embedding in paraffin for microtomy. Specimens cut to 7
ptm thickness were mounted on glass slides and stained with hematoxylin and eosin
(H&E) or Safranin-O using standard histological techniques.
Immunohistochemical staining of type 1I collagen was performed using the
LSAB-2 System (DakoCytomation, Carpinteria, CA) with a Dako Autostainer.
Deparaffinized and rehydrated sections were digested for 40 minutes in 0.1% protease
XIV (Sigma), followed by quenching of endogenous peroxidase activity with 3%
hydrogen peroxide. Non-specific binding was blocked with 5% horse serum. The
primary antibody (CIIC 1, mouse anti-chick type 1I collagen monoclonal antibody,
Developmental Studies Hybridoma Bank, Iowa City, IA) was applied for 30 minutes.
Negative controls were incubated with mouse IgG (DakoCytomation) instead of the
primary antibody. Labeling was detected by incubation with a biotinylated secondary
antibody, followed by streptavidin-HRP and diamenobenzadine (DAB). Counterstaining
was performed using Gill's hematoxylin.
2.4.7 Statistical Analysis
Statistical significance was determined by analysis of variance (ANOVA) and
Fisher's PLSD post hoc testing with a significance criterion ofp < 0.05 using StatView
(SAS Institute Inc., Cary, N.C.).
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2.5 Results
2.5.1 Gross Appearance and Histology
Cell-seeded scaffolds cultured in the bioreactor tended to gradually aggregate in
groups of 5-10 constructs. Constructs from these clusters were easily separated during
media changes and at the termination of the cultures at 1 and 2 weeks.
Scaffolds from both static and dynamic culture conditions maintained their
original size and shape throughout the 2 week culture period. Translucence of the
constructs decreased during the first week, progressing to a glossy, opaque appearance by
the end of the second week. No significant macroscopic differences were observed
between scaffolds from the two culture environments.
Histologic observation revealed the persistence of the collagen scaffold material,
with most of the original porous architecture still visible at 2 weeks. Cells in scaffolds
from static cultures at both 1 and 2 week time points appeared uniformly distributed
throughout the volume of the scaffolds (Fig. 2.1a). At I week small areas of newly
synthesized tissue that stained positively for Safranin-O, indicating the presence of
proteoglycans, could be observed in regions immediately surrounding cells. By 2 weeks
newly synthesized tissue completely filled the pores throughout the volume of the
scaffolds. Tissue within the interior of these constructs stained positively with Safranin-
0, while peripheral regions of the constructs up to approximately 300 gm from the
surface were void of Safranin-0 staining (Fig. 2.1 c).
Cells in bioreactor cultured samples tended to aggregate in clusters appearing
throughout the scaffold volume with no noticeable variation between the central and
peripheral regions of the constructs (Fig. 2.1 b). Bioreactor constructs generally exhibited
less staining by Safranin-0 compared to statically-cultured scaffolds, with more intense
staining concentrated near clusters of cells (Fig. 2.1 d,f).
Cell-seeded constructs from both static and bioreactor culture environments at 2
weeks included regions that stained immunohistochemically for type II collagen (Fig.
2.2). The majority of cells within these regions displayed a chondrocytic morphology
(viz. rounded shape, residing in lacunae). Type II collagen staining was qualitatively
more intense and covered a higher percentage of total tissue area in sections from
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statically cultured constructs compared to bioreactor samples. Areas of tissue containing
type II collagen generally correlated with regions of positive Safranin-O staining in
constructs from both culture environments.
d
Figure 2.1 Histology of chondrocyte-seeded CG scaffolds at 2 weeks. Scaffolds cultured
under static conditions (a, c, e) or in the rotating-wall bioreactor (b, d, f). Hematoxylin and eosin
(a, b) and Safranin-O/Fast green (c-f) stains.
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Figure 2.2 Type II collagen immunohistochemistry. Constructs cultured for 2 weeks (a) under
static conditions or (b) in the rotating-wall bioreactor. Inset shows low magnification image of
construct cross-section. (c) Magnified image of cells in statically cultured construct displaying
chondrocytic morphology.
2.5.2 Mass
Both the length of time in culture and the culture environment affected the dry
mass of chondrocyte-seeded scaffolds (2-factor ANOVA; time: p < 0.001; environment:
p = 0.003). Constructs from the static culture environment exhibited a 26% increase in
mass between the first and second weeks in culture, while dry masses of samples cultured
in the bioreactor increased 37%. At 2 weeks, the mean dry mass of constructs cultured in
the bioreactor was 13% greater than that of constructs cultured under static conditions
(Fig. 2.3).
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Figure 2.3 Dry mass measurements of chondrocyte-seeded constructs. Mean + standard
error of the mean (SEM), n=6.
2.5.3 DNA Content
The DNA content of the constructs was not significantly affected by time (two-
factor ANOVA; p = 0.30), nor culture environment (p = 0.45), indicating a similar
number of cells in scaffolds from each group (Fig. 2.4).
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Figure 2.4 DNA content of cell-seeded constructs following 1 and 2 weeks under static or
dynamic culture conditions. Mean + SEM (n=6).
2.5.4 Protein and GAG Synthesis
There was a significant effect of culture time on rate of protein synthesis as
measured by incorporation of 3H-proline into the cell-seeded scaffolds (2-factor
ANOVA; p = 0.006). Protein synthesis rates decreased between 1 and 2 weeks in
constructs cultured in both static and dynamic conditions (Fig. 2.5a). No significant
effect of culture environment on protein synthesis was determined (p = 0.37).
GAG synthesis, as measured by 35S-sulfate incorporation rates, was affected by
both culture time (2-factor ANOVA; p=0.001) and culture environment (p=0.002). GAG
synthesis rates in constructs cultured under both static and dynamic conditions declined
between weeks 1 and 2. GAG synthesis rates in constructs from static cultures were 99%
and 38% greater than in constructs cultured in the bioreactor at 1 and 2 weeks
respectively (Fig. 2.5b).
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Figure 2.5 Biosynthesis rates. Rates of incorporation of (a) radiolabeled proline (indicating
protein synthesis) and (b) radiolabeled sulfate (indicating GAG synthesis) into cell-seeded
scaffolds at 1 and 2 weeks. Mean + SEM (n=6).
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2.5.5 GAG Content
Accumulation of GAG was greater in scaffolds from static cultures compared to
bioreactor cultures at both 1 and 2 weeks (2-factor ANOVA; p = 0.0 14, Fig. 26). GAG
accumulation in constructs from both culture conditions increased with time (p<0.0001).
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Figure 2.6 GAG content. Accumulation of GAG in constructs from static and bioreactor
culture environments at 1 and 2 weeks. Mean + SEM (n=6).
2.6 Discussion
The results of this study have led to the rejection of the initial hypothesis that the
dynamic culture environment provided by a rotating-wall bioreactor accelerates
chondrogenesis compared to static culture conditions during the first 2 weeks of culture
for the constructs and culture conditions examined. While cells within scaffolds from
both culture environments continued to synthesize new ECM molecules throughout the 2-
week culture period, as demonstrated by proline and sulfate incorporation rates as well as
increases in GAG contents and dry masses of the constructs, histologic observation and
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biochemical analysis demonstrated greater GAG accumulation in constructs cultured in
the static environment compared to constructs cultured in the bioreactor, likely resulting
primarily from higher GAG synthesis rates (as indicated by 3 5S-sulfate incorporation) in
the statically cultured constructs. Fluid flow may also have contributed to lower GAG
accumulation in the bioreactor-cultured constructs by causing a greater percent of newly
synthesized GAG to be released from the highly porous scaffolds into the culture media
by convective transport. This finding is consistent with reports of reduced accumulation
of GAG in dynamically cultured scaffolds compared to static culture conditions at longer
time points as well. Gooch et al. found the percentage of GAG retained in constructs
grown in a static environment for 6 weeks was greater than that retained in constructs
exposed to fluid flow (spinner flasks with a variety of mixing rates,) although the total
amount of GAG synthesized by the cells, including GAG released into the culture
medium, was greater in the dynamic environments.167
While GAG synthesis rates and GAG accumulation in constructs from static
cultures exceeded those of samples cultured in the bioreactor in this study, the final dry
masses were higher in constructs from bioreactor cultures. This may be due to greater
accumulation of proteins in the bioreactor constructs. While not meeting our criterion for
statistical significance, 3H-proline incorporation data suggested that protein synthesis
rates in constructs from bioreactor cultures exceeded those in statically cultured scaffolds
during the second week of culture (Fig. 2.5a). Any increase in total protein synthesis and
accumulation in the bioreactor constructs did not appear to result from increased
synthesis of type II collagen, however, as immunohistochemical stains indicated more of
this cartilage-specific protein present in the statically-cultured constructs.
In studies of chondrocyte-seeded synthetic polymer scaffolds cultured in rotating
wall-bioreactors, Freed et al. have described cartilaginous tissue development in which
tissue synthesis was initiated at the scaffold periphery and progressed toward the central
regions of the construct with time.'4 1 The authors' noted that areas in which
chondrogenesis was initially observed corresponded to regions of high cell concentrations
that were due, in part, to a cell-seeding technique that results in preferential seeding of
the cells at the periphery of constructs compared to the interior. The seeding method
employed in the current study (viz. seeding chondrocytes into the matrices by pipetting
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highly concentrated cell suspension onto the surfaces of the scaffolds) resulted in a more
homogenous distribution of cells throughout the volume of the scaffolds as observed
histologically. As such, the accumulation of newly synthesized tissue occurred in a more
uniform manner throughout the constructs grown both in static conditions and in the
bioreactor.
While tissue synthesis appeared to occur uniformly throughout the constructs,
Safranin-O staining indicated less proteoglycan present in newly synthesized tissue in
peripheral regions of the constructs compared to the interiors in samples from both static
and bioreactor cultures. It may be that newly synthesized GAG molecules are more
readily lost from peripheral regions of the scaffolds by diffusion to the culture media,
resulting in less GAG retention at the periphery compared to the interior volume.
Measurements of DNA content of the cell-seeded scaffolds indicated similar
numbers of cells in constructs from static cultures and those grown in the bioreactor at
both land 2 weeks. Gooch et al. and Hu and Athanasiou reported similar results for
chondrocyte- seeded agarose' 48 and PGA 13 8,14 8 constructs following longer culture
periods. Other long-term studies, however, have indicated increased cellularity in
chondrocyte-PGA constructs grown in bioreactors compared to static culture
environments. 136,144 Of note in the study by Pei et al.144 is that constructs cultured
statically were seeded by pipetting cell suspensions onto the scaffolds, while the
constructs cultured in bioreactors were seeded using a dynamic technique that resulted in
higher percentages of cell attachment to the scaffolds. Thus differences in final cell
content of the constructs may have been an effect related to seeding technique rather than
culture environment. Additionally, initial cell seeding densities employed by Pei et al.
and Vunjak-Novakovic et al. were approximately 5 times higher than the current study.
As suggested by Hu and Athanasiou, chondrocytes may require a critical cell density
before culture in bioreactors can provide significant beneficial effects. 148
2.7 Conclusions
Overall, the results of this study suggest the benefits of the bioreactor to be
minimal compared to a static environment during the first 2 weeks of culture for the
constructs and culture conditions examined. It has been suggested that improvement of
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compositional and mechanical characteristics of constructs grown in bioreactors for
longer periods may result from increased nutrient supply and waste removal arising from
convective mass transport.12 1 Given the highly porous nature of the type II collagen
scaffolds employed in this study, it is likely that the nutrients supplied in static
environments by diffusion are sufficient to promote tissue development during the first
few weeks of culture. As porosity of the construct decreases with synthesis of new
tissue, diffusional limitations may be encountered. In such cases, transport characteristics
provided by the bioreactor may further promote continued development of cartilaginous
tissue. Further work is needed to determine the potential benefits of such a serial culture
approach for engineering cartilaginous tissue in which constructs would be grown in
static culture during the first few weeks, then transferred to a bioreactor to increase
nutrient supply as the tissue begins to mature.
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Chapter 3
Effects of Varying Scaffold Cross-link
Density on Chondrogenesis in
Chondrocyte-Seeded Type II Collagen
Scaffolds in Vitro
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3.1 Introduction
In Chapter 2, the effects of environmental regulators (provided by bioreactor
culture) on chondrocyte-seeded type II collagen scaffolds were examined. In this
chapter, effects of varying the characteristics of another "pillar" of tissue engineering -
biomaterial scaffolds - are evaluated. In vivo, interactions between cells and extracellular
matrices play a critical role in regulating cellular processes, such as migration,
contraction, and biosynthesis. In a similar manner, the behavior of cells in vitro can be
greatly influenced by numerous characteristics of biomaterial scaffolds into which they
are seeded, such as the chemical composition, architecture, or mechanical properties of
the scaffold. The goal of the work presented in this chapter was to evaluate the effects of
one such property - scaffold cross-link density - and the related cell-mediated scaffold
contraction and degradation, on chondrogenesis within chondrocyte-seeded type II
collagen scaffolds in vitro.
3.2 Background
Chondrocytes are known to dedifferentiate when removed from their native
environment and expanded in monolayer, synthesizing type I collagen and small
proteoglycans rather than the type II collagen and aggrecan that characterizes cartilage
and adopting a morphology more characteristic of a fibroblast compared to the rounded
shape of typical of chondrocytes in situ.19-23 The native chondrocyte phenotype can be
partially recovered by returning the cells to a three-dimensional environment,24-26 though
the extent of this recovery remains uncertain.
Much important work related to cartilage tissue engineering reported in the
literature has focused on identifying growth factors and cytokines that aid in promoting
redifferentiation of the cells in vitro. In this regard, it has been shown that the
composition of both the medium employed for monolayer expansion and the medium
used during subsequent three-dimensional culture effects cellular redifferentiation and
chondrogenesis. 7 -30 In addition to biological factors, several studies have investigated
the effects of certain scaffold properties on chondrocyte behavior, including chemical
composition,102,144,168,169 architecture, 144'1 70 and mechanical properties,' 64 each of which
has been shown to influence chondrogenesis.
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One notable finding related to chondrocyte-scaffold interactions was that these non-
muscle cells can express the contractile protein, c-smooth muscle actin (SMA), in situ,
and can contract scaffolds into which they are seeded in vitro.1 7 1 Double staining for type
II collagen and SMA in in vitro immunohistochemical preparations showed that the same
cells expressing the gene for the articular cartilage-specific collagen (i.e., type II
collagen) were capable of expressing the gene for SMA, indicating that SMA expression
by these cells was not solely related to loss of the chondrocyte phenotype during
monolayer expansion.12 Lee et al. demonstrated that SMA-enabled chondrocyte-
mediated contraction of type I collagen scaffolds can be prevented by increasing the
cross-link density of the constructs, thereby increasing scaffold stiffness to the point that
the scaffold resists the contractile forces exerted by the cells. 164 Of interest was the
observation that the cartilage-specific marker type II collagen was demonstrated
immunohistochemically only in constructs of lower cross-link densities that underwent
contraction. One of the suppositions was that chondrogenesis may have been facilitated
by the increased cell and matrix densities and/or decreased diffusion of nutrients resulting
from contraction of the scaffolds, each of which has been indicated to promote cartilage
formation' 35 ,14 2 ,1 73 -17 5. However, multiple methods of cross-linking (dehydration,
ultraviolet irradiation, or chemical treatment with glutaraldehyde or carbodiimide) were
employed in order to vary the cross-link density of the scaffolds, so the possibility of an
effect of cross-linking method or agent could not be ruled out.
In a related study, a remarkable difference in chondrogenesis was observed
between chondrocyte-seeded type II collagen scaffolds that underwent contraction and
those that resisted contraction during in vitro culture.' 59 In this case, the same cross-link
density was employed for cell-seeded scaffolds in groups cultured with media containing
a variety of growth factors. Constructs treated with fibroblast growth factor-2 (FGF-2)
exhibited cell-mediated contraction, extensive remodeling, and synthesis of cartilaginous
tissue, whereas constructs cultured in control medium without FGF-2 supplementation
resisted contraction and displayed little synthesis of new tissue. While it could not be
determined whether the chondrogenesis in contracted constructs was directly related to
treatment with FGF-2 or represented a secondary effect related to the resulting
54
contraction, the finding further suggests an association between scaffold contraction and
chondrogenesis in vitro.
3.3 Objective and Hypothesis
The objective of the present study was to further investigate the potential
relationship between scaffold cross-link density (and related cell-mediated scaffold
contraction and degradation) and chondrogenesis. Based on the studies described above,
the hypothesis was that scaffolds with low cross-link densities would undergo greater
cell-mediated contraction and exhibit increased chondrogenesis (viz. synthesis of GAG
and type II collagen and adoption of chondrocytic morphology by the cells) compared to
scaffolds of higher cross-link densities. Variation in scaffold cross-link density was
achieved by varying the concentration of a chemical cross-linking agent, and all
constructs were cultured under identical conditions, thus eliminating effects of variation
in cross-linking technique or composition of culture medium.
3.4 Materials and Methods
3.4.1 Scaffold Fabrication and Dehydrothermal Cross-linking
A porcine-derived type II collagen material (Geistlich Biomaterials, Switzerland)
was blended for 5 minutes at 15,000 rpm (IKA Works, Inc., Wilmington, NC) in 0.001N
hydrochloric acid (Fisher Scientific, Hampton, NH) to form a 1% (w/v) slurry. The
slurry was de-gassed by centrifugation at 10OOg for 2 minutes. Porous scaffolds
approximately 2.5 mm in thickness were fabricated from the slurry using a freeze-drying
technique previously described1 61 . Approximately 20 ml of slurry was poured into a
custom-designed polysulfone mold and placed into the chamber of a freeze-dryer
(Genesis, Virtis Co., Gardner, NY) at 20'C. The temperature of the freeze-dryer shelf
was lowered at a constant rate (approximately 1.4oC/min.) 61 to a final temperature of -
40'C, then held constant at -40'C for 1 hour to allow completion of the freezing process.
The porous architecture of the scaffolds was then achieved by sublimation of the ice
phase under vacuum (< 300mtorr) at 00C for 17 hours.
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3.4.2 Analysis of Pore Structure
Analysis of pore diameter was performed as has previously been reported.16'
Briefly, scaffold samples were embedded in glycolmethacrylate (JB-4, Polysciences Inc.,
Warrington, PA), sectioned at 5 gm, stained with aniline blue, and photographed. Images
were analyzed with a linear intercept macro using Scion Image software (Scion Corp.,
Frederick, MD), and average pore diameter from the major and minor axis of the best-fit
ellipse constructed to represent an average pore cross-section based on the linear intercept
data. This method of analysis indicated an average pore diameter of 190 ± 25pm.
3.4.3 Dehydrothermal Cross-linking
Disks 8 mm in diameter cut from the porous sheets using a dermal biopsy punch
were sterilized and cross-linked by dehydrothermal treatment'6 2,163 under a vacuum (50
mTorr) and temperature of 105*C for 24 hours. Scaffolds that did not undergo further
cross-linking are referred to as group DHT.
3.4.4 Chemical Cross-linking
Further cross-linking was achieved by treatment with a water-soluble
carbodiimide 64 165. Matrices were immersed in a solution containing 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC; Sigma Chemical Co., St.
Louis, MO) and N-hydroxysuccinimide (NHS; Sigma) at varying molar ratios of
EDAC:NHS:Carboxylic acid (1:1:5, 5:2:5, 10:4:1; Groups: EDAC1, EDAC2, and
EDAC3). Scaffolds were immersed in the solutions (2.5ml/scaffold) for 2 hours. EDAC
and NHS concentrations were calculated based on 1.2 mmol carboxylic acid groups per
gram of collagen165 and mean scaffold mass of 2.2 mg. The mean scaffold mass was
assumed to be representative of the amount of collagen in the scaffold, as GAG content
of the scaffolds was determined to contribute approximately 1% of the scaffold dry
mass.102
3.4.5 Measurement of Swelling Ratio
Relative cross-link densities of the scaffolds were determined indirectly by means
of their swelling ratios 76'177.Scaffolds were gelatinized in water at 90*C for 2 minutes,
placed between sheets of filter paper under a 1 kg weight for 20 seconds to expel excess
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water remaining in the pores, then weighed to determine the wet mass (Mw). Samples
were then dried in an oven at 1 10 C overnight, and weighed to determine the dry mass
(MD). The swelling ratio (SR), defined as the inverse volume fraction of dry collagen
(Vf), was calculated from the wet and dry masses and the densities of collagen (pc = 1.32
g/cm 3) and water (pw = 1.00 g/cm 3) as follows:
SR =-1 [(MD/PC) +( W - MD)/P)]
V, MD/Pc
3.4.6 Mechanical Testing
Scaffolds from each cross-linking group were hydrated in phosphate buffered
saline (PBS) and stored at 4"C prior to mechanical testing. On the day of testing, the
thickness and diameter of the fully hydrated specimen was measured using a micrometer.
Disks were then placed in a PBS-filled polymethylmethacrylate (PMMA) chamber
mounted in the lower jaw of a Dynastat Mechanical Spectrometer (IMASS, Hingham,
MA). A 250-gram load cell (Sensotec, Cleveland, OH) fitted with a 9.5-mm diameter
PMMA cylindrical plunger was fixed in the upper jaw of the Dynastat and the distance
between the plunger and the lower chamber set to the thickness of the hydrated scaffold.
Using displacement-feedback control, successive ramp-and-hold displacements
were applied in radially-unconfined compression, giving sequential strain increments of
2-5% up to a maximum of 20% strain. Radially-unconfined compression was used
because it was desired to employ a single chamber that would accommodate future
testing of cell-seeded scaffolds which are known to contract in diameter over time. Each
strain level was held constant for 5 min. to allow for stress relaxation, and the equilibrium
load was recorded. Stress was computed as the load normalized to the initial unstrained
disk area.
The equilibrium, uniaxial unconfined compressive stress-strain relation was
remarkably linear with coefficients of determination above 90%. The slope of the linear
fit to the stress-strain data was used to define the "apparent compressive modulus" of the
scaffolds.
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3.4.7 Cell Isolation and Monolayer Culture
Specimens of articular cartilage were harvested from the knee joints of one adult
mongrel dog immediately postmortem. Chondrocytes were isolated from the tissue by
digestion in pronase (20 U/ml, Sigma) for 1 hour, followed by type II collagenase (200
U/ml, Worthington Biochemical, Lakewood, NJ) overnight. The resulting cell
suspension was filtered through a 40 ptm cell strainer, re-suspended in Dulbecco's
modified Eagle's medium (DMEM, Gibco Life Technologies, Carlsbad, CA) with 10%
fetal bovine serum (FBS, Hyclone Technologies, Logan, UT) and 10% dimethylsulfoxide
(DMSO, Sigma), and frozen in liquid nitrogen. Upon thawing, cells were plated in 75
cm 2 culture flasks at 2x 106 cells/flask in basal media [DMEM, 0.1 mM nonessential
amino acids, 100 mM HEPES buffer, 100 U/ml penicillin, 100 ig/ml streptomycin, and
0.29 mg/ml L-glutamine, all from Gibco] supplemented with 10% fetal bovine serum,
I ng/ml transforming growth factor P I(TGF-3 1; R&D Systems, Minneapolis, MN),
5ng/ml fibroblast growth factor-2 (FGF-2; R&D Systems), and 10 ng/ml platelet-derived
growth factor PP (PDGF-sp; R&D Systems). Cultures were incubated at 37*C in 5%
C0 2, with medium changed every 2-3 days. Upon reaching confluence, primary culture
(PO) cells were released from the flasks by trypsinization, counted and assessed for
viability by Trypan Blue exclusion, and re-plated in new 75 cm 2 flasks at 2x 106
cells/flask. Cells from the first sub-culture (P1) were collected just prior to confluence
and seeded in type II collagen scaffolds as described below.
3.4.8 Three-Dimensional Culture in Type II Collagen Matrices
Matrices from each of the 4 selected cross-linking protocols were soaked in PBS
for 1 hour, transferred to complete medium for 10 minutes, then briefly blotted on sterile
filter paper to remove excess medium. Each matrix sample was seeded with P1
chondrocytes by pipetting a suspension of 4x10 6 cells in 80 R1 medium onto the surfaces
of the matrix (40 jl per side). Cell-seeded matrices and non-seeded controls were
cultured in 24-well plates coated with 1 ml of 2% agarose to prevent the cells from
attaching to the bottom of the culture dish (n=8 per group). Chondrogenic medium [basal
medium supplemented with 1% ITS+1 Premix (Sigma), 10 ng/ml TGF- , 10 4 M
dexamethasone (Sigma), 0.1 mM ascorbic acid 2-phosphate, and 1.25 mg/ml bovine
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serum albumin] was added to each sample (0.5 ml/well) 2 hours post-seeding, followed
by another 1.0 ml 16 hours later. Media were changed every 2-3 days until the cultures
were terminated at 2 weeks.
Subsequent to the experiments described above, one additional scaffold from the
DHT and EDAC 1 groups were seeded with chondrocytes and cultured under the above
conditions. The specimens were terminated at 2 and 5 days in order to qualitatively
examine microscopically the change in the pore characteristics during the initial period of
contraction, as previously evaluated macroscopically through measurement of the
diameter of the samples.
3.4.9 Measurement of Scaffold Contraction
The diameters of the cell-seeded matrices were measured at various points during
the 2 week culture period using circular templates ranging from 1 mm to 10 mm diameter
in 0.5 mm increments. The change in diameter of the matrices was expressed as a
percentage reduction in the diameter of the scaffolds based on the starting diameter.
3.4.10 Analysis ofDNA and GAG Content
Cell-seeded scaffolds and non-seeded control matrices allocated for analysis of
DNA and sulfated-GAG content (n = 4-5) were washed in PBS and stored at -20'C until
assayed. After lyophilization, the matrices were weighed and dry masses recorded.
Scaffolds were then digested overnight in a papain buffer at 60'C.
Fluorometric quantification of DNA content in the digests was performed using a
Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA). Aliquots of scaffold
digest were diluted 1:10 in Tris-EDTA buffer (TE, 10mM Tris, 1 mM EDTA, pH 8.0)
and processed according to the kit protocol with fluorescence read at 485nm/535nm for
1.Os against a lambda DNA standard on a microplate reader (Wallac Victor 2 1420
Multilabel Counter, PerkinElmer Life and Analytical Sciences, Inc., Wellesley, MA).
The background fluorescence of the matrix was accounted for by subtracting the mean
value obtained for non-seeded control scaffolds from the value of each cell-seeded
construct.
The GAG content of the matrices was determined by the dimethylmethylene blue
(DMMB) dye assay.166 A 5 gl aliquot of papain-digested scaffold was mixed with 195 pl
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of the DMMB dye and the absorbance at 530 nm was measured with a spectrophotometer
(Wallac Victor 2 1420 Multilabel Counter, PerkinElmer). GAG content was derived by
comparison of the absorbance measurements with a standard curve obtained using
chondroitin-6-sulfate from shark cartilage (Sigma).
3.4.11 Histological and Immunohistochemical Evaluation
Chondrocyte-seeded matrices (n = 3) were fixed in 10% formalin for a minimum
of 3 days prior to processing and embedding in paraffin for microtomy. Specimens cut to
7 pm thickness were mounted on glass slides and stained with hematoxylin and eosin
(H&E) or Safranin-O using standard histological techniques.
Immunohistochemical staining of type II collagen was performed using the
LSAB-2 System (DakoCytomation, Carpinteria, CA) with a Dako Autostainer.
Deparaffinized and rehydrated sections were digested for 40 minutes in 0.1% protease
XIV (Sigma), followed by quenching of endogenous peroxidase activity with 3%
hydrogen peroxide. Non-specific binding was blocked with 5% horse serum. The
primary antibody (CIIC 1, mouse anti-chick type II collagen monoclonal antibody,
Developmental Studies Hybridoma Bank, Iowa City, IA) was applied for 30 minutes.
Negative controls were incubated with mouse IgG (DakoCytomation) instead of the
primary antibody. Labeling was detected by incubation with a biotinylated secondary
antibody, followed by streptavidin-HRP and diamenobenzadine (DAB). Counterstaining
was performed using Gill's hematoxylin.
3.4.12 Quantification of Safranin-O Staining
Quantitative analysis of Safranin-O stained sections was performed based on the
method developed by Martin, et al.178 Digital images of stained sections were acquired
using a MicroFire Model S99809 camera (Meyer Instruments, Houston TX) mounted on
an Olympus BX51 microscope (Olympus, Japan) with a 1.25X objective. Using Image J
software (NIH, Bethesda MD), images were normalized by subtracting a background
image, acquired with the same light intensity, and by inverting the resulting negative
image. The image was then split into red, green, and blue (RGB) image planes in a scale
of 255 values (black=0). RGB values for each pixel were imported into MatLab
(Mathworks, Natick MA).
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The tissue sections were defined as areas significantly darker than background
(R+G+B < 675). The red content of each tissue section (Rc), a parameter defined by
Martin as a measure of the intensity of red color in the section, was calculated as the
average of the red content of each pixel (Rc) as follows. For each pixel, the red fraction
(RF) was defined as the ratio of the R component to the sum of the R, G, and B
components: RF= R/(R+G+B). In order to reduce Rc values in nonred bright regions in
which each component (R, G, B) is high, RF was normalized according to the equation
RF,N= 1.5*RF -- 0.5 for all pixels in which R was the dominant fraction (i.e. RF 1/3),
and set to 0 otherwise (i.e. RF <1/3). Rc was then defined as Rc = R*RF,N such that it is
proportional to both the original R component of the image and the normalized fraction
of red color. Red content values (Rc) of the chondrocyte-seeded scaffolds were reported
as the percentage of RAVG values in samples of normal canine cartilage. In the work by
Martin, Rc was shown to be linearly correlated to the wet weight fraction of GAG
determined biochemically in engineered and natural samples of bovine cartilage
(r2=0. 952).
3.4.13 Statistical Analysis
Statistical significance was determined by analysis of variance (ANOVA) and
Fisher's PLSD post-hoc testing with a significance criterion of P<0.05 using StatView
(SAS Institute Inc., Cary, N.C.).
3.5 Results
3.5.1 Swelling Ratios
The swelling ratio of the scaffolds decreased with increasing concentration of
EDAC employed during cross-linking (Fig. 3.1; ANOVA, p < 0.000 1). Post-hoc tests
indicated significant differences in swelling ratios among all groups. As swelling ratio of
collagen based specimens is inversely related to cross-link density, 176' 177 these data
indicate the cross-link density of the scaffolds increased with increasing exposure to
EDAC.
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Figure 3.1 Swelling ratios of cross-linked type II collagen scaffolds. Mean + SEM (n=4).
3.5.2 Unconfined Compression
The compressive modulus of the scaffolds increased with exposure to increasing
concentrations of EDAC during cross-linking (Fig. 3.2, ANOVA, p <0.0001), with the
average modulus of scaffolds from the most highly cross-linked group (EDAC3) 5 times
greater than that of the least cross-linked scaffolds (DHT). Post-hoc tests indicated
significant differences in compressive moduli among all groups with the exception of
DHT and EDAC1.
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Figure 3.2 Compressive moduli of cross-linked scaffolds. Mean + SEM (n=4).
3.5.3 Scaffold Contraction
The cell-mediated contraction of the scaffolds was affected by the cross-link
density (Fig. 3.3), consistent with previous reports for type I collagen scaffolds.164
Diameters of non-seeded scaffolds from the DHT and EDACI groups decreased to 76
2% and 81 ± 2% of the original diameters, respectively, by day 14, likely related to the
plasticizing effect of water as previously noted.179 In contrast, the diameters of
chondrocyte-seeded scaffolds from the DHT and EDAC I groups exhibited a dramatic
decrease in size, with final diameters of 49 + 9% and 54 ± 10% of the original diameters,
respectively. Cell-seeded and non-seeded scaffolds from the two groups with higher
cross-link densities (EDAC2 and EDAC3) did not exhibit any contraction.
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Figure 3.3 Contraction of type II collagen scaffolds with time in culture. Mean SEM (n=4-
5 for cell-seeded constructs, n=3 for controls).
3.5.4 Mass
ANOVA indicated a significant effect (p < 0.0001) of cross-link density on the
dry mass of cell-seeded constructs measured after 2 weeks of culture, the dry mass
increasing with increasing cross-link density (Fig. 3.4). Constructs cross-linked by DHT
alone lost mass during the culture period. Constructs from the EDAC 1 group maintained
their mass during culture, post hoc tests indicating no significant difference between this
group and non-cultured control scaffolds. Constructs with higher cross-link densities
(EDAC2 and EDAC3) gained mass during in vitro culture.
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Figure 3.4 Dry mass measurements. Non-cultured (control) scaffolds and chondrocyte-seeded 
type II collagen scaffolds following the 2 week culture period. Mean + SEM (n=4-5). 
3.5.5 DNA Content and Cell Density 
No significant effect of cross-linking on the DNA content of the constructs was 
determined (ANOVA, p = 0.06), indicating a similar number of cells in scaffolds from 
each of the 4 groups after 2 weeks in culture (Fig. 3.5a). Cell number density in each of 
the constructs was estimated assuming the average DNA content of individual cells to be 
7.7 pg, 180 and calculating construct volumes based on the final measured diameters (Fig. 
3.5b). The cell number densities for the constructs that contracted (DHT and EDAC1) 
were 3-fold higher than for the scaffolds that did not contract (EDAC3 and EDAC4). 
ANOVA revealed a significant effect of cross-linking on cell number density (p < 
0.0001), with values for less cross-linked scaffolds (DHT and EDAC1) nearly 4 times 
those of scaffolds with higher degrees of cross-linking (EDAC2 and EDAC3). 
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Figure 3.5 (a) DNA contents and (b) cell number densities of cell-seeded constructs at 2 
weeks. Mean + SEM, n=4-S . 
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3.5.6 GAG Content and GAG Density 
Sulfated-GAG content of the cell-seeded constructs increased with increasing 
cross-link density (Fig. 3.6; ANOVA,p < 0.001). While there appeared to be a trend to 
increasing GAG/DNA (i.e ., GAG/cell) with increasing cross-link density, no significant 
effect of cross-linking could be found by ANOVA (Fig. 3.7b,p = 0.137). When 
normalized to the calculated volume of the constructs (Fig. 3.7a), GAG density was 
highest in constructs from the EDACI group, followed by constructs cross-linked by 
DHT alone (ANOVA,p < 0.0001). The GAG densities in the contracted constructs were 
2-fold or greater than the non-contracting scaffolds. Post hoc testing revealed no 
significant differences in GAG density between the two groups with the highest cross-
link densities (EDAC2 and EDAC3). 
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Figure 3.6 Accumulated GAG content in chondrocyte seeded scaffolds at 2 weeks. Mean + 
SEM (n=4-5) 
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Figure 3.7 GAG contents. Accumulated GAG content normalized to (a) final construct volume 
and (b) final DNA content at 2 weeks. Mean + SEM (n=4-5). 
3.5.7 Histology and Immunohistochemistry 
Scaffolds from DHT and EDACI groups terminated at 2 and 5 days, when the 
decrease in size of the constructs began to be noticeable, displayed a uniform distribution 
of cells throughout the constructs. Compared to the open, randomly oriented porous 
architecture found in the central region of the constructs, pores around the periphery of 
the scaffolds were notably compressed (Fig. 3.8). 
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Figure 3.8 Light micrographs of chondrocyte-seeded CG scaffold. (a) Periphery and (b)
central region of scaffold from DHT group terminated at 2 days. Hematoxylin and eosin stain;
scale bars= 100pm.
Following 2 weeks of in vitro culture, most of the original scaffold material could
still be seen in constructs from the EDAC2 and EDAC3 groups (Fig. 3.9). Newly
synthesized tissue that stained lightly for GAG (Fig. 3.10) and type II collagen (Fig. 3.11)
filled the pores of the scaffold. Cells within these constructs generally exhibited a
fibroblastic appearance and were sparsely distributed throughout the tissue. Areas within
these constructs in which the local cell density was higher than surrounding tissue
exhibited more intense staining by Safranin-O, indicating a higher local concentration of
GAG (Fig. 3.10). A small percentage of the cells within these areas exhibited a rounded
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morphology and resided within lacunae characteristic of chondrocytes within native
articular cartilage tissue.
P
Figure 3.9 Light micrographs of chondrocyte-seeded scaffolds from group (a) DHT, (b) EDACI,
(c) EDAC2, and (d) EDAC3 following 2 week culture period. Hematoxylin and eosin stain; scale
bars = 1mm.
70
Figure 3.10 Light micrographs of chondrocyte-seeded scaffolds following 2 week culture period
from group (a) DHT, (b) EDAC1, (c) EDAC2, and (d) EDAC3. Regions of (e) low and (f) high
cell number density observed within a scaffold from the EDAC3 group. Images were taken from
central regions of the constructs, which appeared uniform throughout. Safranin-O/fast green
stain; scale bars = 100pm.
In contrast to constructs from EDAC2 and EDAC3, very little of the original
scaffold material remained in constructs from the less cross-linked DHT and EDAC 1
groups following the 2 week culture (Fig. 3.9), with slightly more scaffold remaining in
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the EDACI constructs compared to DHT. Newly synthesized tissue in these constructs
stained very intensely for GAG by Safranin-O (Fig. 3.10) as well as for type II collagen
(Fig. 3.11). Cells within constructs from the DHT and EDACI groups were packed close
together. The vast majority of the cells displayed a rounded morphology, and many were
found residing within lacunae.
Figure 3.11 Type II collagen immunohistochemistry. Light micrographs of chondrocyte-
seeded scaffolds following 2 week culture period from group (a) DHT and (b) EDAC2. Type II
collagen is marked by brown chromogen. Inset is negative control. Scale bars = IOOjm. Images
were taken from central regions of the constructs, which appeared uniform throughout. Images
from DHT and EDAC2 were also representative of samples from EDAC 1 and EDAC3 groups,
respectively.
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3.5.8 Safranin-O Quantification
Red content values (R) of Safranin-O stained sections from contracted scaffolds
(DHT, EDAC1) reached nearly 75% of those from normal canine articular cartilage, and
were 4-fold higher than those from uncontracted scaffolds (EDAC2, EDAC3) (p<0.0001;
Fig. 3.12).
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Figure 3.12 Safranin-O quantification. Red content values (Rc) of Safranin-O stained sections
from each group of chondrocyte-seeded collagen scaffolds, reported as percent of Rc value from
samples of normal adult canine cartilage. Mean + SEM (n=6-12).
3.6 Discussion
Exposure to increasing concentrations of cross-linking agents resulted in
increasing the cross-link densities of type II collagen scaffolds, as indicated by reduction
in swelling ratios (Fig. 3.1) and increase in compressive moduli of the scaffolds (Fig.
3.2). Varying the cross-link density in this manner allowed for broad range of scaffold
stiffness to be achieved, with the stiffness of the most-highly cross-linked scaffolds more
than 5-fold that of the least cross-linked matrices.
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Contraction of the scaffolds observed in this study is consistent with that
previously reported for chondrocyte-seeded type I and type II collagen scaffolds.17'
Increased scaffold stiffness resulting from increased cross-link density reduces cell-
mediated contraction of the scaffolds,164 as was observed in this study with constructs
from EDAC2 and EDAC3 groups.
Investigations of interactions between fibroblasts and type I collagen matrices
have indicated that macroscopic deformation of the scaffold results from buckling of
individual collagen struts as the cells attach and contract.' 8 ' Changing the stiffness of
this system did not affect the level of force generated by the cells, suggesting that
generation of force by cellular contraction was a force-limited process.18 2 This may
explain the differences in scaffold contraction among groups observed in this study.
Increasing the cross-link density of the scaffolds leads to increased stiffness of individual
collagen struts, thereby increasing the applied load required to cause the struts to buckle.
That no contraction was observed in the EDAC2 and EDAC3 groups likely indicates that
the stiffness of these scaffolds resulted in critical loads required for buckling individual
struts beyond that which the chondrocytes were capable of generating.
The remarkable difference in chondrogenesis observed between constructs of low
cross-link densities that underwent contraction (DHT and EDAC1) and constructs with
greater cross-link densities (EDAC2 and EDAC3) that maintained their size throughout
the culture period provides confirmation of our initial hypothesis. Cells within contracted
constructs displayed characteristics of chondrocytes in native cartilage, appearing
rounded and often residing within lacunae. Extracellular matrix synthesized by these
cells stained intensely for GAG and type II collagen. In contrast, constructs with greater
degrees of cross-linking contained cells with an elongated morphology similar to
fibroblasts and demonstrated only light GAG and type II collagen staining.
Also of interest was the observation that there appeared to be less residual collagen
scaffold present in regions displaying chondrogenesis. This suggested an increased rate
of scaffold degradation associated with cartilage formation, i.e., a remodeling process. It
is possible that the same microenvironmental factors that favor the process of
biosynthesis of cartilage-specific matrix molecules also stimulate the production of
enzymes required for the degradation of the ECM in order to facilitate remodeling of the
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ECM. Future studies might undertake the challenge of quantifying the rate of scaffold
degradation to further investigate this putative remodeling process.
The degradation rate of the scaffold is of critical importance during the
development of engineered tissue. If the scaffold degrades too quickly it will not be able
to sustain tissue growth. On the other hand, if the scaffold remains too long, the
continuity of newly synthesized tissue can be compromised. Ideally, the rate of scaffold
degradation would match the rate at which new tissue is synthesized. In this study, the
measurement of scaffold mass at 14 days was the net effect of degradative and formative
processes, and can be interpreted in light of the histological observations, including the
amount of scaffold material remaining. The decrease in mass of the scaffolds from the
DHT group relative to non-cultured control scaffolds was due to degradation of the type
1I collagen material, which was not offset by matrix synthesis. Masses of constructs from
the EDAC1 group, which also demonstrated little remaining scaffold histologically, were
comparable to those of non-cultured scaffolds; this indicated that the rate of tissue
formation over the 2-weeek period was comparable to the rate of scaffold degradation.
Net gains in mass exhibited by scaffolds with greater cross-link densities (EDAC2 and
EDAC3) reflected the histological finding that the degradation of the scaffold proceeded
at a slower rate than tissue synthesis in these constructs. These issues related to rates of
scaffold degradation and tissue formation and underlying mechanisms warrant additional
investigation.
Collectively, the findings of the study demonstrate an association between scaffold
contraction and chondrogenesis. The reduction in size of the cell-seeded scaffolds in the
DHT and EDAC 1 groups - referred to as contraction - appeared to be accompanied by
reduction in pore diameter within the first week of culture when most of the contraction
was occurring, as demonstrated by the microscopic examination of the specimens
terminated after 2 and 5 days in culture. This is consistent with prior studies of
chondrocyte-seeded collagen scaffolds demonstrating reduction in pore size due to
chondrocyte contraction. 172 That scaffold degradation is not the likely cause of the
contraction seen in the first week of culture, is supported by previous studies of non-cell-
seeded type I and type II collagen scaffolds which noted that degradation of the scaffolds
resulted in solubilization, and eventual disintegration, of the bulk material leading to loss
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of mechanical integrity without a reduction in diameter. 171,183 Degradative processes
may, however, promote contraction by reducing the mechanical stiffness of the scaffold
and its resistance to cell contraction.
The results of this study thus point to interrelated processes of pore reduction,
chondrogenesis, and scaffold degradation. While there is evidence that pore reduction
occurs earlier (within the first week) than the other two, it is not yet possible to determine
causal relationships. The samples with the lower cross-link densities, which favored
chondrogenesis, displayed scaffold degradation as well as contraction. Isolating the roles
of scaffold contraction and scaffold degradation in chondrogenesis may require the use of
another (non-collagenous) material system.
The decrease in pore diameter may have acted to favor the greater extent of
chondrogenesis observed in constructs with low levels of cross-linking by increasing the
cell number density in the scaffold. The total number of cells (as indicated by DNA
content) was similar in scaffolds from each of the four groups following the 2-week
culture period. The reduction in volume resulting from contraction of the scaffolds in the
DHT and EDAC I groups led to the large increase in cell number density. Cell number
densities in these constructs reached levels approximately twice the value reported for
human cartilage (-10,000 cells/mm 3).'1 8" 84 A correlation between cell density and
chondrogenesis is further supported by the observation that, although the majority of
tissue found in constructs from the EDAC2 and EDAC3 groups was fibrous in nature,
areas in which cells were densely packed exhibited more intense GAG staining and a
greater percentage of cells with chondrocytic morphology compared to surrounding tissue
in which the cells were sparsely distributed (Fig.8).
A number of benefits of employing high cell densities for in vitro synthesis of
cartilage tissue have been reported, including increased cellular proliferation 18 and
expression of cartilage-specific genes,' 8 6 as well as enhanced GAG and type II collagen
content,135 '"87 mechanical properties,' 8 7 and cartilage-like morphology of the resulting
tissue.' 85 In such studies, two approaches have typically been employed as means of
increasing the density of cells in tissue engineered constructs: increasing the number of
cells initially seeded into the scaffold, and stimulating cellular proliferation within the
construct. Initial seeding density is often limited by the nature of the porous structure of
76
the scaffold; although scaffolds with small pores have more surface area available to
which the cells can attach, larger pores are often required to facilitate cell seeding and
migration to the central regions of the construct. Additionally, the final cell density is
limited by the proliferative capacity of the cells.
"Dynamic pore reduction" (DPR), as demonstrated in this study, represents an
alternative approach in which the desired cell density is achieved by volume reduction
resulting from cell-mediated contraction and remodeling of the porous scaffold. This
method allows the use of scaffolds with large, interconnecting pores that accommodate
infiltration and migration of the cells during the process of seeding the scaffolds with
cells. Contraction of the scaffold then results in increased cell density, and may act to
retain cells and newly synthesized matrix molecules within the construct.
Increasing cell density by DPR resembles "condensation" that is prerequisite to
chondrocyte differentiation during developmental chondrogenesis in vivo. During
condensation, the intercellular space is reduced through an aggregation of cells (as
opposed to local proliferation), 18 8 leading to development of cell-to-cell junctions 189 and
subsequently to chondrocytic differentiation. It may be that increased chondrogenesis
observed in constructs undergoing DPR is a result of cell-to-cell signaling in a manner
similar to that occurring during condensation.
A notable feature of the chondrogenesis in the scaffolds with the greatest degree of
contraction (DHT and EDACI groups) was the high density of GAG (i.e., mass of
GAG/volume of construct). The increase in GAG density in contracted constructs
accounted for the remarkable differences observed in Safranin-O staining, with constructs
that contracted exhibiting much more intense staining and hyaline-like appearance
compared to constructs that resisted contraction (Fig. 3.10). Reduction in the pore
volume during contraction and remodeling may have had a concentrating effect on
existing GAG and/or allowed for the capture and retention of newly synthesized matrix
molecules, which would have been more readily lost to the medium in the more open
porous structures of groups EDAC3 and EDAC4. Alternatively, the increase in the
density of the extracellular matrix in the contracted constructs may have, in turn, limited
the diffusion of nutrients and reduced the oxygen tension in the microenvironment of the
cells thus further favoring chondrogenesis. However, while it was not statistically
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significant there was a trend toward decreasing, rather than increasing, GAG/cell with
increasing contraction. The reason for this is not yet clear. It may simply be that the
GAG/cell value in the DHT and EDAC 1 constructs with more mature cartilage,
histologically, reflected a nearer to normal level of GAG rate of synthesis of articular
chondrocytes in mature cartilage. Future studies will be needed to further investigate this
finding.
3.7 Conclusions
The results of this study further indicate a correlation between cell-mediated
contraction and degradation of tissue-engineered constructs and chondrogenesis.
Additional work is needed to elucidate whether a causal relationship exists between these
processes. Further, DPR may represent a novel approach to tissue-engineering of
cartilage with the potential to overcome certain limitations of alternative methods, such
as limited cell-seeding densities and inadequate retention of newly synthesized
molecules.
Within the context of the overall objectives of this thesis, controlling the cross-link
density of chondrocyte-seeded type II collagen scaffolds such that they undergo DPR
dramatically increases chondrogenesis compared to the highly cross-linked scaffolds
employed as implants in our prior work in cartilage repair, and may provide opportunity
to evaluate the effects of implant maturity on repair outcome.
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Chapter 4
Effects of Varying Scaffold Cross-link
Density on Mesenchymal Stem Cell
Differentiation and Histogenesis in Type
II Collagen Scaffolds in Vitro
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4.1 Introduction
Strategies for treating damaged articular cartilage involving cell-based therapies
hold much promise for this important orthopedic problem. One such procedure,
autologous chondrocyte implantation (ACI), in which in vitro expanded chondrocytes
isolated from minimally load-bearing regions of healthy cartilage are injected into defect
areas, has been employed in the clinic for more than a decade. ''66'67190'19' More recently,
biodegradable scaffolds have been used as delivery vehicles for the cells to facilitate
retention of the chondrocytes within the defect space.192-197 While significant
improvements in terms of pain relief and restoration of joint function have been reported
for both of these procedures, 66,67 ,197 ,198 one important problem associated with these
approaches is morbidity of the site from which the cells are obtained. Defects created in
healthy cartilage during the biopsy are not expected to heal and may further degenerate,
compromising the integrity of the surrounding joint surface. Indeed, animal studies have
indicated that the harvest procedure required to obtain the cells has potentially deleterious
effects on certain properties of surrounding tissue (e.g. up to 3-fold increases in dynamic
stiffness and streaming potential measured 18 weeks after the surgical procedure.) 99
Much work has been reported recently identifying alternative sources of cells with
72-77 78-83chondrogenic potential, including cells derived from periosteum, bone marrow,
synovium, 84-9 and adipose tissue.90-97 The use of such cells for cartilage repair
procedures could circumvent the problem of donor site morbidity encountered with the
use of native chondrocytes.
4.2 Objective, Hypothesis, and Rationale
The objective of the present study was to investigate the chondrogenic potential of
mesenchymal stem cells (MSCs) derived from bone marrow stroma when cultured in
porous type II collagen scaffolds. Previous work has demonstrated the benefits of
employing such scaffolds as cell-delivery vehicles in cartilage repair procedures 44'0 1'104
and as a three-dimensional culture system for engineering of cartilaginous tissues in
vitro. 103, 159,170,171,199,200 As demonstrated in Chapter 3, one property of these scaffolds
shown to have dramatic influence on the behavior of chondrocytes cultured in the
constructs is the degree of cross-linking, a determinate of scaffold stiffness and
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degradation rate. Scaffolds with low cross-link densities that underwent cell-mediated
contraction and degradation demonstrated greater chondrogenesis (viz. chondrocytic
morphology of the cells, synthesis of GAG and type II collagen) compared to more
highly cross-linked scaffolds that resisted cellular contraction degradation. Based on this
finding, the hypothesis for the current study was that decreasing scaffold cross-link
density increases chondrocytic differentiation of MSCs and cartilaginous tissue formation
in type II collagen scaffolds in vitro.
4.3 Materials and Methods
4.3.1 Scaffold Fabrication and Cross-linking
A porcine-derived type II collagen material (Geistlich Biomaterials, Switzerland)
was blended for 2 minutes at 15,000 rpm (IKA Works, Inc., Wilmington, NC) in 0.001N
hydrochloric acid (Fisher Scientific, Hampton, NH) to form a 1% (w/v) slurry. The
slurry was de-gassed by centrifugation at 1 OOOg for 2 minutes, then mixed on a magnetic
stir plate for 5 minutes. Porous scaffolds approximately 1.5 mm in thickness were
fabricated from the slurry using a freeze-drying technique previously described 61.
Thirty-five ml of slurry was poured into 12.4 x 12.4 mm stainless steel pans (Virtis Co.,
Gardner, NY) and placed into the chamber of a freeze-dryer (Genesis, Virtis) at 20C.
The temperature of the freeze-dryer shelf was lowered at a constant rate (approximately
1.40C/min.) 6 ' to a final temperature of -10C, then held constant at -10C for 1 hour to
allow completion of the freezing process. The porous architecture of the scaffolds was
then achieved by sublimation of the ice phase under vacuum (< 700mtorr) at 0C for 17
hours. Morphometric analysis of the pore structure performed as previously reported16 1
indicated a pore diameter of approximately 350 pm.
Disks 8 mm in diameter cut from the porous sheets were sterilized and cross-
linked by dehydrothermal treatment' 62,163 under a vacuum (50 mTorr) and temperature of
105'C for 24 hours (Group: DHT). Further cross-linking was achieved by treatment with
a water-soluble carbodiimide. 164'165 Matrices were immersed in a solution containing 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC; Sigma Chemical
Co., St. Louis, MO) and N-hydroxysuccinimide (NHS; Sigma) at varying molar ratios of
EDAC:NHS:Carboxylic acid (1:1:5, 5:2:5, 10:4:1; Groups: EDAC1, EDAC2, and
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EDAC3). Scaffolds were immersed in the solutions (1 ml/scaffold) for 30 minutes.
EDAC and NHS concentrations were calculated based on mean scaffold mass of 1.25 mg
and 1.2 mmol carboxylic acid groups per gram of collagen. 165
Relative cross-link densities of the scaffolds were determined indirectly by means
of their swelling ratios.1 76"177 Scaffolds were gelatinized in water at 90'C for 2 minutes,
placed between sheets of filter paper under a 1 kg weight for 20 seconds to expel excess
water remaining in the pores, then weighed to determine the wet mass (Mw). Samples
were then dried in an oven at 11 C overnight, and weighed to determine the dry mass
(MD). The swelling ratio (SR), defined as the inverse volume fraction of dry collagen
(Vf), was calculated from the wet and dry masses and the densities of collagen (pc = 1.32
g/cm 3) and water (pw= 1.00 g/cm 3) as follows:
SR = 1 = [(MD p )+((MW - MD/PW)
Vj MD Pc
4.3.2 Cell Isolation and Monolayer Culture
Bone marrow aspirates were obtained from the posterior iliac crests of 5 female
Spanish goats. After skin incision, penetration of the cortical bone was accomplished
with a Jamshidi-Needle for bone marrow aspiration, 8 gauge x 10 cm (Henry Schein Inc.,
Melville, NY). From each iliac crest, 2 ml of bone marrow was aspirated into a 10ml
syringe containing 50U heparin (lOU/ml, BD PosiFlush Syringe, Becton, Dickenson and
Co., Franklin Lakes, NJ). Isolation and primary culture of the MSCs was performed using
a modification of published protocols. 80' 97 Briefly, 2 ml of the anticoagulated bone
marrow was diluted with 2 ml of phosphate-buffered saline (PBS, Invitrogen, San Diego,
CA), layered on 3 ml of Ficoll Paque (GE Healthcare, Piscataway, NJ) and centrifuged at
3000 rpm for 30 minutes. The resulting mononuclear cell layer was transferred from the
interface, washed two times with PBS, resuspended in low-glucose Dulbecco's modified
Eagle's medium (DMEM-LG, Invitrogen,) containing 10% heat inactivated (56 0C, 30
minutes) fetal bovine serum (FBS, Invitrogen), 100 U/ml penicillin and 100 pig/ml
streptomycin (Invitrogen) and plated in 150 cm 2 tissue culture flasks at a density of
approximately 4x10 3 cells/cm 2 . The MSCs were selected based on their ability to adhere
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to the tissue culture polystyrene. Non-adherent cells were removed with the first media
change after 48 hours. The culture medium was changed 3 times per week. Upon
reaching 80-90% confluence, the cells were trypsinized and frozen in liquid nitrogen in
0.5 ml aliquots containing 5x10 5 cells in DMEM-LG with 20% FBS and 10%
dimethylsulfoxide (DMSO, Sigma).
Frozen MSCs were thawed and expanded through 2 subcultures (i.e. P2) in
DMEM-LG containing 10% FBS, 100 U/ml penicillin, 100 pg/ml streptomycin, and
lOng/ml recombinant human fibroblast growth factor-2 (FGF-2, R&D Systems,
Minneapolis, MN). For each subculture, cells were plated at a density of approximately
3.3x10 3 cells/cm 2 in 150 cm 2 flasks and split upon reaching 80-90% of confluence. At
the end of the second subculture, the cells were harvested, resuspended at a final
concentration of 80x106 cells/ml in a chondrogenic medium80 [high-glucose Dulbecco's
Modified Eagle's Medium (DMEM-HG, Invitrogen), 0.1 mM Non-Essential Amino
Acids (Invitrogen), 10mM HEPES buffer (Invitrogen), 100 U/ml penicillin and 100
pg/mL streptomycin (Invitrogen), 1% ITS+I (Sigma), 0.1mM ascorbic acid 2-phosphate
(Wako Chemicals USA, Inc., Richmond, VA), 1.25 mg/ml bovine serum albumin (BSA,
Invitrogen), 10 ng/mL recombinant human transforming growth factor-PI (TGF-p1,
R&D Systems), and 100 nM dexamethasone (Sigma)], and seeded into type II collagen
scaffolds as described below.
4.3.3 Three-Dimensional Culture in Type II Collagen Matrices
Matrices from each of the 4 cross-linking protocols were soaked in complete
medium for 30 minutes, then briefly blotted on sterile filter paper to remove excess
medium. Each matrix sample was seeded with P2 MSCs by pipetting a suspension of
2x10 6 cells in 20 gl medium onto one surface of the scaffold. After 10 minutes, the
scaffolds were flipped and an additional 20 pl of cell suspension was added to the
opposite side, for a total of 4x10 6 cells per scaffold. Cell-seeded matrices were placed in
12-well plates coated with 1.5 ml of 2% (w/v) agarose (Cambrex BioScience, Rockland,
ME) to prevent the cells from attaching to the bottom of the culture dish, and incubated at
371C in 5% CO2. Chondrogenic medium was added to each sample (0.5 ml/well) 1 hour
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post-seeding, followed by another 0.5 ml 16 hours later. Medium was changed every 3
days until the cultures were terminated at 3 days, 2 weeks, and 4 weeks. Non-cell-seeded
scaffolds were cultured in parallel under similar conditions (viz. chondrogenic medium,
but without addition of TGF- 1) as controls.
4.3.4 Scaffold Contraction
The diameters of the cell-seeded matrices and unseeded controls were measured
every 3 days using circular templates ranging from 1 mm to 10 mm diameter in 0.5 mm
increments. Upon termination of the cultures, the thickness of each construct was
measured with a micrometer and the volume estimated based on the thickness and final
diameter measurement.
4.3.5 Analysis ofDNA and GAG Content
Cell-seeded scaffolds and non-seeded control matrices allocated for analysis of
DNA and sulfated-GAG content (n = 4-5) were washed in PBS and stored at -20'C until
assayed. After lyophilization, scaffolds were digested overnight with Proteinase K
(100pjg/ml; Sigma) in Tris-HCl-buffer (50 mM Tris, 1mM CaCl 2, pH 8.0) at 60'C.
Fluorometric quantification of DNA content in the digests was performed using a
Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA). Aliquots of scaffold
digest were diluted 1:10 in Tris-EDTA buffer (TE, 10mM Tris, 1 mM EDTA, pH 8.0)
and processed according to the kit protocol with fluorescence read at 485nm/535nm for
1.Os against a lambda DNA standard on a microplate reader (Wallac Victor2 1420
Multilabel Counter, PerkinElmer Life and Analytical Sciences, Inc., Wellesley, MA).
The background fluorescence of the matrix was accounted for by subtracting the mean
value obtained for non-seeded control scaffolds from the value of each cell-seeded
construct. Aliquots of cells from 2 of the animals containing 4x10 6 cells each (by
hemacytometer count) were lyophilized, digested, and assayed for DNA content in the
same manner as the cell-seeded constructs.
The GAG content of the matrices was determined by the dimethylmethylene blue
(DMMB) dye assay 66. Aliquots of scaffold digest were diluted 1:10 in TE buffer. A 20
pl aliquot of diluted digest was mixed with 200 pl of the DMMB dye and the absorbance
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at 530 nm measured with a microplate reader (Wallac Victor2 1420 Multilabel Counter,
PerkinElmer). GAG content was derived by comparison of the absorbance measurements
with a standard curve obtained using chondroitin-6-sulfate from shark cartilage (Sigma).
4.3.6 Histological and Immunohistochemical Evaluation
MSC-seeded matrices (n = 5) were fixed in 10% phosphate-buffered formalin
(Fisher) for 1 hour prior to processing and embedding in paraffin for microtomy.
Specimens cut to 6 pm thickness were mounted on glass slides and stained with
hematoxylin and eosin (H&E) or Safranin-O using standard histological techniques.
Immunohistochemical staining of type II collagen was performed using the
LSAB-2 System (DakoCytomation, Carpinteria, CA) with a Dako Autostainer.
Deparaffinized and rehydrated sections were digested for 40 minutes in 0.1% protease
XIV (Sigma), followed by quenching of endogenous peroxidase activity with a
peroxidase blocking reagent (DakoCytomation). Non-specific binding was blocked with
5% goat serum (Sigma). The primary antibody (CIICI, mouse anti-chick type II collagen
monoclonal antibody, Developmental Studies Hybridoma Bank, Iowa City, IA) was
applied for 30 minutes. Negative controls were incubated with mouse IgG
(DakoCytomation) instead of the primary antibody. Labeling was detected by incubation
with a biotinylated secondary antibody, followed by streptavidin-HRP then AEC
substrate chromogen (all from DakoCytomation). Counterstaining was performed using
Mayer's hematoxylin (Sigma).
4.3.7 Statistical Analysis
Statistical significance was determined by analysis of variance (ANOVA) and
Fisher's PLSD post-hoc testing with a significance criterion of p < 0.05 using StatView
(SAS Institute Inc., Cary, N.C.). All results are reported as mean ± standard error of the
mean.
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4.4 Results 
4.4.1 Swelling Ratios 
ANOVA demonstrated an effect of cross-linking on swelling ratio (p<O.OOOI), 
with post-hoc tests indicating that swelling ratios ofDHT and EDACI groups were 
significantly different from those of EDAC2 and EDAC3 groups (Fig. 4.1). As the 
swelling ratio of collagen based specimens is inversely related to cross-link density,176,177 
these data indicated that the cross-link density of the scaffolds increased with exposure to 
increasing concentration of EDAC. 
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Figure 4.1 Swelling ratios of cross-linked type II collagen scaffolds. Mean + SEM (n=4). 
4.4.2 Scaffold Contraction 
Contraction of the scaffolds was affected by the cross-link density, consistent with 
previous findings for chondrocyte-seeded type II collagen scaffolds.2oo Scaffolds from all 
groups swelled upon wetting, resulting in an initial increase in diameter of approximately 
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a 
13%. By day 27 diameters of non-seeded scaffolds from the DHT and EDAC1 groups 
decreased to 78 ± 2% and 84 ± 2% of the original non-swollen diameters, respectively, 
likely related to the plasticizing effect of water as previously noted,179 while non-seeded 
scaffolds with higher cross-link densities (EDAC2 and EDAC3) maintained their swollen 
diameters throughout the culture period (Fig. 4.2). In contrast, the MSC-seeded scaffolds 
from all groups exhibited a decrease in size, with final diameters 36 ± 3% (DHT), 40 ± 
5% (EDAC1), 62 ± 5% (EDAC2), and 92 ± 2% (EDAC3) of the original diameters. 
Most of this cell-mediated contraction occurred early in the culture period, with diameter 
reductions generally approaching asymptotic values by approximately 2 weeks. 
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Figure 4.2 Contraction of type II collagen scaffolds with time in culture. Mean ± SEM. 
4.4.3 DNA Content and Cell Density 
No significant effect of time on DNA content of the cell-seeded constructs was 
determined (p = 0.29), indicating a similar number of cells present in the scaffolds 
throughout the 4 week culture period. While not meeting our criterion for statistical 
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significance, there appeared to be a trend toward increasing DNA content with increasing 
cross-link density of the scaffolds (p = 0.068, Fig. 4.3). 
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Figure 4.3 DNA contents of MSC-seeded type II scaffolds with time in culture. Mean ± SEM 
(n=5). 
DNA content of cell pellets from 2 of the animals containing 4x 1 06 cells was 
determined to be 5.64 ± 1.33 pg DNA/cell. Based on this value, the cell number density 
in each of the constructs was estimated from the DNA content and the calculated 
construct volume (Fig. 4.4). Final cell number densities were inversely related to cross-
link density, with values from the least cross-linked scaffolds that exhibited the most cell-
mediated contraction (DHT group) 6-fold higher than values for the most highly cross-
linked constructs (EDAC3 group; p = 0.04). 
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Figure 4.4 Cell number densities of MSC-seeded scaffolds at 4 weeks. Mean + SEM (n=5). 
4.4.4 GA G Content 
There was a significant effect of time on sulfated-GAG content of the cell-seeded 
constructs (p < 0.000 I), with post-hoc testing indicating an increase in GAG content 
between weeks 2 and 4 for all cross-linking groups except EDAC 3 (Fig. 4.5). No 
significant effect of cross-linking group on total GAG content was determined 
(p=0.1882), though there appeared to be a trend toward decreasing GAG content with 
increasing cross-link density for the 4-week constructs. When normalized to construct 
volume, the final GAG/volume values from 4-week constructs decreased with increasing 
cross-link density (p = 0.04, Fig. 4.6). Similarly, GAG/cell values from 4-week 
constructs were inversely related to cross-link density, with values for DHT constructs 4 
times that of EDAC3 constructs (p=0.0 16, Fig. 4.7). 
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Figure 4.5 GAG accumulation in MSC-seeded type II collagen scaffolds following 2 and 4 
week cultures. Mean + SEM (n=5). 
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Figure 4.6 GAG accumulation in MSC-seeded scaffolds at 4 weeks normalized to construct 
volume. Mean + SEM (n=5). 
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Figure 4.7 GAG accumulation in MSC-seeded scaffolds at 4 weeks normalized to the 
number of cells in the construct (as determined from DNA data). Mean + SEM (n=5). 
4.4.5 Histology and Immunohistochemistry 
Histologic observation of scaffolds terminated 24 hours post-seeding revealed a 
uniform distribution of cells throughout the constructs (Fig. 4.8). Following 2 weeks of 
in vitro culture, most of the original scaffold material could still be seen in constructs 
from all groups. Scaffolds with the highest cross-link density (EDAC3) retained an open, 
porous architecture throughout the volume of the construct. Central regions of scaffolds 
from the EDAC2 group retained much of the original porous structure, while pores on the 
periphery of the constructs appeared notably compressed. Cell densities in these 
peripheral regions were markedly higher compared to the open-pore regions in the center 
of the constructs. Scaffolds from DHT and EDACI groups displayed compressed pores 
throughout, with some regions in which the pores had completely collapsed. Cells within 
these constructs were found densely packed within the porous regions. Very small 
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amounts of little newly-synthesized tissue could be detected in some of the 2-week
constructs in regions of high cell densities where the pores were compressed.
Figure 4.8 Histology of MSC-seeded type II collagen scaffold 24 hours post-seeding.
Hematoxylin and eosin stain. Scale bar = 200 jm.
DHT and EDAC 1 constructs terminated at 4 weeks exhibited large regions of
newly synthesized tissue that stained positively with Safranin-O for GAG (Fig. 4.9) and
immunohistochemically for type II collagen (Fig. 4.10). Many cells within these regions
displayed a morphology characteristic of chondrocytes: rounded and residing within
lacunae. Less of the original scaffold material remained in regions with high amounts of
newly-synthesized tissue.
Four-week constructs from the EDAC2 group continued to exhibit a more open,
porous structure in the central regions compared to compressed pores located at the
periphery, while EDAC3 scaffolds generally maintained the original porous architecture
throughout. Small amounts of tissue staining lightly with Safranin-O and populated by
cells with chondrocyte-like morphology filled some of the pores at the periphery of these
scaffolds. Very little newly-synthesized tissue was found in the central regions of these
constructs where the open, porous architecture was retained. Cells within the central
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regions displayed a more fibroblastic appearance and were generally found spread along
the scaffolds struts.
a
C
Figure 4.9 Histology of MSC-seeded type II collagen scaffolds at 4 weeks. Images in the
right column are magnified regions from corresponding scaffolds in left column. Scaffolds from
cross-linking groups (a) DHT, (b) EDAC 1, (c) EDAC2, (d) EDAC3. Safranin-O/fast green stain.
Cells in scaffolds presented in this figure originated from a single animal. Images are
representative of replicate constructs seeded with cells from additional animals (n=5).
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Figure 4.10 Type II collagen immunohistochemistry of MSC-seeded construct at 4 weeks.
Type II collagen marked by reddish-brown chromogen. Inset is low-magnification image of the
construct cross-section. Scale bar = 50 tm.
4.5 Discussion
The results of the present study demonstrate the ability of bone marrow-derived
MSCs to differentiate to a chondrocytic phenotype within porous, type II collagen
scaffolds in vitro. During 4 weeks of culture in chondrogenic medium, cells within these
scaffolds synthesized an extracellular matrix containing two major components of
cartilage tissue, GAG and type II collagen. Many cells within the newly-synthesized
tissues had adopted a morphology characteristic of chondrocytes (viz. a rounded
appearance and residing within lacunae).
A notable finding of the study is the dramatic effect of cross-link density (and
associated stiffness and resistance to cell-mediated contraction and degradation) on
chondrogenesis in MSC-seeded scaffolds, supporting our initial hypothesis. Scaffolds
with low cross-link densities (DHT, EDAC 1) that experienced greater cell-mediated
contraction contained many more cells with chondrocytic morphology and greater
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amounts of newly synthesized cartilaginous tissue compared to more highly cross-linked
scaffolds displaying less accumulation of new tissue and containing cells with a
predominantly fibroblastic appearance. Similar results were reported in Chapter 3 when
employing chondrocyte-seeded scaffolds. When employing chondrocytes, however,
cartilaginous tissue formation was achieved within a 2 week culture period, while
histologic observation and biochemical assays indicated that the MSCs employed in this
study did not exhibit significant synthesis of new tissue until between the second and
fourth weeks of culture. This may be explained by noting that MSCs must first
differentiate to a chondrocytic phenotype prior to initiation of chondrogenesis within the
scaffolds. Future work may investigate methods of accelerating MSC differentiation in
order to shorten the culture period required to achieve formation of a cartilaginous
construct.
MSCs derived from bone-marrow have been shown to possess the ability to express
the gene for the contractile actin isoform, u-smooth muscle actin (SMA) and contract
porous scaffolds into which they are seeded.20 ' 2 In the present study, volume reduction
resulting from cell-mediated contraction of scaffolds with lower cross-link densities led
to increased cell number densities within the scaffolds, which may have promoted the
increase in chondrogenesis within these constructs. Indeed, several reports in the
literature have related high cell number densities to increased chondrogenesis in cultures
employing MSCs186 and chondrocytes,135'1851 87 although the mechanism behind this
relationship remains unclear. In these studies, two approaches have typically been
employed as means of increasing the cell number density in tissue engineered constructs:
increasing the number of cells initially seeded into the scaffold, or stimulating cellular
proliferation within the construct. Initial seeding density is often limited by the nature of
the porous structure of the scaffold; although scaffolds with small pores have more
surface area available to which the cells can attach, larger pores are often required to
facilitate cell seeding and migration to the central regions of the construct. This may
present particular difficulty when employing MSCs for cartilage tissue engineering, as
the large size of the cells (compared to native chondrocytes) can prevent adequate initial
infiltration of the scaffolds during seeding (see Appendix 1). Farrell et al., reported that
rat MSCs seeded onto type I collagen scaffolds aggregated at the surface of the
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constructs, with little infiltration observed until the cells began to migrate through the
scaffold between the second and third week of culture.203 Takahashi et al. encountered
similar difficulties when seeding MSCs in a non-woven polyethylene terephtalate
scaffolds using a variety of seeding techniques. In this case, the authors demonstrated
that a homogenous distribution of MSCs within the scaffolds could be achieved at the
time of seeding, but required a dynamic seeding technique in which the constructs were
vigorously shaken (300 rpm for 6 hours) within a high concentration cell suspension.204
"Dynamic pore reduction" (DPR), as discussed in Chapter 3, represents an
alternative approach to achieving the desired cell density by means of pore volume
reduction resulting from cell-mediated contraction and remodeling of the porous scaffold.
This method allows the use of scaffolds with large, interconnecting pores to
accommodate infiltration and migration of the cells during the process of seeding the
scaffolds with cells. Contraction of the scaffold then results in increased cell density, and
may act to retain cells and newly synthesized matrix molecules within the construct.
In this study, the total number of cells within the scaffolds (as indicated by DNA
content) did not change significantly with time throughout the 4-week culture (Fig. 4.3),
indicating that the increase in cell number densities in contracted constructs primarily
resulted from aggregation of cells during DPR rather than cellular proliferation.
Increasing cell number densities by DPR in this manner resembles cellular condensation
that is prerequisite to chondrocyte differentiation during developmental chondrogenesis
in vivo. During condensation, the intercellular space is reduced through an aggregation
of cells (as opposed to local proliferation),'18 8 leading to development of cell-to-cell
junctions189 and subsequently to chondrocytic differentiation. It may be that increased
chondrogenesis observed in constructs undergoing DPR is a result of cell-to-cell
signaling in a manner similar to that occurring during pre-cartilage condensation.
In addition to increased cell number densities, GAG/volume values of 4-week
MSC-seeded constructs increased with increasing cell-mediated contraction (Fig. 4.6).
While this is likely primarily related to the concentrating effect of volume reduction
experienced by the contracted scaffolds, normalizing the total GAG content to the
number of cells within the scaffolds revealed increasing GAG per cell values with
increasing contraction as well (Fig. 4.7). This may indicate a beneficial effect of DPR in
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stimulating higher average rates of GAG synthesis by cells within the contracted
constructs. Alternatively, it is possible that GAG synthesis rates were similar among
constructs from different cross-linking groups, but that constructs undergoing DPR
retained more of the newly synthesized molecules that may have been more readily lost
to the culture medium from the large, open-pore structure maintained in the highly cross-
linked scaffolds. Future studies involving assays for GAG retention and biosynthesis
rates may better elucidate these findings.
4.6 Conclusions
Demonstration of the chondrogenic potential of bone marrow-derived MSCs within
type II collagen scaffolds in vitro in this study supports their potential use as an
alternative to autologous chondrocytes for cell-based cartilage repair procedures. Further
work is needed to determine the ability of MSCs to maintain the chondrocytic phenotype
in vivo and facilitate regeneration of cartilage. Additionally, results of this study further
support DPR as a novel approach to tissue-engineering of cartilage with the potential to
overcome certain limitations of alternative methods, such as limited cell-seeding densities
and inadequate retention of newly synthesized molecules.
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Chapter 5
Effects of Autologous Chondrocyte-Seeded
Type II Collagen Scaffolds on Repair of
Chondral Defects in a Caprine Model
99
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5.1 Introduction
As described in Chapter 1, one of the variables related to tissue engineering
strategies employing cell-seeded scaffolds to treat such defects in articular cartilage is the
amount of cartilage that should be formed in the construct prior to its implantation.
Animal studies employing a canine model developed in our laboratory have indicated that
providing some degree of histogenesis in cell-seeded scaffolds through in vitro culture
prior implantation in chondral defects can improve short-term repair outcomes compared
to implantation of cell-seeded scaffolds lacking tissue formed in vitro prior to
implantation. 01 Histological and biochemical examination of constructs similar to those
employed indicated that the implants contained very little of the major components of
native cartilage.' 03' 159 As such, it was hypothesized that implantation of a cell-seeded
scaffold that achieved a greater degree of chondrogenesis in vitro prior to implantation
may improve the in vivo repair outcome.
In Chapter 3 it was shown that controlling the cross-link density of chondrocyte-
seeded type II collagen scaffolds such that they experienced cell-mediated contraction
while resisting degradation to a degree sufficient for maintaining functional integrity long
enough to allow tissue formation resulted in a dramatic increase in chondrogenesis
compared to the highly cross-linked scaffolds previously employed. These results
suggest a framework for fabrication of chondrocyte-seeded scaffolds with varying
degrees of compositional maturity, providing the opportunity to begin to investigate the
effects of the degree of cartilage formation within tissue engineered implants on the
reparative processes in cartilage defects in vivo.
5.2 Objective
The objective of this study was to test the hypothesis that implantation of a
chondrocyte-seeded type II collagen scaffold achieving a degree of chondrogenesis in
vitro such that the GAG content of the implant is 30% of that in native cartilage improves
repair of chondral defects in a caprine model. The GAG content was chosen as a
measure of the degree of compositional maturity of the implant based on the facility of a
well-established method of quantification and the availability of data in the literature for
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comparison to the GAG content of native and tissue-engineered cartilaginous tissues.
The decision to employ a caprine model as opposed to the canine model previously
developed in our laboratory was based on the limited availability of the large breed of
dogs required. While the rabbit remains the most common animal model for cartilage
repair procedures, goats are increasingly being employed as the composition, structure,
and mechanical properties of caprine cartilage more closely resemble that of
humans.1 28,205-209
5.3 Materials and Methods
5.3.1 Animal model
Eleven skeletally mature (ages 3-5 years) female Spanish goats were used for this
study. All protocols for the animal experiment were approved by the Animal Care
Committee of the VA Boston Healthcare System. Prior to surgery, animals were
roentgenographically examined to exclude animals with degenerative joint disease of the
knee (stifle).
All operations were performed with the animal under general anesthesia and using
sterile technique. To obtain autologous chondrocytes for the cell-seeded implants,
shavings of articular cartilage were harvested from non-articulating regions of the
trochlear ridges and trochlear notch of the left knee of each animal. Chondrocytes were
isolated from these cartilage shavings and cultured as described below.
A second operation for creation of defects in the right knee was performed 3-4
weeks after the initial harvest procedure. At this time, the right knee was opened by an
anteromedial approach and the patella laterally displaced to expose the trochlea. Two
defects, each 4 mm in diameter, were created approximately 1.25 and 2.25 cm proximal
to the intercondylar notch slightly lateral or medial to the midline (Fig. 5.1). A 4 mm
diameter dermal biopsy punch was used to outline the defect. Using loupe visualization,
non-calcified cartilage was removed from the defect using a customized curette. The
objective was to remove as much non-calcified cartilage from the defect as possible while
preserving the integrity of the calcified cartilage and the subchondral plate. No bleeding
was observed in any of the defects at the time of creation. In 9 of the animals, one
scaffold seeded with autologous chondrocytes was placed in each defect and secured with
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three to four 8-0 coated Vicryl sutures (Fig. 5.1). Defects in the animals from the control
group (2 animals) did not receive implants, but remained untreated (empty). The knee
joint closed and immobilized by external fixation for 8 days, after which the animals
were allowed to ambulate normally until euthanasia at 16 weeks. Upon euthanasia, the
knee joints were opened, photographed, and grossly evaluated. The distal region of the
femur containing the defect sites was removed and prepared for histologic evaluation as
described below.
Figure 5.1 Implantation of chondrocyte-seeded scaffolds in chondral defects. Scale bar
equals 4 mm.
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Upon opening of the knee joints at the time of defect creation, two animals were
found to have degeneration of the articular cartilage extending from the intercondylar
notch into the trochlear groove that was undetectable during roentgenographic screening.
These animals were treated with implants, then sacrificed at 1 or 2 weeks following
implantation of cell-seeded constructs to evaluate retention of the constructs immediately
after removal of external fixation and following 1 week of ambulation.
Figure 5.2 Degenerated cartilage
5.3.2 Scaffold Fabrication and Cross-linking
A porcine-derived type II collagen material (Geistlich Biomaterials, Switzerland)
was blended for 5 minutes at 15,000 rpm (IKA Works, Inc., Wilmington, NC) in 0.001N
hydrochloric acid (Fisher Scientific, Hampton, NH) to form a 1% (w/v) slurry. The
slurry was de-gassed by centrifugation at IOOOg for 2 minutes. Porous scaffolds
approximately 2.5 mm in thickness were fabricated from the slurry using a freeze-drying
technique previously described. 16' Twenty ml of slurry was poured into customized
polysulfone molds and placed into the chamber of a freeze-dryer (Genesis, Virtis,
Gardiner, NY) at 200C. The temperature of the freeze-dryer shelf was lowered at a
constant rate (approximately 1.40C/min.)1 61 to a final temperature of -40'C, then held
constant at -40'C for 1 hour to allow completion of the freezing process. The porous
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architecture of the scaffolds was then achieved by sublimation of the ice phase under
vacuum (< 300mtorr) at 0C for 17 hours. Morphometric analysis of the pore structure
performed as previously reported 161 indicated a pore diameter of 190 ± 25pm.
Disks 8 mm in diameter cut from the porous sheets were sterilized and cross-
linked by dehydrothermal treatment162,163 under a vacuum (50 mTorr) and temperature of
105'C for 24 hours. Further cross-linking was achieved by treatment with a water-
soluble carbodiimide.164'165 Matrices were immersed in a solution containing I-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC; Sigma Chemical Co., St.
Louis, MO) and N-hydroxysuccinimide (NHS; Sigma) at a 5:2:5 molar ratio of
EDAC:NHS:Carboxylic acid. EDAC and NHS concentrations were calculated based on
mean scaffold mass of 2.2 mg and 1.2 mmol carboxylic acid groups per gram of
collagen.165 Scaffolds were immersed in the solutions (1 ml/scaffold) for 30 minutes,
washed in PBS (2 x 10 minutes), then washed in sterile water for 1 hour on a rocker to
remove any residual EDAC and NHS. The scaffold cross-linking protocol was chosen
based on pilot experiments in which seeding caprine chondrocytes in such scaffolds
resulted in constructs with GAG content approximately 30% of that in normal caprine
cartilage at 2 weeks.
5.3.3 Cell 1iolation and Monolayer Culture
Chondrocytes were isolated from harvested articular cartilage tissue by digestion
in protease (20 U/ml, Sigma) for 1 hour, followed by type II collagenase (200 U/ml,
Worthington Biochemical, Lakewood, NJ) overnight with constant stirring. The resulting
cell suspension was filtered through a 40 pm cell strainer, resuspended in basal medium
[Dulbecco's modified Eagle's medium DMEM, 0.1 mM nonessential amino acids, 100
mM HEPES buffer , 100 U/ml penicillin, 100 jig/ml streptomycin, and 0.29 mg/ml L-
glutamine, all from Invitrogen, Carlsbad, CA] supplemented with 10% fetal bovine serum
(FBS; invitrogen), Ing/ml transforming growth factor-pi(TGF- 1; R&D Systems,
Minneapolis, MN), 5ng/ml fibroblast growth factor-2 (FGF-2; R&D Systems), and 10
ng/ml platelet-derived growth factor-pp (PDGF-pp; R&D Systems) and plated in 75 cm2
culture flasks at 2x10 6 cells/flask. Cultures were incubated at 37 0 C in 5% C0 2, with
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medium changed every 2-3 days. Upon reaching confluence, primary culture (PO) cells
were released from the flasks by tripsinization, counted and assessed for viability by
Trypan Blue exclusion, and re-plated in new 75 cm 2 flasks at 2x10 6 cells/flask. Cells
from the first sub-culture (P1) were collected just prior to confluence and seeded in type
II collagen scaffolds as described below.
5.3.4 Three-Dimensional Culture in Type II Collagen Matrices
Following 1 hour wash in water, scaffolds were transferred to complete medium
for 10 minutes, then briefly blotted on sterile filter paper to remove excess medium.
Each matrix sample was seeded with P1 chondrocytes by pipetting a suspension of 4x10 6
cells in 80 pl medium onto the surfaces of the matrix (40 pl per side). Cell-seeded
matrices and non-seeded controls were cultured in 12-well plates coated with 1.5 ml of
2% agarose to prevent the cells from attaching to the bottom of the culture dish (n=8 per
group). Chondrogenic medium [basal medium supplemented with 1% ITS+1 Premix
(Sigma), 10 ng/ml TGF-1, 107 M dexamethasone (Sigma), 0.1 mM ascorbic acid 2-
phosphate, and 1.25 mg/ml bovine serum albumin (Invitrogen)] was added to each
sample (0.5 ml/well) 2 hours post-seeding, followed by another 1.0 ml 16 hours later.
Medium was changed every 2-3 days until implantation at 2 weeks. During this time
scaffolds underwent varying degrees of cell-mediated contraction, as has been
reported.200 Scaffolds with final diameters of approximately 4mm were sutured directly
into the defect sites, while constructs with diameters greater than 4mm at 2 weeks were
trimmed using a 4 mm diameter biopsy punch prior to implantation. Trimmed portions
from the periphery of these constructs were processed for histological evaluation.
At the time of scaffold seeding, cells from 3 animals had reached sufficient
numbers to allow seeding of additional scaffolds, which were cultured in parallel with the
implants. These additional constructs were terminated at 2 weeks and processed for
histological and biochemical evaluation.
5.3.5 Analysis of GAG content
Cell-seeded scaffolds and samples of normal caprine articular cartilage allocated
for analysis of sulfated-GAG content (n = 3-5) were washed in PBS and stored at -20*C
until assayed. After lyophilization, the samples were weighed and dry masses recorded.
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Scaffolds and tissues were then digested overnight in a proteinase buffer at 60'C. The
GAG content of the constructs was determined by the dimethylmethylene blue (DMMB)
dye assay. 66 Aliquots of scaffold digest were diluted 1:10 in TE buffer. A 20 pl aliquot
of diluted digest was mixed with 200 pA of the DMMB dye and the absorbance at 530 nm
measured witi a microplate reader (Wallac Victor2 1420 Multilabel Counter,
PerkinElmer). GAG content was derived by comparison of the absorbance measurements
with a standard curve obtained using chondroitin-6-sulfate from shark cartilage (Sigma).
5.3.6 Histological and Immunohistochemical Evaluation
Defect sites removed from the joint were fixed in 10% formalin for at least 1
week and decalcifed in 25% (w/v) ethylenediamine tetraacetic acid (EDTA, pH ~7.7) for
at least four weeks. These decalcified samples and formalin-fixed cell-seeded constructs
cultured in parallel to those implanted in the animals were dehydrated and embedded in
paraffin. Microtomed sections 6 pm in thickness were stained with hematoxylin and
eosin (H&E) or Safranin-O/Fast Green using standard histological techniques.
Immunohistochemical staining of type II collagen was performed using the
LSAB-2 System (DakoCytomation, Carpinteria, CA) with a Dako Autostainer.
Deparaffinized and rehydrated sections were digested for 40 minutes in 0.1% protease
XIV (Sigma), followed by quenching of endogenous peroxidase activity with a
peroxidase blocking reagent (DakoCytomation). Non-specific binding was blocked with
5% goat serum (Sigma). The primary antibody (CIICI, mouse anti-chick type II collagen
monoclonal antibody, Developmental Studies Hybridoma Bank, Iowa City, IA) was
applied for 30 minutes. Negative controls were incubated with mouse IgG
(DakoCytomation) instead of the primary antibody. Labeling was detected by incubation
with a biotinylated secondary antibody for 15 minutes, followed by streptavidin-HRP (15
minutes) then AEC substrate chromogen (10 minutes, all from DakoCytomation).
Counterstaining was performed using Mayer's hematoxylin (Sigma).
Immunohistochemical staining of proteoglycan 4 (PRG4, also called superficial zone
protein or lubricin) was performed in an identical fashion employing an antibody to
PRG4 (from T.M. Schmid, Rush University Medical Center, Chicago, IL).
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5.3.7 Histomorphometry
A quantitative histomorphometric analysis of specific tissue types was used to
evaluate the tissue filling the defects. A recent study evaluated the inter-observer error
associated with this quantitative histological method.13 3 One histological section from
the center portion of each defect, stained with hematoxylin and eosin, was evaluated.
Digital micrographs of the defect and surrounding tissue were recorded. The total area of
the tissue and the percentages of the specific tissue types (hyaline cartilage,
fibrocartilage, and fibrous tissue) filling the original defect region were measured using
ImageJ (NIH). Evaluation of some sections revealed resorption of subchondral bone,
with cartilaginous and fibrous tissues extending from the chondral space into the
subchondral region. Other sections revealed ingrowth of subchondral bone into the
chondral space. In order to analyze the reparative tissue in the chondral space, defects
were outlined as created. The location of the original base of the defect was estimated
using the trajectory of the adjacent calcified cartilage layer and remnants of the tidemark
remaining intact within the defect. As such, newly formed tissue in the subchondral bone
space was not included in the quantitative analysis of the reparative tissue filling the
original defect.
Classical criteria relating to the morphology of the cells and the presence or
absence of lacunae and the composition and structure of the extracellular matrix were
used to distinguish tissue types, as has previously been reported.132 In brief, tissue was
classified as hyaline cartilage if the cells were in well-defined lacunae and there was no
fibrous appearance to the extracellular matrix. The type I composition and GAG content
of the hyaline matrix was assessed in selected sections. Normally, hyaline cartilage
exhibits positive Safranin-O staining, although the intensity can be variable. As in
previous studies, regions of tissue with little Safranin-O staining but meeting the other
criteria for hyaline cartilage were classified as hyaline. Fibrocartilage was identified as
having rounded cells in lacunae but with a distinct fibrous appearance to the matrix. Cells
in fibrous tissue were elongated, with no lacunae, and were surrounded by an
extracellular matrix with a distinct fibrous appearance and no detectable proteoglycan by
Safranin-O staining. The linear percentage of the calcified cartilage layer that was intact
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and the linear percentage of the reparative tissue exhibiting bonding to the calcified
cartilage or subchondral bone were also measured.
5.3.8 Statistical Methods
Statistical significance was determined by analysis of variance (ANOVA) and
Fisher's PLSD post-hoc testing with a significance criterion ofp < 0.05 using StatView
(SAS Institute Inc., Cary, N.C.). All results are reported as mean ± standard error of the
mean.
5.4 Results
5.4.1 Cell-seeded scaffolds
All scaffolds experienced cell-mediated contraction during the 2 week in vitro
culture period, with final diameters ranging from 4 to 6.5 mm, consistent with previous
results from type II collagen scaffolds seeded with canine chondrocytes presented in
Chapter 3. Biochemical analysis indicated that the GAG content of the cell-seeded
scaffolds was 36% of that in normal cartilage. Histologic observation of the peripheral
regions of cell-seeded scaffolds from which implants were punched, as well as additional
scaffolds cultured in parallel but not implanted, indicated a uniform distribution of cells
throughout the volume of the scaffolds. Most of the original scaffold material and
porous architecture was still visible, though pores in the peripheral regions of constructs
appeared compressed compared with pores in the central regions of the scaffolds. Newly
synthesized tissue that stained positively with Safranin-O filled the pores throughout the
scaffolds. The vast majority of the cells within this tissue displayed a rounded
morphology and were found residing within lacunae (Fig. 5.3), characteristics typical of
chondrocytes in native cartilage.
5.4.2 Gross observations and qualitative histologic assessment of reparative tissue
At the time of sacrifice, all animals were ambulating normally with the exception of one
animal that, upon opening of the knee joints, exhibited lateral patellar displacement with
denuded cartilage on the trochlea and patella consistent with patellar
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Figure 5.3 Histology of cell-seeded type 11 collagen implant. High magnification and low
magnification (inset) of images of peripheral region of scaffold from which 4 mm implant was
cut (inset image). Proteoglycan content is indicated by red staining (Safranin-O). Yellow arrows
indicate cells with chondrocytic morphology. Black arrows indicate residual collagen scaffold.
Scale bar = 100 pm.
subluxation in both knees. Defects from this animal were excluded from subsequent
analysis. The center of the trochlea in the right knee of one additional animal displayed
significant degradation of the cartilage, though this did not extend to the location of the
treated defects. No other joints displayed signs of significant pathology, although there
was evidence of slight hypertrophy of the synovial tissue in some animals.
All 4 implants from the 2 animals sacrificed at 1 and 2 weeks were located within
respective defect sites at time of euthanasia, demonstrating the ability of the suturing
method to retain the implants throughout the period of external fixation and 1 week of
subsequent ambulation. Histology of these defect sites indicated that immobilization of
the joint in flexion during the immediate post-operative period resulted in compression of
110
the implant by the patella, reducing the thickness of the implant below that of the
surrounding host cartilage (Fig. 5.4a). The subchondral bone plate in each of these
samples remained fully intact, with the exception of a small fracture in one sample
extending approximately 300 pm into the subchondral bone. No communication between
the defect space and the marrow space in the trabecular bone was evident in any of these
samples. While no integration of the implants with the calcified cartilage at the base of
the defects was demonstrated, small amounts of tissue were observed at the edges of the
defects bridging the gap between the implants and host cartilage (Fig. 5.4b).
Figure 5.4 Cell-seeded type II collagen scaffold at 1 week post-implantation. (a) Cross-
section of chondral defect with implanted scaffold. (b) Magnified image of interface between the
host cartilage and implanted scaffold. Hematoxylin and eosin stain. Scale bars = (a) Imm, (b) 50
9m.
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Defect sites in the right knee joints of animals sacrificed at 16 weeks contained
variable amounts of reparative tissue that was grossly distinguishable from surrounding
cartilage (Fig. 5.5). Gross observation at the time of euthanasia indicated that greater
than 90% of the base of each defect was covered with reparative tissue. The defect
volume appeared to be at least 50% filled in 10 of the 12 defects that received implants, 4
of which filled to a level flush with or above the surface of the adjacent host cartilage.
Figure 5.5 Chondral defect repair at 16 weeks. Arrows indicate location of defect sites.
Histological examination revealed notable changes in the host cartilage near the
edges of the defects, including chondrocyte cloning and loss of proteoglycan as indicated
by reduced Safranin-O staining (Fig. 5.6). Suture paths created in the host cartilage when
implants were sutured into the defects were visible in several of the histologic sections,
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with complete separation of the cartilage on either side of the suture path. Tissue along
the edges of these suture paths generally displayed chondrocyte cloning and loss of
proteoglycans (Fig. 5.6). Defects that were incompletely filled by reparative tissue
generally contained significant matrix "flow" in which host cartilage was observed
collapsing or "flowing" into the defect space (Fig. 5.6).
Figure 5.6 Changes to host articular cartilage. Arrows indicate regions of depleted
proteoglycan along suture track (white arrow) and at the edge of host cartilage bordering the
defect space (black arrow). Safranin-O/fast green stain. Scale bar = 500 gm.
While subchondral bone appeared normal in animals sacrificed up to 2 weeks
following surgery, defects in animals sacrificed at 16 weeks displayed dramatic changes
in the calcified cartilage and underlying bone. In 15 of the 16 defects, very little of the
calcified cartilage and subchondral bone plate remained intact, resulting in direct
communication between the marrow space and the chondral defects. Two untreated
control defects and 4 implanted defects displayed severe resorption of the subchondral
bone and replacement with soft tissue of variable composition (Fig. 5.7), whereas 5
defects (1 untreated, 4 implanted) exhibited growth of the bone into the chondral defect
space (Fig 5.8). Neovascularization was evident in regions of bone ingrowth and
frequently within connective tissue adjacent to the new bone within the defect.
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Figure 5.7 Bone resorption. Host articular cartilage (AC), repair tissue (RT), tidemark (TM),
and region demonstrating severe subchondral bone resorption (BR) and replacement with soft
repair tissue. Hematoxylin and eosin stain. Scale bar = 1 mm.
I
Figure 5.8 Bone ingrowth into chondral space. Host articular cartilage (AC), repair tissue
(RT), tidemark (TM), and bone ingrowth (BI). Orange arrow marks approximate location of the
original defect edge. Hematoxylin and eosin stain. Scale bar = 500 [tm.
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Very small (< 100 prm) pieces of residual collagen scaffold were visible in the
reparative tissue of several of the treated defects (Fig. 5.9). The majority of the tissue
filling defects treated with cell-seeded constructs was fibrocartilage, while the primary
constituent of the reparative tissue in untreated defects was fibrous tissue. Hyaline-like
tissue was observed in several samples located at the base and edges of the defect. Most
of the defects that received implants contained a small amount of fibrous tissue typically
located at the surface of the reparative tissue. Tissues classified as hyaline or
fibrocartilage in the morphometric analysis of H&E stained sections contained
proteoglycan and type II collagen as indicated by Safranin-O staining and
immunohistochemistry. A very small percentage of these tissues contained chondrocytes
oriented in a columnar fashion typical of native articular cartilage (Fig. 5.10).
Repair tissue and host articular cartilage from all samples stained positively for
PRG4 by immunohistochemistry (Fig. 5.11). In the host tissue, a very dense layer of
positive staining approximately 6 pm in thickness was located at the articular surface. In
regions of certain samples where the surface of the tissue was no longer intact, but
appeared fibrillated, this layer of PRG4 staining followed the contour of the fibrillated
surface. Intracellular deposits of the chromogen employed in staining were observed in
many of the chondrocytes near the cartilage surface to a depth of- 175 pim (Fig. 5.11).
In a few of the samples, extracellular matrix stained diffusely within this region (Fig.
5.12). PRG4 staining was largely absent from deeper regions of host cartilage, though
intercellular deposits were found in a very few cells (estimated < 1%) in the middle and
deep zones of a few samples. As with the host cartilage, a dense layer of positive PRG4
staining appeared at the surface of repair tissue filling both implanted and untreated
defects (Fig. 5.11). A band of diffuse staining of the ECM was observed more frequently
and extended to a greater depth in the repair tissue compared to host cartilage.
PRG,4 staining was also located along the borders of suture paths in host cartilage,
and along the surface of repair at the edge of the defect that exhibited little integration
with host articular cartilage or calcified cartilage (Fig. 5.13).
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Figure 5.9 Repair tissue formed in chondral defect implanted with a cell-seeded type II
collagen scaffold. (a) Host articular cartilage (AC), newly formed fibrocartilaginous repair tissue
(FC) and newly formed hyaline cartilage (HC). Orange arrow indicates residual collagen
scaffold. Black arrow marks approximate location of original defect edge. Hematoxylin and
eosin stain. Serial sections from same sample demonstrate the presence of type II collagen (b,
immunohistochemical stain, brown chromogen) and GAG (c, Safranin-O/fast green stain) in
repair tissue classified as hyaline cartilage. Scale bars = 200 gm.
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Figure 5.10 Columnar arrangement of chondrocytes in fibrocartilaginous repair tissue.
Hematoxylin and eosin stain. Scale bar = 200 gm.
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Figure 5.11 PRG4 immunohistochemistry. Red chromogen indicates presence of PRG4 in (a)
host articular cartilage and (b) repair tissue. Scale bar = 100 gm.
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Figure 5.12 PRG4 immunohistochemistry. Red chromogen marks a diffuse band of
extracellular matrix staining positively for PRG4 in host articular cartilage. Scale bar = 100 ptm.
Figure 5.13 PRG4 staining along suture paths in (a) host cartilage and (b) repair tissue.
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5.4.3 Histomorphometry
Results from the histomorphometric evaluation of the amounts and types of tissue
filling the defects and the linear percentage of the calcified cartilage remaining intact are
presented in Table 1. ANOVA revealed no significant effect of defect location (proximal
or distal) on any of the outcome variables, indicating each defect could be treated as an
independent observation. Mean values of defects receiving implants were higher for total
fill, hyaline, and fibrocartilage and lower for fibrous tissue, bone ingrowth, and matrix
flow compared to untreated control defects. However, only the percentage of the defect
filled with fibrous tissue was demonstrated to be statistically significant (p = 0.01). No
statistically significant difference between the implanted and control groups was found
for any of the other outcome variables [total fill (p=0.4 7 ); hyaline (p=0. 3 6 ); fibrocartilage
(p=0.4 0); bone ingrowth (p=0.5 9 ); matrix flow (p=0.82 )]. Furthermore, there was no
significant effect of treatment with respect to the percentage of the calcified cartilage
remaining intact (p=0.60).
Table 5-1 Results of histomorphometric analysis of reparative tissues. Data are reported as
percentage of original defect cross-sectional area.
Implanted Defects Untreated Defects
Mean ± SEM Range Mean ± SEM Range
Total Fill 69 ±10 13-107 57 ±12 21 -75
Hyaline Cartilage 9 ±5 0-48 1 ±1 0-3
Fibrocartilage 46±10 0-100 29±11 0-53
Fibrous Tissue 5 ±2 0-17 16 6 0-27
Matrix Flow 7 ±2 0-18 2 2 0-8
Bone lngrowth 1±1 0-7 9±3 2-15
Intact Tidemark 25 ±17 1 0-100 17 12 0-51
A direct relationship was noted between the integration of reparative tissue at the
base of the defect, and existence of an intact calcified cartilage layer. In all regions
where the calcified cartilage remained intact, no integration with the repair tissue was
observed, whereas integration of the repair tissue with subchondral bone was evident
along 100% of the base of defects in which no calcified cartilage could be detected.
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5.5 Discussion
Histomorphometric analysis of the defect sites showed little overall benefit of the
chondrocyte-seeded implant compared to untreated control defects with regard to the
amount and type of reparative tissue formed at 16 weeks. While the mean values for the
implanted group suggested improvement over controls in several outcome variables (e.g.
greater total fill, greater amount of hyaline cartilage, less fibrous tissue, and less
disruption of the calcified cartilage), the only outcome variable demonstrating a
statistically significant effect of treatment was the amount of fibrous tissue formation.
Whether such reduction in fibrous tissue formation represents a meaningful functional
benefit (e.g. improved mechanical properties) or clinical benefit (e.g. pain relief) warrants
further study.
It should be noted that the data from both the treated and untreated groups
demonstrated a great degree of variability for all categories evaluated. In determining the
sample numbers used in this study, we assumed a 30% difference between mean values
for a given outcome variable (e.g. total fill or percentage of hyaline-like tissue) would
indicate a meaningful benefit of one treatment group over another. Sample number was
then chosen to detect a 30% difference between groups, estimating the standard deviation
for each group to be 20% of the mean. The actual standard deviation for each outcome
variable evaluated proved to be greater than 40% of the mean value. As such, it is
possible that increasing the sample numbers may have resulted in demonstration of
significant differences between treatment groups that were not exhibited in the current
analysis. However, as the difference between treatment groups is small compared to the
mean values for most of the outcome variables evaluated (e.g. total fill= 69% for the
implant group, 57% for the untreated controls) it may be unlikely that such an increase in
sample number would result in demonstration of 30% difference of the means. Future
studies may benefit from increased sample numbers in order to account for the inherent
variability exhibited in this animal model.
An important limitation of this study is that repair was evaluated at only one time
point. This time period was chosen based on studies in the canine model that evaluated
the time-course of healing for untreated chondral defects and defects treated with ACI,
which indicated that most of the reparative tissue forms within 16 weeks following
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surgery.13 3 Whether the chronology of reparative processes in the goat is similar to those
observed in the dog is uncertain. Additionally, the implantation of the engineered tissue
construct employed in this study may affect rate of remodeling. As such, future studies
would benefit from evaluation of repair at multiple time points.
Comparison of the outcome variables from the untreated control defects in this
study with historical data from defects of identical size and anatomic location created in
canines and evaluated at a similar time point (3 months) reveals several differences in the
natural healing response between the two species. Defects in the caprine model exhibited
57±12% filling of the defect cross-sectional area (including matrix flow), with
fibrocartilage and fibrous tissue comprising the majority of the reparative tissue. Defects
in the canine model filled to only 36±7%, but the majority of the reparative tissue
consisted of hyaline and articular cartilage. These differences in amount and type of
reparative tissue may be related to the degree to which the calcified cartilage layer
remained intact. In the canine defects, 95±2% of the calcified cartilage was intact at 3
months, thus minimizing the contribution of cells and soluble regulators from the
subchondral space to the repair. While histologic examination of defects from goats
sacrificed at early time points in the currect study revealed nearly 100% intact calcified
cartilage up to 2 weeks post-surgery, the linear percentage of the calcified cartilage
remaining intact at 16 weeks was only 17±12%. Comparing data across several
treatments employed in the canine model, Breinan et al. demonstrated a correlation
between disruption of the calcified cartilage layer and the amount of reparative tissue
formation. 132 This is consistent with the finding in this study that the one implanted
defect exhibiting a fully intact calcified cartilage layer at 16 weeks resulted in the least
amount of newly synthesized tissue filling the defect space (6%). It may be that the
tendency toward post-operative disruption of the calcified cartilage and subchondral plate
in the caprine model leads to increased contribution of cells and regulators from the
subchondral space promoting improved filling of the defect.
That all cell-seeded constructs implanted in the animals sacrificed at short time
points were located within the defect sites at time of euthanasia demonstrates the efficacy
of the suturing procedure and external fixation protocol in preventing dislodgement of the
implants up through the initial week of ambulation. Additionally, the histologic
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observation of small scaffold remnants within the reparative tissue evaluated at 16 weeks
provides evidence of implant retention over the long term. While retention of the implant
within the defect space in important if it is to contribute to repair, suturing and joint
immobilization are not without disadvantages. Sutures tracks in the host cartilage were
observed histologically in several of the samples. The tissue bordering these newly
created defects displayed evidence of degenerative changes, such as loss of proteoglycan
as demonstrated by Safranin-O staining. Additionally, immobilization of the joint in
flexion resulted in static compression of the implant during the first week post-surgery.
As in vitro studies have indicated that subjecting chondrocyte-seeded type II collagen
scaffolds to static compression reduces biosynthetic activity of the cells, 199
immobilization of the joint in flexion may have adverse effects on the reparative process.
Future studies may investigate effects of alternative post-operative protocols (such as
continuous passive motion 210-218) on repair outcomes.
A notable finding of this study is the demonstration of PRG4 within the reparative
tissue filling both treated and untreated defects. While the origin of the cells in the
reparative tissue that stained positively for PRG4 is uncertain, the absence of staining in
histological sections from cell-seeded scaffolds that were not implanted indicates that
synthesis of PRG4 by cells in the reparative tissue was stimulated by factors within the in
vivo environment that may not be present in vitro. The observation of PRG4 staining at
the border of suture tracks and edges of repair tissue displaying poor integration with host
tissue raises the question whether the presence of the lubricating molecule hindered
integration of the tissues at these locations. That good integration of repair tissue with
host cartilage was achieved in the near vicinity of these items, however, suggests that the
presence of PRG4 may be an effect of the lack of integration rather than the cause. The
possibility that shear deformation experienced at the articulating surfaces and in regions
of non-integration stimulates synthesis of this lubricating molecule deserves further
consideration.
5.6 Conclusions
Although mean values of several outcome variables suggested improvement in
cartilage repair provided by the implantation of the chondrocyte-seeded scaffolds, the
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only effect determined to be statistically significant was a reduction in the formation of
fibrous tissue within the defect. Future studies will evaluate the effects of implanting
constructs with GAG contents 50% and 75% of that in normal cartilage, achieved by the
same methods described here, but extending the in vitro culture period prior to
implantation. Such studies will benefit from increasing sample numbers to account for
the large variability in this animal model revealed in this study.
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Chapter 6
Evaluation of a Composite Collagen
Implant for Repair of Osteochondral
Defects in a Caprine Model
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6.1 Introduction
Defects in articular cartilage that extend into the subchondral bone gain access to
cells and soluble regulators from the marrow and vasculature, leading to an improved
spontaneous healing response compared to defects that are fully retained within chondral
space. This healing response, however, does not lead to regeneration of the articular
cartilage, but rather results in the formation of fibrocartilaginous tissue. As the
mechanical properties of fibrocartilage differ from those of articular cartilage, the long-
term persistence of the repair tissue in load-bearing environments such as the knee or hip
remains in question. Additionally, there is evidence that large osteochondral defects
frequently exhibit incomplete filling of the bone and cartilage regions with reparative
tissue, degeneration of the surrounding tissue, and deformation of the joint surface.209
Biomaterial scaffolds, when implanted into osteochondral defects, may prevent collapse
of tissue into the defect space, promote filling of the defect with reparative tissue, and
serve as delivery vehicles for cells, growth factors, or genes that may facilitate repair.
Repair of osteochondral defects involves two distinct tissues: articular cartilage
and subchondral bone. The requirements of implants designed to facilitate repair of each
of these tissues are also distinct, and in some cases potentially contradicting (e.g.
mechanical properties and support/prevention of neovascularization,). In light of this,
several recent endeavors have focused on the development of composite (or multiphase)
scaffolds for treatment of osteochondral defects consisting of an osseous compartment
intended to promote bone formation and a compartment designed to promote
chondrogenesis.208 219 222
6.2 Objective and Hypotheses
The purpose of this study was to evaluate the potential benefits of a novel
composite scaffold for facilitating repair of osteochondral defects in a goat model. The
chondral region of the composite implant consisted of a type II collagen scaffold similar
to those employed in Chapter 4 of this thesis that supported differentiation of marrow-
derived mesenchymal stem cells and subsequent chondrogenesis in vitro. A novel bone
growth substitute material comprised of mineralized type I collagen formed the osseous
compartment of the implant. The hypotheses were that implantation of the composite
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collagen scaffold would improve bone formation within the subchondral region of an
osteochondral defect, and lead to greater total filling of the chondral space with a higher
percentage of cartilaginous tissue compared to untreated (empty) control defects.
6.3 Materials and Methods
6.3.1 Composite Collagen Implants
The composite collagen implants were provided by OrthoMimetics Limited. The
exact fabrication process and characterization are proprietary information and were not
made known to the author. The type II collagen material comprising the cartilaginous
compartment was the same as that employed in Chapter 4 of this thesis, kindly provided
by Geistlich Biomaterials (Wolhusen, Switzerland). The osseous compartment consisted
of mineralized type I collagen. Cylindrical implants (4 mm in diameter, 6 mm length)
were cut from blocks of the composite material that included a 5 mm thick compartment
of the mineralized type I collagen integrated with a 1mm thick type II collagen scaffold
(Fig. 6.1).
6.3.2 Animal model
Six female Spanish goats (ages 3-5 years) were used for this study. All protocols
for the animal experiment were approved by the Animal Care Committee of the VA
Boston Healthcare System. Prior to surgery, animals were roentgenographically
examined to exclude animals with degenerative joint disease of the knee (stifle).
All operations were performed with the animal under general anesthesia and using
sterile technique. The right knee was opened by an anteromedial approach and the
patella laterally displaced to expose the trochlea. Two defects, each 4 mm in diameter,
were created approximately 1.25 and 2.25 cm proximal to the intercondylar notch slightly
lateral or medial to the midline. A 4 mm diameter dermal biopsy punch was used to
outline the defect. Using loupe visualization, cartilage was removed from the defect
using a customized curette. Bone was then removed by low-speed drilling to a depth of 6
mm from the cartilage surface. A 4 mm diameter reaming instrument was employed to
create a perpendicular edge between the base and walls of the cylindrical hole. In 3
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animals, a scaffold (4 mm diameter by 6 mm length) was placed into each of the defects.
Defects in the remaining 3 animals remained untreated (empty). The knee joint was then
closed and immobilized by external fixation for 8 days, after which the animals were
allowed to ambulate normally until euthanasia at 16 weeks. Upon euthanasia, the knee
joints were opened, photographed, and grossly evaluated. The distal region of the femur
containing the defect sites was removed and prepared for histologic evaluation as
described below.
Mineralized
type I collagen
Figure 6.1 Implantation of composite collagen scaffolds in osteochondral defects in a
caprine stifle. (a) Immediately pre-implantation. (b) Immediately following implantation. The
scaffold on the right is beginning to be infiltrated with blood and marrow.
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6.3.3 Histological and Immunohistochemical Evaluation
Defect sites removed from the joint were fixed in 10% formalin for at least 1
week and decalcified in a 25% (w/v) ethylenediamine tetraacetic acid (EDTA, pH ~7.7)
for at least four weeks. These decalcified samples and formalin-fixed cell-seeded
constructs cultured in parallel to those implanted in the animals were dehydrated and
embedded in paraffin. Microtomed sections 6 pm in thickness were stained with
hematoxylin and eosin (H&E) or Safranin-O/Fast Green using standard histological
techniques.
Immunohistochemical staining of type II collagen was performed using the
LSAB-2 System (DakoCytomation, Carpinteria, CA) with a Dako Autostainer.
Deparaffinized and rehydrated sections were digested for 40 minutes in 0.1% protease
XIV (Sigma), followed by quenching of endogenous peroxidase activity with a
peroxidase blocking reagent (DakoCytomation). Non-specific binding was blocked with
5% goat serum (Sigma). The primary antibody (CIIC 1, mouse anti-chick type II collagen
monoclonal antibody, Developmental Studies Hybridoma Bank, Iowa City, IA) was
applied for 30 minutes. Negative controls were incubated with mouse IgG
(DakoCytomation) instead of the primary antibody. Labeling was detected by incubation
with a biotinylated secondary antibody for 15 minutes, followed by streptavidin-HRP (15
minutes) then AEC substrate chromogen (10 minutes, all from DakoCytomation).
Counterstaining was performed using Mayer's hematoxylin (Sigma).
Immunohistochemical staining of proteoglycan 4 (PRG4) was performed in an identical
fashion employing an antibody to PRG4 (from T.M. Schmid, Rush University Medical
Center, Chicago, IL.
6.3.4 Histomorphometry
A quantitative histomorphometric analysis of specific tissue types was used to
evaluate the tissue filling the chondral region of the osteochondral defects.6 4' 10" A recent
study evaluated the inter-observer error associated with this quantitative histological
method.133 One histological section from the center portion of each defect, stained with
hematoxylin and eosin, was evaluated. Digital micrographs of the defect and surrounding
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tissue were recorded. The total area of the tissue and the percentages of the specific
tissue types (hyaline cartilage, fibrocartilage, and fibrous tissue) filling the original defect
region were measured using ImageJ (NIH). Classical criteria relating to the morphology
of the cells and the presence or absence of lacunae and the composition and structure of
the extracellular matrix were used to distinguish these tissue types, as has previously been
reported.132 In brief, tissue was classified as hyaline cartilage if the cells were in well-
defined lacunae and there was no fibrous appearance to the extracellular matrix. The type
II composition and GAG content of the hyaline matrix was assessed in selected sections.
Normally, hyaline cartilage exhibits positive Safranin-O staining, although the intensity
can be variable., Fibrocartilage was identified as having rounded cells in lacunae but with
a distinct fibrous appearance to the matrix. Cells in fibrous tissue were elongated, with no
lacunae, and were surrounded by an extracellular matrix with a distinct fibrous
appearance and no detectable proteoglycan by Safranin-O staining. The amount of host
cartilage collapsing or "flowing" into the defect space and amount of bone ingrowth from
the subchondral space were also quantified.
6.3.5 Statistical Methods
Statistical significance was determined by analysis of variance (ANOVA) and
Fisher's PLSD post-hoc testing with a significance criterion ofp < 0.05 using StatView
(SAS Institute Inc., Cary, N.C.). All results are reported as mean + standard error of the
mean.
6.4 Results
6.4.1 Gross observations and qualitative histologic assessment of reparative tissue
At the time of sacrifice, all animals were ambulating normally. The lateral, distal
region of the trochlea in one animal that received implants (1 implanted, 1 untreated
control) displayed significant wear of the articular surface, with exposure of the
subchondral bone adjacent to the location of the implanted defect. No other joints
displayed signs of significant pathology, although there was evidence of slight
hypertrophy of the synovial tissue in some animals.
Gross examination at the time of euthanasia indicated that all the defect sites were
filled with reparative tissue to within ~ 0.5 mm of the articular surface, with tissue from
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one implanted defect appearing flush with the adjacent cartilage. Repair tissue was
grossly distinguishable from host cartilage, and the borders of all defects remained visible
to the naked eye (Fig. 6.2). No gross signs of residual collagen scaffold remaining in the
implanted defects were observed.
Figure 6.2 Osteochondral defect repair at 16 weeks.
6.4.1.1 Repair of chondral space
Histologic examination of the implanted defect that exhibited macroscopic wear
of the articulating surface revealed almost no native cartilage remaining above the
calcified cartilage layer surrounding the defect, and no repair tissue filling the chondral
portion of the original defect space, though newly formed bone and soft connective tissue
filled the subchondral region of the defect. The cartilage region of this sample was thus
excluded from further analysis.
Defects that were incompletely filled by reparative tissue generally contained
significant matrix "flow" in which host cartilage was observed collapsing or "flowing"
into the defect space (Fig. 6.3). Notable changes in the host cartilage near the edges of
the defects included chondrocyte cloning and loss of proteoglycan as indicated by
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reduced Safranin-O staining. In all but one case, repair tissue filling the chondral regions
of defects exhibited good integration with adjacent host cartilage.
Ir
Figure 6.3 Chondral repair tissue. Host articular cartilage (AC), matrix flow into defect space
(MF), fibrocartilaginous reparative tissue (FC). Approximate location of the original defect edge
is indicated by the black arrow. Hematoxylin and eosin stain. Scale bar = 500 im.
The majority of the repair tissue in both treated and untreated defects was
fibrocartilaginous. Fibrous tissue was evident in many of the samples, typically located
in the central region of the defects and at the surface of the reparative tissue. One sample
from the implant group contained a small amount of hyaline cartilage. Tissues classified
as hyaline or fibrocartilage in the morphometric analysis of H&E stained sections
contained proteoglycan and type II collagen as indicated by Safranin-O staining and
immunohistochemistry (Fig. 6.4).
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Figure 6.4 Type II collagen immunohistochemistry and Safranin-O staining of osteochondral repair
tissue. Type II collagen (a) indicated by reddish-brown chromogen. Safranin-O (b) indicated by red stain.
Dashed lines mark approximate location of original defect. Scale bars = 1 mm.
Repair tissue and surrounding host articular cartilage from all samples stained
positively for PRG4. In both host and repair tissues, a very dense layer of positive
staining approximately 6 pm in thickness was located at the articular surface (Fig. 6.5).
In regions of certain samples where the surface of the tissue was no longer intact, but
exhibited fissures or fibrillation, this layer of PRG4 staining followed the contour of the
fibrillated surface. Intercellular deposits of the chromogen employed in staining were
observed in chondrocytes near the cartilage surface to a depth of 175 ptm in many of the
samples. In other samples, however, no intracellular staining was observed. In one
sample exhibiting lack of integration at the interface of the host cartilage and the
reparative tissue, PRG4 staining was also located along the borders of both tissues (Fig.
6.6).
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Figure 6.5 PRG4 staining. (a) Host articular cartilage and (b) chondral repair tissue. Red
chromogen. Arrows indicate cells with intercellular deposits staining positively for PRG4. Scale
bars = 50 m.
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Figure 6.6 PRG4 staining along tissue surfaces in a region of poor integration of host
cartilage (left) and repair tissue (right). Scale bar = 100 gm.
6.4.1.2 Repair of subchondral space
The subchondral region in 5 of 6 defects treated with the collagen implants were
filled with a network of bony trabeculae that bridged the space between the edges of the
defects. In most cases the new trabeculae appeared slightly thinner than those of the
surrounding host bone. Medullary spaces within the trabecular network were filled with
marrow stroma, and were similar in size to those within adjacent host bone (Fig. 6.7).
Cartilaginous tissue from the chondral region frequently extended into the central portion
of the subchondral space to a depth ranging from 0.5-1mm from the original tidemark.
This tissue stained positively with Safranin-O and demonstrated the presence of type II
collagen immunohistochemically (see Fig. 6.4 above).
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Figure 6.7 Repair of osteochondral defects implanted with composite collagen scaffolds.
Dashed lines indicate the approximate location of the original 4 x 6 mm defects.
One defect treated with a collagen implant displayed a large mass of fibrous tissue
filling nearly half of the subchondral region of the defect, with a small amount of residual
collagen scaffold in the central region of the fibrous tissue (Fig. 6.8). There was no
evidence of residual collagen scaffold in any of the other samples.
Figure 6.8 Formation of fibrous tissue mass in subchondral region of implanted defect. The
image on the right is a magnification of the central region of the fibrous tissue mass. Arrows
indicate residual implant material. Scale bar = 100 Rm.
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Untreated control defects exhibited less new bone formation compared to the
implanted samples. New trabeculae within these samples were located at the base and
edges of the defects but typically did not span the central regions, which were filled with
marrow, fibrous, or cartilaginous tissues (Fig. 6.9a). Two of the untreated defects, and
one implanted defect contained a large marrow space absent of trabeculae at the base of
the defect comprising approximately half of the original defect cross-sectional area (Fig.
6.9b). Areas of soft tissue extending from the chondral space into the subchondral region
of the defects were larger and more fibrous than those observed in defects that received
the collagen implants.
6.4.2 Histomorphometry
Results from the histomorphometric evaluation of the amounts and types of tissue
filling the defects and the linear percentage of the calcified cartilage remaining intact are
presented in Table 6-1. ANOVA demonstrated no statistically significant effect of defect
location (i.e. proximal or distal) for all outcome variables, indicating that each defect
could be considered an independent observation. Mean values of defects receiving
implants were higher for total fill, hyaline cartilage, fibrocartilage, and matrix flow
compared to untreated control defects. The amount of fibrous tissue formation in the
chondral region of untreated controls was the same as that in implanted defects, and the
percentage of the subchondral space comprised of soft tissue was higher in untreated
defects. None of these differences, however, represented a statistically significant effect
of treatment (p = 0.14 for total fill, p>0.35 for all other outcome variables).
138
/U
Figure 6.9 Repair of untreated osteochondral defects at 16 weeks. Dashed lines indicate
approximate location of the original 4 x 6 mm defects. Black arrows indicate soft tissue.
Enlarged marrow space is indicated by the orange arrow. Hematoxylin and eosin.
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Table 6-1 Results of histomorphometric evaluation of reparative tissue filling chondral
region of osteochondral defects. Data are presented as percentage of original defect cross-
sectional area.
Implanted Defects Untreated Defects
Mean SEM Range Mean SEM Range
Total Fill 82 7 65-102 52 14 3-91
Hyaline Cartilage 2 2 0-12 0 0 0-0
Fibrocartila e 57 11 26-90 32 12 0-68
Fibrous Tissue 12±6 0-32 12 5 0-38
Bone ingrowth 0 0 0-0 0 ±0 0-3
Matrix Flow 10 3 0-19 6 ±2 0-13
6.5 Discussion
Although mean values from the histomorphometric evaluation of reparative
tissues filling the chondral region of osteochondral defects suggested benefit of the
implanted composite scaffold over untreated controls in several outcome variables (e.g.
greater total reparative fill, greater amount of hyaline cartilage and fibrocartilage), none
of the outcome variables demonstrated a statistically significant effect of treatment. As
was the case in the chondral repair study presented in Chapter 5, data for the outcome
variables in this study exhibited a high degree of variability, particularly in the untreated
control group. In determining the sample numbers used in this study, a 30% difference
between mean values for a given outcome variable (e.g. total fill or percentage of
hyaline-like tissue) was chosen as indicative of a meaningful benefit of one treatment
group over another. Sample number was thus chosen to detect a 30% difference in mean
values between groups, estimating the standard deviation for each group to be 20% of the
mean based on prior work in the canine model. The actual standard deviation for each
outcome variable in the untreated control group proved to be greater than 50% of the
mean value. As such, it is possible that increasing the sample numbers may have resulted
in demonstration of significant differences between treatment groups that were not
exhibited in the current analysis. Future studies may benefit from increased sample
numbers in order to account for the inherent variability exhibited in this animal model.
Qualitative differences evident in the subchondral region of the defects indicated
benefits of the composite collagen implants in promoting new bone formation. A
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network of bony trabeculae spanned the subchondral space of defects treated with the
implants. The medullary spaces within this network were of similar size to those in the
surrounding host bone. While some bone formation was evident along the walls and base
of the untreated defects, central regions of these samples contained far fewer trabeculae
and much larger medullary spaces compared to the adjacent host bone. Additionally,
untreated defects tended to exhibit more fibrous and fibrocartilaginous tissue filling the
subchondral region compared to defects receiving the composite implant.
Experimental studies in which osteochondral defects of similar size to those
employed in the current study were created in canine trochlea reported spontaneous
formation of cancellous bone covered by fibrocartilaginous tissue by 8-12 weeks. While
formation of cancellous bone within untreated control defects was observed in the current
study at 16 weeks, notable differences in architecture between the newly formed bone
and that of the native bone, particularly with regard to the large medullary spaces and few
trabeculae (Fig. 6.9), raises the question whether the tissue will withstand physiological
joint loading over the long term. Whether the more natural architecture of the cancellous
bone formed within the implanted defects by 16 weeks provides superior mechanical
support of joint loads and leads to improved repair over the long term warrants further
study. In this regard, an important limitation of this study is that repair was evaluated at
only one time point. This time period was chosen based on several cartilage repair
studies in a variety of large-animal models that have indicated that most of the reparative
tissue forms in chondral and osteochondral defects within 12-16 weeks following
surgery."1 32,13 3,20 6,20 8 However, much about the chronology of the reparative process in
osteochondral defects in the goat remains unknown. Future studies would benefit from
evaluation of repair at multiple time points.
A notable finding of this study is the demonstration of PRG4 at the surface of the
reparative tissue filling both treated and untreated defects. Intercellular deposits of PRG4
in cells within the superficial zone of the host cartilage and cells near the articulating
surface of repair tissue indicate the potential of these cells to synthesize this important
cartilage lubricating molecule. The presence of PRG4 at the surface of tissues lacking
positively staining cells suggests that the dense band of PRG4 at the articulating surface
may result from deposition of the molecule from the synovial fluid. Regardless of the
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origin, the presence of PRG4 at the surface of reparative tissues may facilitate low-
friction articulating motion within the joint.
The demonstration of PRG4 along the surfaces at the interface of host cartilage
and repair tissue exhibiting little integration raises the question whether the presence of
the lubricating molecule inhibited integration of the tissues. Indeed, Schaefer et al. have
recently reported the addition of PRG4 to culture media reduced integration of cartilage
explants in vitro.22 3 Whether a causal relationship exists between the presence of PRG4
and integration of cartilaginous tissues warrants further study.
6.6 Conclusions
The composite collagen implants evaluated in this study facilitated qualitative
improvements in repair of subchondral bone within osteochondral defects compared to
untreated control defects at 16 weeks. Although mean values of several outcome
variables suggested improvement in repair of the chondral region of the defects with
implantation of the construct, no statistically significant effect of treatment on cartilage
repair was demonstrated. Future studies will benefit from increasing sample numbers to
account for the large variability in this animal model revealed in this study. The presence
of PRG4 at the surface of reparative tissues represents a notable finding that warrants
further study.
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Chapter 7
Conclusions
143
144
In Chapter 1, the statement of the thesis was presented as follows: cell-seeded
type II collagen scaffolds exhibiting a degree of chondrogenesis achieved in vitro can
facilitate reparative processes when implanted into defects in articular cartilage. In the
following chapters, several studies investigating methods for increasing chondrogenesis
within cell-seeded type II collagen scaffolds in vitro were reported, along with two in
vivo studies examining the effects of cell-seeded and non-cell seeded implants on the
repair of chondral and osteochondral defects in a caprine model. The following
discussion reviews the key findings of these studies with regard to the initial objectives
and hypotheses. Limitations of the studies are addressed and suggestions for future work
are presented.
7.1 Effects of bioreactor culture environment
The objective of the first study was to compare the effects of a rotating-wall
bioreactor culture system and a static culture environment on chondrogenesis in
chondrocyte-seeded type II collagen scaffolds. Constructs cultured in the bioreactor
exhibited greater dry masses, but lower GAG synthesis rates and GAG accumulation, as
well as qualitatively less type II collagen content, compared to constructs cultured in
under static conditions for up to 2 weeks. These results led to the rejection of the
hypothesis that dynamic culture environment provided by the rotating-wall bioreactor
system accelerates chondrogenesis within chondrocyte-seeded type II collagen scaffolds
compared to static culture conditions during the first 2 weeks of culture.
One limitation of this study is that only short time points were examined. Most
studies involving bioreactor culture environments have focused on longer time points (4-
12 weeks) for the development of cartilaginous tissues. Future studies may evaluate
potential benefits of the bioreactor environment for overcoming diffusional limitations
that may be encountered as the porosity of the scaffold decreases with synthesis of new
tissue at longer time points.
A second limitation of this study is that only highly cross-linked scaffolds were
employed. Results of the study presented in Chapter 3 indicate that chondrocyte-seeded
scaffolds with high levels of cross-linking exhibited less chondrogenesis compared to
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scaffolds with lower cross-link densities. As the porosity of scaffolds with low cross-link
densities may be reduced at a more rapid pace than highly cross-linked scaffolds due to
cell-mediated contraction of the construct, mass transport characteristics provided by the
bioreactor may further promote chondrogenesis within the contracted scaffolds at short
time points.
7.2 Effects of scaffold cross-link density
The objectives of the studies presented in Chapters 3 and 4 were to evaluate the
effects of scaffold cross-link density (and associated resistance to cell-mediated
contraction and degradation) on chondrogenesis within chondrocyte-seeded and MSC-
seeded type II collagen scaffolds in vitro. Results of these studies indicated scaffolds
with low cross-link densities experienced cell-mediated contraction and displayed
increased GAG and type II collagen content, and a higher percentage of cells with
chondrocytic morphology, compared to more highly cross-linked scaffolds that resisted
cellular contraction, supporting the hypotheses that decreasing scaffold cross-link density
increases chondrogenic differentiation of MSCs and cartilaginous tissue formation within
MSC-seeded and chondrocyte-seeded type II collagen scaffolds in vitro. Prior work with
collagen scaffolds demonstrated that variation of scaffold cross-link density affects
cellular migration, contraction, mitosis, and biosynthetic activity in vitro,164,224 as well as
histogenesis in vivo. In addition to these effects, the results of the work presented in
Chapters 3 and 4 of this thesis add the important findings that varying scaffold cross-link
density can also direct cellular differentiation and histogenesis in vitro.
Varying scaffold cross-link density can affect numerous scaffold properties,
including stiffness, degradation rate, and availability of ligands, thus complicating the
identification of the variable (or combination of variables) responsible for the observed
differences in chondrogenesis. Future studies may investigate methods of isolating
individual variables in order to better understand their effects on cartilaginous tissue
formation.
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7.3 Effects of chondrocyte-seeded type 11 collagen scaffolds on cartilage repair
To begin to test the effects of implant compositional maturity (viz. GAG content)
on in vivo cartilage repair outcome, chondrocyte-seeded type II collagen scaffolds
achieving GAG content approximately 30% of that in normal cartilage were implanted in
chondral defects in a caprine model and the repair tissue evaluated at 15 weeks. Results
of this study were presented in Chapter 5. The reparative tissue consisted primarily of
fibrocartilage, and also contained small amounts of hyaline tissue. Implantation of the
cell-seeded construct reduced the amount of fibrous tissue formation compared to
untreated controls, but did not demonstrate statistically significant effects on other
outcome variables. A notable finding from this study was the presence of PRG4 in
reparative tissues formed in both implanted and control chondral defects.
Data from this study revealed a large degree of variability inherent in the repair
outcome of chondral defects in this animal model. As such, one limitation of this study
was the small sample size. Design of future studies may benefit from increasing sample
numbers in order to account for this variability.
A second limitation of this study is that repair was evaluated at only one time
point (16 weeks). Prior studies in a canine model evaluating the repair of untreated
chondral defects and defects treated with implantation of chondrocytes alone indicated
that most of the reparative tissue formed by this time. The extent to which the
chronology of reparative processes in the goat is similar to those observed in the dog is
uncertain. Additionally, implantation of the cell-seeded scaffolds may alter the natural
time course of healing. Future studies may benefit from evaluating effects of cell-seeded
implants at multiple time points.
In order to more fully understand effects of implant compositional maturity on in
vivo cartilage repair processes, further studies are required in which the amount of
cartilage formed within the implants is varied. As such, future animal investigations are
planned that will evaluate the effects of implanting constructs with GAG contents 50%
and 75% of that in normal cartilage, achieved by the same methods described in this
thesis, but extending the in vitro culture period prior to implantation.
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7.4 Evaluation of a composite collagen implant for osteochondral repair
An additional in vivo study was conducted to evaluate the benefits of a composite
construct comprised of a non-cell-seeded type II collagen scaffold and a bone graft
substitute material for treating osteochondral defects in a goat model. These implants
exhibited qualitative improvement in repair of subchondral bone with regard to number
and size of trabeculae and medullary spaces, but did not demonstrate statistically
significant improvements in repair of articular cartilage compared to untreated controls.
The results of this study thus support the hypothesis that implantation of the composite
collagen scaffold improve bone formation within the subchondral region of an
osteochondral defect, but do not validate the hypothesis that implantation of the construct
leads to greater total filling of the chondral space with a higher percentage of
cartilaginous tissue compared to untreated control defects.
As with the chondral repair study reported in Chapter 5, data from this study
revealed a large degree of variability inherent in the repair outcome of osteochondral
defects in this animal model. As such, one limitation of this study was the small sample
size. Design of future studies may benefit from increasing sample numbers in order to
account for this variability. An additional limitation is that repair was evaluated at only
one time point (16 weeks). In order to better understand the time course of healing of
osteochondral defects in the caprine model, future studies may evaluate repair of
untreated defects or implantation of biomaterial constructs at multiple time points.
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Appendix 1
Pilot Studies: Seeding Marrow-derived
Stem Cells in Collagen Scaffolds
165
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A1.1 Introduction
One important problem encountered when employing autologous chondrocytes
for tissue-engineering approaches to cartilage repair is morbidity of the site from which
the cells are obtained. Defects created in healthy cartilage during the biopsy are not
expected to heal and may further degenerate, compromising the integrity of the
surrounding joint surface. Much work has been reported recently identifying alternative
sources of cells with chondrogenic potential, including cells derived from periosteum,
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bone marrow, 78-83 synovium, 84-89 and adipose tissue.90-97 The use of such cells for
cartilage repair procedures could circumvent the problem of donor site morbidity
encountered with the use of native chondrocytes.
In Chapter 4, a study was reported investigating the effects of scaffold cross-link
density (and related cell-mediated scaffold contraction and degradation) on
chondrogenesis when employing of bone marrow-derived mesenchymal stem cells
(MSCs) as an alternative to chondrocytes. Several reports in the literature have indicated
difficulties achieving homogeneous cell distributions when seeding MSCs in porous
scaffolds. Farrell et al., reported that rat MSCs seeded onto type I collagen scaffolds
aggregated at the surface of the constructs, with little infiltration observed until the cells
began to migrate through the scaffold between the second and third week of culture. 20 3
Takahashi et al. encountered similar difficulties when seeding MSCs in a non-woven
polyethylene terephtalate scaffolds using a variety of seeding techniques. In this case, the
authors demonstrated that a homogenous distribution of MSCs within the scaffolds could
be achieved at the time of seeding, but required a dynamic seeding technique in which the
constructs were vigorously shaken (300 rpm for 6 hours) within a high concentration cell
suspension.2 04 In light of these findings, several pilot studies were conducted in order to
investigate methods of seeding MSCs in type I and type II collagen scaffolds with the
goal of achieving a homogenous distribution of cells throughout the volume of the
constructs within 24 hours of seeding.
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A1.2 MSC Seeding Pilot Study 1
A 1.2.1 Materials and Methods
Porous type II collagen scaffolds were fabricated by freeze-drying a porcine-
derived type II collagen slurry (1% w/v; Geistlich Biomaterials, Wolhusen, Switzerland)
to form sheets approximately 2.5 mm thick, as described in Section 3.4.1. Morphometric
analysis of the pore structure performed as previously reported16 ' resulted in a pore
diameter of 190 + 25ptm. Type I/III collagen scaffolds were fabricated in identical
fashion from porcine-derived type I and type III collagen (Geistlich Biomaterials). Disks
8 mm in diameter cut from the porous sheets were sterilized and cross-linked by
dehydrothermal treatment' 62,163 under a vacuum (50 mTorr) and temperature of 105'C for
24 hours. Further cross-linking was achieved by treatment with a water-soluble
carbodiimide.164'165 Further cross-linking was achieved by treatment with a water-soluble
carbodiimide164 '165 as described in Section 3.4.4, with EDAC:NHS:COOH ratios of either
5:2:5 or 5:2:1.
Adult caprine MSCs from a single animal were isolated and expanded in
monolayer as described in Section 4.3.2, but without addition of FGF-2 to the culture
medium. Passage 2 MSCs were seeded onto the type 1/111 and type II collagen scaffolds
(n=2) by pipetting a suspension of 2x106 cells in 20 pl medium onto each surface of the
scaffold (total 4x10 6 cells per scaffold) as described in Section 4.3.3. Cell-seeded
scaffolds were cultured in chondrogenic medium (see Section 4.3.2) for 2 weeks, then
processed for histology.
A 1.2.2 Results
All scaffolds experienced cell-mediated contraction during the 2 week culture
period, with type I/III collagen scaffolds exhibiting greater reduction in diameters
compared to type 11 collagen scaffolds at both cross-link densities (Fig. A1.1). Histologic
observation demonstrated aggregation of the cells at the surfaces of the scaffolds, with
very little cellular infiltration into the central regions of the scaffolds (Fig. A1.2). Large
regions of the cell aggregates at the scaffold surfaces appeared necrotic. However, a
small region of newly synthesized tissue stained positively with Safranin-O, indicating
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the presence of GAG, and contained cells with chondrocytic morphology, demonstrating
the potential of these cells to differentiate to a chondrocytic phenotype.
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Figure A1.1 Contraction of MSC-seeded collagen scaffolds with time in culture.
Mean ± SEM (n=2).
A1.2.3 Discussion
MSCs seeded onto type I/111 and type II collagen scaffolds of various cross-link
densities demonstrated initial aggregation of the cells at the scaffold surfaces and very
little cell migration into the central regions of the scaffolds during the 2-week culture
period. These results are similar to those reported by Farrell et al.203 While there was
evidence of chondrocytic differentiation of some cells, methods of improving cellular
infiltration of the scaffolds are needed in order to fabricate a cartilaginous construct
within a 2-week timeframe.
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Figure A1.2 MSC-seeded collagen scaffolds at 2 weeks. (a) Cross-sectional image.
Black arrow indicates newly synthesized tissue. Yellow arrow indicates necrosis. Scale
bar = 1 mm. (b) Magnified image of newly synthesized tissue showing chondrocytic
cells and positive Safranin-O staining. Scale bar = 20 gm.
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A1.3 MSC Seeding Pilot Study 2
Based on aggregation of cells at the scaffold surfaces and the lack of cellular
infiltration of the scaffolds observed in the first pilot study, a second pilot study was
conducted to investigate the effects of cell seeding density on distribution of MSCs
within the scaffolds. Type I/III and type II collagen scaffolds were seeded with a total of
.2x0 cells (1x10 6 cells in 20 jI medium per side of scaffold) using the pipetting
technique described above, and culture for 2 weeks in chondrogenic medium. Histologic
examination of the constructs again demonstrated aggregation of the cells at the scaffold
periphery, with very little infiltration into the central region of the constructs.
A1.4 MSC Seeding Pilot Study 3
While the first two pilot studies indicated poor infiltration of the MSCs into
porous collagen scaffolds, seeding chondrocytes into the scaffolds under identical
conditions resulted in homogenous distribution of cells throughout the volume of the
scaffolds. One difference noted between chondrocytes and MSCs is the size of the cells;
when observed in hemacytometer during cell counting, the projected area of the MSCs in
the suspension is approximately 3-4 times larger than that of chondrocytes (Fig. A1.3).
As such, it was hypothesized that the large size of the MSCs may be hindering their
infiltration of the porous scaffolds. Solchaga et al. reported that expanding MSCs in the
presence of FGF-2 resulted in ~ 30% reduction in the size of the cells, and had further
benefits increasing cellular proliferation in monolayer and subsequent chondrogenesis in
a pellet culture assay.226 Based on these findings, a third pilot study was conducted to
test the effects of reduction in cell size (induced by FGF-2 supplementation) on initial
distribution of cells in the scaffolds.
Two additional variables were also examined in this pilot study: seeding
technique and pre-wetting of the scaffolds. A dynamic seeding technique using an orbital
shaker was chosen based on reports by Takahasi et al. of improved cell distributions
when employing this technique compared to static seeding methods (viz. pipetting).
Finally, the effects of pre-wetting the scaffold with alcohol to reduce their hydrophobicity
were evaluated.
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Figure A1.3 Cell size. Chondrocytes (left panels) and MSCs (right panels) in
suspension above a hemacytometer. Bottom panels are magnified images of cells shown
in corresponding images in top panels. Scale bars = 25 gm.
A1.4.1 Materials and Methods
Type 1/111 collagen scaffolds were fabricated as described above, and cross-linked
using a EDAC:NHS:COOH ratio of 5:2:5. Half of the scaffolds were then immersed in
100% reagent alcohol for 30 minutes, washed 3 times in dH20 for 1 hour each, then
stored in dH2 0 overnight.
MSCs from 3 animals were isolated and expanded as described above, with or
without the addition of FGF-2 (IOng/ml) to the culture medium. Following 2
subcultures, 2x10 6 MSCs were seeded into each of the collagen scaffolds either by
pipetting as described above, or by incubation of the cells and scaffold with 250 gl of
culture medium in the bottom of a 50 ml conical centrifuge tube on an orbital shaker at
300 rpm for 4 hours. Cell-seeded constructs were then cultured under static conditions in
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12-well tissue culture plates for 48 hours, and processed for histology or analysis of DNA
content.
A1.4.2 Results
Analysis of the DNA content of the cell-seeded constructs indicated that 75-100%
of the cells attached to the scaffolds, with no significant differences among groups.
However, histologic observation again demonstrated aggregation of the cells at the
periphery of the scaffolds, with very little infiltration of the cells into the central region of
the constructs (Fig. Al.4).
Figure A1.4 Aggregation of MSCs at the periphery of collagen scaffolds. Right
panel is a magnified image of the top surface of the scaffolds shown in the left panel.
Hematoxylin and eosin stain.
A1.5 MSC Seeding Pilot Study 4
In the first 3 pilot studies, the porous structure of the scaffolds was not changed,
due to an objective of comparing tissue formation by chondrocytes and MSCs when
cultured in the same scaffolds. In this final pilot study, the porous structure of the
scaffold was changed in an attempt to improve the distribution of the MSCs within the
scaffolds.
A 1.5.1 Materials and Methods
Porous type 1I collagen scaffolds were fabricated as described in Section 4.3.1.
Compared to the scaffolds employed in Chapters 2 and 3 and the first 3 pilot studies
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described above, these scaffolds were thinner (1.5mm vs. 2.5mm) and had a larger pore
diameter (- 350 gm vs. 190 gm).
MSCs from 3 animals were expanded as described above, supplementing the
culture medium with FGF-2 (10 ng/ml). Cells (P2) were seeded onto the scaffolds (4x10 6
cells per scaffold) using the pipetting technique. Scaffolds were culture for 24 hours in
chondrogenic culture medium and processed for histology.
A1.5.2 Results
Histologic observation demonstrated good infiltration of the MSCs into the
central regions of the scaffolds. The distribution of the cells appeared generally
homogenous throughout the volume of the constructs (Fig. A 1.5).
Figure A1.5 Distribution of MSCs in collagen scaffolds with large pore diameters.
Hematoxylin and eosin stain. Scale bar = 200 pm.
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Appendix 2
Internalization of Quantum Dots by
Chondrocytes In Vitro
175
176
A2.1 Introduction
An important aspect of cartilage repair procedures involving delivery of cells is
the extent to which the cells are integrated into new repair tissue or other host tissues
within the body. While certain markers allow localization of delivered cells in tissues
harvested up to a few weeks following implantation, the fate of these cells at longer time
points remains uncertain.
In recent years, much work has been reported involving the development of light-
emitting semiconductor nanocrystals, often referred to as quantum dots (QDs). The
intense brightness, resistance to photobleaching, and narrow emission spectrum
dependent on QD size and composition represent significant advantages of employing
QDs over other traditional fluorescent markers. Tagging individual cells with QDs may
provide opportunity for longer-term tracking of the cells in vivo. As such, the objective
of this pilot study was to examine the ability of chondrocytes to internalize QDs.
A2.2 Materials and Methods
Adult canine chondrocytes were isolated from articular cartilage and expanded in
monolayer through 1 subculture. Following trypsinization, the cells were plated in 12-
well tissue culture plates at a density of 2.7x10 4 cell/cm 2 and incubated in expansion
medium (see Section 2.4.2). After 24 hours, the expansion medium was replaced with
250 pl of expansion medium containing 25 gl of a solution containing QDs at a
concentration of 1.3 gM, for a final QD concentration in culture medium of 0.13 jiM.
Following 24 hour incubation with the QDs, the medium was removed, and the cells
washed 5x 10 min. in PBS, then imaged with a confocal microscope.
A2.3 Results
Clusters of QDs were observed around many of the chondrocytes. Analysis of the
confocal images indicated that while a few clusters of QDs could be found internalized
within the cells, most of the QDs were attached to the cell surface (Fig. A2.1).
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A2.4 Discussion
This pilot study provides evidence of the ability of chondrocytes to internalize
QDs, suggesting potential use of these nanoparticles for in vivo cell tracking. Further
study will be required to determine any effects internalized QDs may have on cellular
processes.
Figure A2.1 Top: projection of a stack of confocal images onto a single plane
demonstrating QDs internalized by chondrocytes, and attached to the cell surfaces.
Bottom: location of the cells from the top image viewed by transmitted light.
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Scaffold Fabrication Protocols
Type II Collagen Slurry Preparation
Materials
" Type II collagen-GAG material (Geistlich Biomaterials, Wolhusen Switzerland)
" Hydrochloric acid (Fisher Cat. # A508-212)
Procedure
1. Prepare 0.001N HCl
" Add 50 g stock 12.lN HCl to 6.05ml dH 20 to make 0.IN HCl.
* Dilute 1:100 in dH 20 (example, 2ml 0.IN HCl in 198ml dH 20).
* pH to 3.0
2. Add type II collagen (1% w/v)
0 Example, add 2g type II collagen to 200ml 0.001N HCl
3. Cool solution with an ice water bath while blending at 15,000 rpm for 3-5 minutes.
4. Transfer slurry to 50ml tubes.
5. Centrifuge at IOOOg for 3 minutes to remove air bubbles.
If the viscosity of the slurry is low, centrifuging may result in a higher density of
collagen at the bottom of the tubes. Always mix by aspirating with a pipette several
times to ensure homogeneity. Be sure not to introduce air bubbles when aspirating.
6. Transfer slurry to pans for freeze-drying, or store at 4'C.
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Type I/I1 Collagen Slurry Preparation
Materials
" Type I/III collagen powder (BioGide, Geistlich Biomaterials, Wolhusen
Switzerland)
* Hydrochloric acid (Fisher Cat. # A508-212)
Procedure
1. Prepare 0.00 IN HCl
" Add 50gl stock 12.1N HCl to 6.05ml dH 20 to make 0.1N HCl.
* Dilute 1:100 in dH20 (example, 2ml 0.1N HCl in 198ml dH 20).
* pH to 3.0
2. Add type I/III collagen (1% w/v)
* Example, add 2g type II collagen to 200ml 0.001N HCl
3. Stir while checking pH. Adjust pH to 3.0 with HCl.
4. Cool solution with an ice water bath while blending at 15,000 rpm for 10 minutes.
.5. Stir while checking pH again. Adjust pH to 3.0 with HCl.
6. Blending at 15,000 rpm for another 10 minutes.
7. Transfer slurry to 50ml tubes.
8. Centrifuge at 1 OGOg for 3 minutes to remove air bubbles.
If the viscosity of the slurry is low, centrifuging may result in a higher density of
collagen at the bottom of the tubes. Always mix by aspirating with apipette several
times to ensure homogeneity. Be sure not to introduce air bubbles when aspirating.
9. Transfer slurry to pans for freeze-drying, or store at 4"C.
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Porous Collagen Scaffold Fabrication
Adapted from protocols of Fibers and Polymers Laboratory (Prof I. V. Yannas),
originally written by Brendan Harley.
Summary
Sheets of porous, collagen scaffolds are prepared by controlled lyophilization. Pore
structure (pore size, porosity, etc...) of the scaffolds is determined by the freezing rate
and final temperature of freezing.
References:
O'Brien, et al., Biomaterials 2004; 25:1077-1086
Materials
" Collagen-glycosaminoglycan suspension
* 5" x 5" stainless steel pans or plastic molds
* Virtis Genesis freeze-dryer
Procedure
1. Turn on the freeze-dryer:
" Check that the vacuum oil level is at least 2/3, the oil appears clean, and that the
vacuum pump is properly vented (either outside or into a fume hood)
* Plug the drain valve leading from the condenser and close the condenser door
* Turn the main Power switch on
" Turn the Condenser switch on
* Set the SV gauge to 20'C and turn on the Freeze and Heat switches
* You need to leave approximately 60 minutes for the freeze-dryer temperature to
stabilize and for the condenser to reach a cold enough temperature to continue.
2. Clean the stainless steel pan with ethanol and wipe the inside with Kim-Wipes to
removal all dust and remaining collagen. When cleaning and handling the pan, do not
touch the inside of the pan with your bare hands. Use gloves. Allow the pan to air dry.
3. Pipette desired volume of CG suspension into the pan or mold. For metal pans, 50 ml
slurry yields sheets ~ 3 mm thick. For plastic molds, use ~ 21 ml slurry.
4. Remove an air bubbles introduced into the pan using a 2 00 pl pipette tip. Drag the
bubbles to the edge of the pan, allowing them to stick to the edge. Place the pan into
the freeze-dryer.
5. Check the appropriate program is selected using the wizard controller. Press the
button under Program X (X = 1 - 12) (Button #1) on the digital display. Select the
appropriate program number using the Up and Down keys and then press the Edit
key. Check the program following the appropriate progression. If the progression is
incorrect, correct the values. Use the outer two buttons to scroll left or right through
the program and the inner two keys to change the value of the selected criteria to
match the program.
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Program 2: Ramp to -40'C. Total time from start to sublimation: -135 minutes
Average pore size: 95.9 ± 12.3pjm.
Percent Porosity: 0.995
Specific Surface Area (S.A./Vol): 0.00748 ptm- _
Freezing Step Temperature, 'C Time, min R/H
1 (start) 20 5 H
2 ("ramping") 40 15 R
3 ("annealing") -40 > 60 H
Program 3: Ramp to -30'C. Total time from start to sublimation: -105 minutes
Average pore size: 109.5 + 18.3ptm.
Percent Porosity: 0.995
Specific Surface Area (S.A./Vol): 0.00655 pm-
Freezing Step Temperature, 0C Time, min R/H
1 (start) 20 5 H
2 ("ramping") -30 10 R
3 ("annealing") -30 > 60 H
Program 4: Ramp to -20'C. Total time from start to sublimation: -90 minutes
Average pore size: 121.0 + 22.5 pm.
Percent Porosity: 0.995
Specific Surface Area (S.A./Vol): 0.00593 pm- _
Freezing Step Temperature, 'C Time, min R/H
1 (start) 20 5 H
2 ("ramping") -20 10 R
3 ("annealing") -20 > 60 H
Program 5: Ramp to -10'C. Total time from start to sublimation: ~80 minutes
Average pore size: 150.5 ± 32.1pim.
Percent Porosity: 0.995
Specific Surface Area (S.A./Vol): 0.00477 pm-
Freezing Step Temperature, 'C Time, mm R/H
1 (start) 20 5 H
2 "ramping") -10 5 R
3 ("annealing") -10 > 60 H
NOTES:
0 In all cases, step 3 should run for 60 minutes, but it is given a longer time in case
you are delayed in returning. It is acceptable for that step to run longer than 60
minutes, as you are just canceling the program after 60 minutes to start the
vacuum.
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0 All values given for pore structures are for slurries prepared from bovine type I
collagen and chondroitin-6-sulfate, freeze-dried in metal pans.
6. After confirming the program, press the two middle keys on the Wizard together to
cancel out of the program. Select the Save option from the menu. The Wizard screen
should return to the original screen seen at start-up.
7. Turn off the Freeze and Heat buttons, turn the Auto button on, and press the Start
key. The program should start running. Leave the program to run for the specified
length of time.
8. At the end of the 60 minute annealing period, cancel the program. Press the middle
two buttons on the wizard controller together, and then when prompted press the
outer two keys. Turn off the Auto switch, then turn on the Freeze and Heat switches
and set the SV to the appropriate temperature of freezing (-10, -20, -30, or -40'C).
9. Turn on the Vacuum switch. Make sure the seal on the condenser and chamber doors
in tight and put pressure on the door to the condenser until a vacuum pressure
registers on the pressure reading in the wizard control screen (typically ~1900mTorr).
10. When the vacuum pressure reaches below 300mTorr, raise the temperature in the SV
display to 00C. Allow the freeze-dryer to run for 17 hours at a temperature of 0"C and
a pressure <300mTorr.
11. After 17 hours, raise the value of the SV control to 200C. Wait for the chamber
temperature to equilibrate to 20'C (temperature displayed in the PV display). Turn off
the Vacuum switch and turn on the Chamber Release switch. Wait for the pressure to
be equilibrated. Remove the pan.
12. Turn off the freeze-dryer:
* Turn off the Chamber Release switch
* Turn off the Freeze and Heat switches
* Turn off the Condenser Switch
" Turn off the Power Switch
" Open the condenser door, unplug the condenser drain line and place it into the
drain bucket.
13. Remove the CG scaffold from the pan with gloved hands. Place the scaffold into an
aluminum foil packet and store in a desiccator.
14. Wash the stainless steel pan with ethanol or 0.05M acetic acid and wipe down with
Kim-Wipes to remove any portion of the scaffold that may have torn during removal.
15. Return the pan to storage.
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16. Make notation on run sheet attached to the front of the freeze-drier in order to keep
track of the total number of runs between oil changes. When a row is completely
checked off (8 freeze-drier runs), the vacuum oil needs to be changed.
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Cross-linking Collagen Scaffolds by Dehydrothermal (DHT) Treatment
Summary
Cross-links are formed by removal of bound water from collagen molecules, resulting in
condensation reactions between the carboxyl and amino groups on adjacent amino acid
side chains. (From Weadock, et al., below).
References
Weadock, et al., J Biomed Mat Res, 1995; 29: 1373-1379.
Procedure
1. Place matrix in aluminum foil bags (leave one end open).
2. Place in vacuum oven at 105 C.
3. Turn on vacuum pump (should reach 50 mtorr).
4. Remove after 24 hours.
Notes: Longer treatment times can increase cross-link density.
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Cross-linking Collagen Scaffolds by Carbodiimide Treatment
Summary
"Contrary to the use of bifunctional reagents like GA (gluteraldehyde), [carboxylic acid
activation] methods do not result in the incorporation of cross-linking agents in the
material.. .Cross-linking using [EDAC] involves the activation of the carboxylic acid
groups of glutamic or aspartic acid residues... Cross-links are formed after nucleophilic
attack by free amine groups of lysine or hydroxylysine residues" (Olde Damink, et al.
t996).
References
Olde Damink, et al., Biomaterials, 1996; 17: 765-73.
Lee, et al. Biomaterials, 2001; 22: 3145-3154.
Materials
" 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC)
MW = 191.7 g/mol (Sigma #E-7750; stored in desiccator at -20'C)
" N-hydroxysuccinimide (NHS)
MW = 16g/mol (Sigma #H-7377; stored in dessicant at room temp)
" Sterile, distilled water
* 50 ml centrifuge tubes or smaller if only cross-linking few matrices
* Phosphate Buffered Saline (PBS; Invitrogen #4190-250)
" Sterile filter (0.22gm) and sterile container
" Sterile pipettes and pipetteman
Procedure
1. Let EDAC warm to room temperature for about 30 minutes before use in order to
prevent condensed moisture inside bottle.
2. Hydrate matrices using sterile, distilled water.
3. Calculate the amounts of EDAC and NHS required for desired molar ratios of
EDAC:NHS:COOH, according to the following equations:
# Scaffolds x g collagen mol COOH mol EDAC g EDAC = g EDAC
scaffold g collagen mol COOH mol EDAC
#Scaffoldsx g collagen mol COOH mol NHS g NHS#Safdsxx x x = gNHS
scaffold g collagen mol COOH mol NHS
Notes: We make the assumptions that the scaffolds are primarily collagen (i.e., the mass
of other components is negligible), and that there are 1.2mmol COOH per mole of
Collagen (see Olde Damink). Typical values for mass of 8mm scaffolds is 2-3 mg.
188
Typical calculations for molar ratios of 5:2:1 would be as follows:
0.002g collagen 0.00 12mol COOH 5 mol EDAC 191.7g EDAC50 scaffoldsx x x x = 0.1l5g EDAC
scaffold g collagen 1 mol COOH mol EDAC
0.002g collagen 0.0012mol COOH 2 mol NHS 116g NHS
50 scaffolds x x x x = 0.278g NHS
scaffold g collagen 1 mol COOH mol NHSC
Notes: The amounts ofEDAC and NHS required are frequently very small and difficult
to weigh out, especially when only a small number of scaffolds are required. It is often
easier to weigh out a larger amount of the chemicals, dissolve in dH2O, and dilute to the
desired concentration.
4. Dissolve EDAC and NHS in dH20.
The final volumes should be Jml solution per scaffold.
5. Sterile filter EDAC/NHS solutions into sterile containers.
6. Transfer hydrated matrices to EDAC/NHS solutions.
Hydrated scaffolds will retain a small volume of water within the pores, which will
cause the final concentration of the EDAC/NHS solution to be very slightly diluted. If
this is a concern, hydrate the scaffolds in half of the final volume (i.e. 0.5ml dH2O per
scaffold), prepare the EDAC/NHS solution at 2X the final desired concentration, and
add the solution directly to the water in which the scaffolds being hydrated.
7. Pipette solution over matrices to ensure good mixture.
8. Cross-link at room temperature for desired time (usually 30 minutes).
9. After cross-linking, transfer matrices to 50ml centrifuge tubes. Rinse matrices in
sterile PBS. Pipette out PBS and put fresh PBS and allow removal of residual
NHS/EDAC solution by rocking on nutator for about 1 hr.
10. Remove PBS and rinse in sterile dH20 for 10 minutes twice.
11. Store matrices in sterile dH20 at 4*C for up to one week (effects of longer storage
unknown, usually used within 1 days of cross-linking).
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Swelling Ratio Analysis
Summary
The swelling ratio of collagen-based specimens is inversely related to the cross-link
density for randomly coiled polymer networks. Absolute values of the cross-link density
are obtained provided that the collagen-based specimens have been gelatinized in
conditions that lead to ideal rubber-like behavior.
References
Yannas, et al., J Biomed Mater Res 1980;14:107-32.
Weadock, et al. Biomater Med Devices Artif Organs 1983; 11:293-318
Materials:
Distilled water Thermometer
Hot plate Filter paper sheets (Whatman #2)
100 ml beaker 1.0 kg weight
Tweezers
Procedure:
1. Fill beaker with distilled water and heat to 90'C on hot plate. Place thermometer
inside beaker to adjust the hot plate over time.
2. Place matrix in the hot water bath for 2 min. in order to denature the collagen and
allow it to swell with water. Samples will shrink in size.
3. Expel water from pores by placing hydrated matrix between sheets of filter paper
with the 1.0 kg weight placed on top for 20 seconds. Need sufficient number of
filter papers (4-5 per side) so that there is no water visible on the outer layers of
the filter paper when the weight is taken off.
4. Immediately weigh sample and record as wet mass (Mw).
5. Dry samples in oven overnight at 1 10 C.
6. Weigh samples and record as dry mass (MD).
7. The swelling ratio (SR), defined as the inverse volume fraction of dry collagen
(V), is calculated from the wet and dry masses and the densities of collagen (pc
1.32 g/cm 3) and water (p= 1.00 g/cm 3) according to the following equation:
SR -= 1 (MD jc ) + ((MW - MD )/,)]
Vf MD/Pc
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Analysis of Scaffold Pore Structure
Procedures
Slides should be stained with aniline blue prior to image acquisition.
Image Acquisition
* Photograph samples at 4x magnification.
" Photograph scale bar slide at same magnification for length calibration.
* Save images in BMP or TIFF format (analysis software does not read JPG files).
Image Pre-processing
" Open the image in Scion Image
" Click on Threshold in the Options menu. Slide red region on the palette bar to
optimize the selection of matrix struts without selecting pore space.
* Click on Binary under the Process menu. Click on Make Binary. The pixels
will then be assigned to black or white.
Pore Analysis
1. Load the "pore characterization macros" by using Load Macro under the Special
menu.
2. Run Compute Percentage Area [P] under the Special menu.
The % value in the little data window is the black percentage of the area, which can
be converted to porosity by subtracting it from 100.
3. Select an area of the image with the oval drawing tool.
To get a circle, hold the down the shift key at the same time you are using the oval
tool. Try to get as much of the image in the selected area as possible.
4. Calibrate the Scale
* Determine the scale of your images (# pixels/mm) using a captured scale bar
image at the same magnification from which matrix images were captured.
* Select Set Scale from the Analyze menu.
* Change the units to mm. In the measured distance box enter 1. In the known
distance box, enter the number of pixels in 1 mm.
5. Run Linear Intercept under the Special menu. This will produce the mean intercept
length between scaffold struts along directions incremented by 5 degrees in the
selected area.
6. Run Plot Intercepts in the Special menu. This will plot the results from step 5 and
the calculated best-fit ellipse. Another window will give parameters of the ellipse:
CO, Cl, C2.
7. Transfer the CO, C1, and C2 data to an Excel spreadsheet. Determine the mean pore
diameter from the major and minor axes using the following equations:
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1
a=
CO + JC'+ C2
b JIC + C2
C C + C2 + C2 C
aspect ratio (AR)= a/b
pore diameter = 3a+b
2
The factor '3' comes from 2 (converting radius to diameter) multiplied by 1.5
(multiplication factor used to take into account the underestimate of pore diameter due to
angle at which pore was sectioned). The majority of pores will not be sectioned along
their true cross-section, but rather at an arbitrary angle which would skew their calculated
pore size. This multiplication factor corrects this underestimate (See Gibson and Ashby,
Cellular Solids: Structure and Properties, 1999).
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Cell Culture Protocols
Chondrocyte Harvest and Isolation
Modifiedfrom H. A. Breinan, BWH Orthopaedics Research Lab and Kuettner et al., 1982
and C. Lee Thesis, 2001
Materials
If removing only shavings (eg: for subsequent autologous seeding):
50 ml tubes with PBS
Scalpel handle (#3)
Scalpel blades (2 #10)
Sterile gloves
If removing whole joint
Surgical saw
Sterile specimen bags
Sterile towels/wrap
Sterile PBS to moisten towels
Sterile petri dish (100 mm)
Sterile spatula
Sterile forceps (2)
Solutions:
1) Proteae solution (20 U/ml), ~ 40ml/2 joints
Dissolve appropriate amount of protease
medium without FBS)
50ml centrifuge tubes
Small, sterile stir bar
Clean stir plate in incubator
PBS
T-75 and/or T-25 tissue culture flasks
Sterile cutting board
in media (usually use expansion base
V x20Ul/ml
pronase(mg) = U/mg#Un its 1 mg
where V=volume of solution (usually ~ 40ml/2 joints).
* Sterile filter (0.22gm) solution (use syringe filter; allow time for protease to
dissolve and it may be difficult to pass solution through filter).
2) Collagenase solution (200 U/ml), ~ 40ml/2 joints
" Dissolve appropriate amount of type II collagenase (Worthington Biochemical
CLS2) in media (this dissolves quickly)
collagenase(mg) = Vx200Uml
#Units / mg
where V= volume of solution.
* Sterile filter solution using a 0.2gm syringe filter
Procedure
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1. Open joint and remove slices of articular cartilage from joint surfaces. Place in PBS
(or in tubes and store on ice if harvesting in OR).
" Don't dig into the hard calcified cartilage or subchondral bone. Cartilage
should offer little resistance to the blade; full thickness slices should be 0.5-
1. 5 mm thick depending on joint location
" If harvesting whole joint, open joint in sterile hood, cutting ligaments and
removing menisci; take cartilage from tibial, femoral and patellar surfaces
" If slices are large, cut into pieces no larger than 3x3xlmm
2. Using forceps and spatula, transfer cartilage pieces into tube/bottle with stir bar and
protease solution. ***Cap loosely*** to allow air exchange.
3. Incubate I hr (37 C, 5% GO 2) on spinner plate.
4. Centrifuge the protease and tissue solution, remove the protease, and resuspend pellet
in collagenase solution.
5. Incubate overnight (maybe as short as 4-6 hours until all tissue is digested) on spinner
plate. ***Make sure cap is loose***
6. Strain through 40-70 gm pore strainer into new 50ml centrifuge tube.
7. Centrifuge (10 min @ 1500 rpm).
8. Aspirate media and resuspend pellet in media; centrifuge again and resuspend in
known amount of complete media to do cell count (usually 10-20ml).
9. Count cells and assess viability.
10. Plate in culture flasks or freeze.
194
Freezing Cells
References
Rendal-Zaquez, et al., Crybiology, 2001; 42: 2-10.
Materials
Complete medium (including 10% FBS)
Dimethyl sulfoxide (DMSO; Sigma D2650)
Sterile, DMSO safe, syringe filters
Pipettes
Sterile cryogenic tubes
Nalgene Cryo 1* C Freezing Container (Cat #5100-0001)
Procedure
1. Determine amount of medium needed (1 ml per 2x10 6 cells).
2. Prepare solution of 10% DMSO in complete medium.
Sterilize the medium +DMSO solution by filtering through 0.22 pm sterile filter,
or by autoclaving DMSO prior to adding it to the medium.
3. Adjust cell concentration to 2x 106 cells/ml of complete medium + DMSO solution.
4. Pipette into cryogenic tubes (1 ml per 2 ml tube).
5. Place tubes in Nalgene freezing container in the -80'C freezer overnight. If Nalgene
container is not available, place tubes at -20'C for 2-4 hours, then transfer to -80 0 C
overnight.
6. Transfer to liquid nitrogen tanks.
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Thawing Cells
Materials
Complete medium
Tissue culture flasks
37'C water bath
Aspirating pipettes
Vacuum suction
Sterile pipettes
Pipette Aid
15 ml tubes
Procedure
1. Place cell vials directly into a 37 0C water bath. Agitate gingerly while cells thaw for
40-60 seconds.
2. When defrosted minimally (see liquid around outer edges) slowly add complete
medium one drop at a time until tube is full.
3. Transfer the cells to a centrifuge tube and wash them clean of medium+DMSO for 10
minutes in the centrifuge.
4. Count the cells, and resuspend at the proper concentration. Cells should be cultured
at least 3-4 days before being used for experimentation (or before changing medium,
depending on when they attach).
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Culture Media for Chondrocytes
Summary
Expanding chondrocytes in medium supplemented with serum and the listed growth
factors enhances proliferation, dedifferentiation, and capacity to redifferentiate to a
chondrocytic phenotype when returned to a 3D culture system (e.g. pellets or scaffolds).
Redifferentiation is greatest when the 3D culture medium is serum-free, and contains the
listed supplements (excludes FGF).
References
Jakob, et al., J Cell Biochem 2001;
Base Medium
Ingredient
DMEM (Gibco 10313-021)
MEM Nonessential Amino Acids
(Gibco 11140-050)
Hepes Buffer (Gibco 15630-080)
PSG (Gibco 10378-016)
Monolayer Expansion Medium
Add the following to Base Media
Ingredient
Fetal Bovine Serum
(FBS: Gibco 10270-106)
TGF-1 (R&D 240-B-002)
FGF-2 (R&D 233-FB-025)
PDGF-PP (R&D 220-BB-010)
81(2): 368-377
Amount
500ml
5ml
5ml
5ml
Notes
High glucose (4.5%) w/o
L-Glutamine, w/ Sodium Pyruvate
10mM solution
Make IM solution, sterile filter
10,OOOU/ml of penicillin,
10,000 pg/ml streptomycin
glutamate
just prior to use.
Amount
~10%
lng/ml
5ng/ml
lOng/ml
Notes
Ex., add 50ml FBS to the 515ml base
Add 1Il stock per lml media
Add 0.5pl stock per Iml media
Add I jtl stock per lml media
To passage cells, before trypsinization, incubate cells with 0.15% collagenase type 2 in
PBSfor 10 minutes
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3-D culture / Re-differentiation Medium
Add the following to 515ml to Base Media (add supplements just prior to use)
Ingredient Amount Notes
ITS +1 (Sigma #12521) 5ml Liquid Media Supplememt (IOOX)
Human Serum Albumin (HSA) 5m If not using human cells, use BSA at
1.25mg/ml of media
TGF-p1 (R&D 240-B-002) 1Ong/ml Add 10pd stock per 1 ml media
Dexamethasone (Sigma ????) OnM Add 10pIl stock per 1 ml media
L-Ascorbic acid 2-phosphate 0.1mM Add 10d stock per 1 ml media
Reconstitution of growth factors
TFG-P I (R&D 240-B, Recombinant Human)
"Purified recombinant human TGF-PI is an extremely hydrophobic protein that adheres
strongly to surfaces. To ensure recovery, lyophilized samples should be reconstituted
with sterile 4mM HCl containing lmg/ml BSA or HAS to a final TGF-11 concentration
of no less than Ip g/ml."
For 2tg of TGF-s3I:
* Make 0.1N HCl ( add 0.5ml of stock 12.1N HCl to 60.5ml dH2O)
" Make desired amt. of 4mM HC1 (ex. 0.1ml of 0.1N HC to 2.4ml dH2 O)
" Add 2.5mg BSA to 2.5ml 4mM HCl. Vorex and sterile filter.
" Add 2ml of 4mM HCL+BSA to 2ptg TGF-3 1 for stock concentration of 1p g/ml.
* Aliquot in sterile microtubes and store at -70*C up to 3 months. Avoid repeated
freezing.
FGF-2 (R&D 233-FB, Recombinant Human FGF Basic)
"It is recommended that sterile phosphate-buffered saline containing at least 0.1% HSA
or BSA and ImM DTT (???) be added to the vial to prepare a stock solution of no less
than O1g/ml of the cytokine."
For 25pg of FGF-2
" Add 0.0025g BSA and 0.0004g DTT to 2.5 ml PBS
" Sterile filter
" Add above solution to 25pg FGF-2 for stock concentration of 10ptg/ml
* Aliquot in sterile microtubes and store at -70*C up to 3 months. Avoid repeated
freezing.
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PDGF- p (R&D # 220-BB, Recombinant Human)
"It is recommended that sterile 4mM HCl containing at least 0.1% (lmg/ml) HAS or
BSA be added to the vial to prepare a stock solution of no less than 10tg/ml of the
cytokine."
For 10pg of PDFG-P
" Make 0.lN HCl ( add 0.5ml of stock 12.1N HCl to 60.5ml dH 20)
" Make desired amt. of 4mM HCl (ex. 0.lml of 0.lN HCl to 2.4ml dH2O)
" Add 2.5mg BSA to 2.5ml 4mM HCl. Vorex and sterile filter.
* Add lml of 4mM HCL+BSA to 10tg PDGF-pp for stock concentration of
10tg/ml.
" Aliquot in sterile microtubes and store at -70'C up to 3 months. Avoid repeated
freezing.
Supplements
Dexamethasone (Dex: Sigma # ???, water soluble)
There is ~65mg dexamethasone per gram of powder. MW of dexamethasone
392.5g/mol
" Make 10-3 M dexamethasone stock solution. Store for 1 year at -20'C.
o Add 6.03mg Dex. powder to 1ml of 100% ethanol.
" Make 10-5 M dexamethasone stock solution in low-glucose (LG) DMEM.
o Add 20pl of 10 3 M Dex. stock to 1.98ml LG-DMEM.
" Aliquot and store at -20'C.
L-Ascorbic acid 2-Phosphate
I pI of a 1/100 dilution of ascorbate 2-phosphate (MW = 289.54g/mol)
. Add 37.5 mg ascorbate 2-phosphate + 10 ml Tyrodes solution
. Tyrodes solution is made from Tyrodes salts and prepared following the instructions
that came w/ the Tyrodes bottle. For preparation of 100ml of Tyrodes solution:
" Add lg of Tyrodes salt + 90ml of dH20 (15-20'C)-gently stir the water while
adding salt until completely dissolved
" Add 0.lg sodium bicarbonate or 1.33 ml of sodium bicarbonate solution
(7.5%w/v) for each liter of final volume of medium being prepared (ie. 0.01g
sodium bicarbonate for 1 00ml of Tyrodes solution). Stir until dissolved.
- While stirring, adjust the pH of the medium to 0.1-0.3 pH units below the desired
pH since it may rise during filtration (desired pH is 8.0) using IN HCl or IN
NaOH
- Add additional water to bring the solution to the final volume (ie. 1 00ml)
" Sterilize immediately using a 0.22 ptm filter
" Double check pH of the solution each time solution is used
" Store the dry powdered salts at 2-8'C under dry conditions and liquid medium at
2-8'C in the dark.
Dry salt is no longer good if there is a color change, granulation! clumping, or
insolubility. Liquid medium is no longer good if there is a pH change, precipitate
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or particulate matter throughout the solution, cloudy appearance, or a color
change.
* Sterile filter the ascorbate 2-phosphate solution and store frozen (-20'C) in 2ml
aliquots
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Harvesting Mesenchymal Stem Cells from Bone Marrow
Protocol written by T. Gotterbarm, 2006
Materials
2x 50ml Falcon Tubes (per Goat)
12x 15ml Falcon Tubes (per Goat) (white cap, round bottom Falcon 352059)
lx DMEM-low glucose (Invitrogen cat# 11885-092) Stored in cold room at 4'C
lx FBS 45 ml (heat inactivated) (Invitrogen cat# 16000-044) Stored at -20'C
Ix 10 ml Penicillin-Streptomycin (Invitrogen cat# 15140-122) Stored at -20'C
Ix Phosphate Buffered Saline (PBS-Invitrogen cat# 14190-250) Stored at 4*C
Ix Ficoll-Paque PLUS (GE Life Sciences cat#17-1440-02) Stored at 4*C
lx 20 ml syringe
lx 18 gauge needle
2x Jamshidi Bone Marrow Needles, 8G x 4 inches (10cm) manufacturer cat# DJ4008X
Henry Schein cat # 9018239)
3x Heparin Lock Flush Solution 5 ml in lOml syringe (BD cat# BD3065 10)
T-150 Culture Flasks (VWR cat# 15705-074)
T-75 Culture Flasks (VWR cat# BD353136)
Expansion Media
Make sterile media in the hood as follows:
* Get one 500 ml bottle of DMEM-low glucose and warm to 37 0C in the water bath
0 Thaw one tube of 45 ml Fetal Bovine Serum and one tube of 10 ml Penicillin-
Streptomycin
* Remove 50 ml of DMEM Bottle and save in a 50 ml in the refrigerator (4C)
0 To the remaining 450 ml add:
* 45 ml (the whole tube) of FBS
* 5 ml IOOX Pen/Strep
0 Mix gently by inversion (avoid bubbles)
* Label bottle with date and 10%FBS, 1%P/S, and your name
Isolate MSC enriched Lymphocyte layer from Bone Marrow
" Warm PBS and Ficoll-Paque PLUS to room temperature
* Prepare a 50 ml aliquot of PBS in Falcon tube
" Prepare an 18 ml aliquot of Ficoll into one 50 mL Falcon tube
o The Ficoll comes in a bottle with a rubber seal. Take off the white top. Leave the
aluminum.
o Take a 20 ml syringe and 18 gauge needle and put 5 ml air into the bottle
o Remove 18-20 ml into the syringe.
" Remove the needle and push the Ficoll into the 50 ml tube
Prepare the tubes for gradients as follows:
" Take 12 x 15 ml tubes and place in a rack with 6 tubes in front and 6 tubes behind
* Label the front tubes PBS or P and the back tubes Ficoll or F
* Using 1 ml pipetman, aliquot
o 2 ml PBS into each P tube (front) and
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o 3 ml of Ficoll into the F tubes (back)
Note: the Ficoll is viscous so pull up in the 1 ml pipetman slowly
Bring to ARF OR: 2 x 50mL tubes for each goat, Jamshidi bone marrow needles
(sterile)
Collect anticoagulated bone marrow from iliac crest placing each side in a tube. Collect no more
than 2ml per side into 10ml Heparin containing syringe (Heparin/Bone Marrow Ratio 1:2)
Return to the tissue culture hood:
" Mix the aliquots form both sides into one 50ml Falcon tube
* Take 2 mL of anticoagulant treated blood and add to 2 mL of PBS, mix well
" A good draw will give you 12 mls or 6 tubes of BM+PBS
* Using p 1000, gently and slow layer the 4 ml BM+PBS onto the 3 ml of Ficoll, don't mix
* This will give you 6 gradients to spin
" Spin in Allegra Tabletop Centrifuge at 3000 rpm, for 30 minutes, at 20C, decel= 0
" Label clean 50 mL Falcon tubes (sterile) one per goat
* Remove the gradient from Centrifuge and put back in the hood, don't shake!
The top should be a slight reddish color and the bottom should have the red blood cells pelleted
" Take the top 2 ml off with an aspirating pipet. This will take off the sticky white layer at
the top containing most of the platelets.
* DO NOT come near the interface between plasma and Ficoll gradient
" Take p1000 and remove the whitish band at the interface and put in the 50 ml tube.
" Take two times 1 ml in total from the white layer, above and below
Avoid taking red clotted blood. It may be white, or it may have some red with it. Don't worry
about the red. Just collect everything at the interface and make a note of what it looked like.
This is the low density "Lymphocyte layer" containing MSCs, Lymphocytes, Monocytes and
some Platelets.
* Transfer all 6 "layers" for 1 animal into one 50 ml tube
" Add PBS to the 50 ml mark
" Invert to mix
Centrifuge 1500 rpm for 10 minutes, decel= 3, temp = 20C
" Aspirate supernatant, leaving a little so as not to disturb the pellet.
" Add 5 ml PBS, mix gently but thoroughly with the pipetaid
* Add PBS up to the 50 ml mark
Centrifuge 1500 rpm for 10 minutes, decel= 3, temp = 20C
* All Platelets should know be washed out of the cell pellet.
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" Resuspend the pellet in 10 ml DMEM-lg, 10%FBS, P/S (at 37C)
" Count 5 ul + 195 ul Trypan Blue (1:40)
Depending on how big the pellet you may want to dilute sample to 15 or 30 ml and then dilute
and count the cells. If the draw is good you will get 50-100 million cells.
I like to plate 50 million cells in a T-75 with 15 ml of expansion media
And 100 million cells in a T-150 with 30 ml of DMEM-lg (Density: 600,000 /cm 2)
Leave for 2 days before changing the media for the first time, you should see cells attaching and
in a good prep there will be some cells starting to elongate after 2-3 days.
When you change the media, if you see attaching cells, rinse the flask with 37C PBS and then add
the new media (also at 37C)
If you don't see attachment, don't rinse, just change the media.
Change the media every other day (Mon-Weds-Fri), can go over the weekend Friday to Monday
At 80% confluence, freeze PO cells at le6 cells /ml, 500 ul/tube = 5e5
Or if you have a great many cells put 1 ml of the 1 e6 cells/ml in a tube.
Expansion of MSCs in monolayer cultures
Expansion Media:
DMEM-Low Glucose
(take out 50 ml)
Add 45 ml FBS (10%)
Add 5 ml Pen/Strep (1%)
For each ml of media that you are using add lul/ml of FGF (1 Ong/gi) to enhance
chondrogenic differentiation potential.
Thaw PO cells from liquid nitrogen (carry on ice) and put at 37 0C or hold in hand to thaw
and add 1 ml of expansion media place into a 15 ml Falcon tube. Add another ml of
media and the rest of the PO and put into the tube with 10-15 ml expansion media.
Spin at 1500 rpm (375g) for 10 minutes, 20 0C.
Aspirate supernatant and resuspend pellet completely in 10 ml expansion media.
Count cells using a 1:4 dilution 25 ul in 75 ul Trypan Blue. Count 10 squares.
Figure total cell number by the formula # of cell in 10 squares/10 * 4 * 10 * 104.
Assess viability
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For plating use 200,000 viable cells in a T-75 and 400,000 cells in a T- 150
(2.6x 10E3/cm 2)
We call these cells P1.
Incubate at 37 0C for 2 days. The cells will adhere in the first 8 hours.
Change media three times a week. Day 3,5,7. Can leave over the weekend.
When cells have reach 80% confluence, split and start another culture at the same density
for P2.
Splitting protocol:
Make Collagenase at 0.15% in PBS. Use 5 ml for a T-75, 8 ml for a T-150.
Thaw Trypsin/EDTA.
Remove supematant form P1 cells. Add 5 ml (T-75) collagenase and incubate 5 minutes
at 37 0C.
Remove and place in 15 ml Falcon tube.
Add 5 ml Trypsin (warm) at incubate at 37 0C for 5 minutes.
Tap side of flask to unclump and remove from bottom. Check to see that all cells are free
from the bottom. If not incubate a little longer. When cells are all off the bottom, add to
15 ml Falcon tube.
Add 5 ml DMEM expansion medium. = 15ml.
Spin at 1500 rpm for 10 minutes, 20C.
Remove supernatant. Resuspend in 1 Oml Expansion media and count as before.
Plate at the same density as before.
Cells are ready to use at 80-90% confluence.
204
Passaging Cells
Materials
Complete medium Sterile plastic pipettes
Trypsin-EDTA (Gibco 25300-062) Centrifuge tubes
Phosphate-buffered saline (PBS; Gibco 14190-250) Tube holders
Aspirating pipettes Tissue culture flasks
Vacuum setup
Procedure
1. Warm the medium, trypsin, and PBS in 37 0C water bath.
2. Remove medium from flasks with vacuum pipette (change pipettes for different
animals).
3. Rinse with PBS (enough to cover bottom of flask, ~ 10 ml for 75 cm 2 flask).
Trypsin will not detach the cells if it has come into contact with the serum.
4. Remove PBS.
a. If culturing chondrocytes, add 0.15% type II collagenase (Worthington #CLS2,
10ml for 75 cm 2 flask) for 10 minutes. Collect collagenase (and any detached
cells) and add trypsin (0.5 ml per well of 6 well plate, 2 ml for 25 cm 2 flask, 5 ml
for 75 cm 2 flask - may need more if cells aren't detaching well).
b. If culturing other cell types, collagenase may not be necessary.
5. Place in incubator for 5 minutes (unless otherwise instructed).
6. Remove from incubator and tap on the sides of the flask to loosen the cells. Check
under microscope to ensure the cells are no longer attached. If they are, return them
to the incubator and check each minute until they are unattached.
7. Once the cells are floating, return to the hood and add complete medium to inactivate
the trypsin (1.5 ml per well of 6 well plate, 3 ml for 25 cm 2 flask, 10 ml for 75 cm 2
flask).
8. Using a sterile plastic pipette, transfer the medium/trypsin/cell suspension to a
centrifuge tube. At this point you can combine the contents of the flasks if they are
from the same sample.
9. Balance the tubes and centrifuge at 1500 rpm for 10 minutes.
10. Once you have the cell pellet at the bottom of the tube, draw off the medium with the
vacuum pipette (be sure not to draw up the cells!!!).
11. Resuspend and count the cells. While counting, centrifuge the cell suspension a
second time to ensure all trypsin has been removed.
12. Decant medium from second centrifugation and resuspend at desired seeding density.
Transfer to culture flasks and add complete medium to bring the flasks up to final
volume.
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Cell Counting
Adapted from Current Protocols in Cell Biology Online 2001 John Wiley & Sons, Inc.
Materials
Complete medium
Trypan Blue
70% ethanol
Micropipetters
Calculator
Hemacytometer
Procedures
1. Clean hemacytometer and coverslip with 70% alcohol.
2. (Optional) Wet edge of coverslip slightly with tap water
and press over grooves on hemacytometer. The coverslip
should rest evenly over the silver counting area.
3. Beginning with a cell pellet, suspend the cells in a known
amount of complete medium
4. Collect a 100 RI sample from the cell suspension and dilute
with trypan blue (1:2 dilution if few cells are expected, 1:5
or 1:10 if a large number is expected).
5. Mix well. Collect 15 pA of suspension in a micropipette tip.
6. Load the cell suspension into the hemacytometer, allowing
it to be drawn under the coverslip by capillary action.
Load just enough cell suspension to reach the edges of the
silvered surface. Do not overfill as this may change the
volume and make the count inaccurate.
7. Count cells in each of the central and four corner squares
(clear cells are viable, stained cells are dead). Count cells
that lie on the top and left lines but not those on the bottom
or right lines of each square in order to avoid counting the
same cells twice for adjacent squares. Repeat counts for
other counting chamber. A maximum cell count of 20 to 50
coverslip
grid
load cell
sspension
1mm
1mm
cells per lxl-mm square
is recommended. When a count of living cells is complete, count the number of dead
cells in order to report viability.
8. Calculate total cell number from the following:
T _ - c x D x104xV
Ns
T = Total number of cells in suspension
Nc = Number of cells counted.
Ns Number of squares counted.
D = Dilution factor
V = Volume of media used to suspend cell pellet.
The number 10 4 is the volume correction factor for the hemacytometer: each square
is lxI mm and the depth is 0.1 mm.
9. Begin preparing samples for culturing and freezing.
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Pipette tips
Seeding Scaffolds
Materials
SeaPlaque Agarose (BioWhittaker #50101)
Sterile forceps
Sterile filter paper
Complete medium
12-well culture plates
Procedures (Pipette Method)
1. Prepare and autoclave 2% (w/v) agarose (2g in 100ml dH20).
2. Pipette 1.5 ml agarose into each well of 12-well plates and allow to harden. Warm in
incubator at 37*C prior to use.
3. Pre-wet matrices in PBS for 1 hour. (Matrices will already be wet if cross-linked by
EDAC).
4. During this time, passage cells from flasks. Suspend cells at desired concentration.
Use 50 gl of cell suspension for each 8 mm disc. For example, for a desired
concentration of 2 x 106 cells/disc, the concentration should be 4 x 107 cells/ml.
5. Transfer matrices to medium for at least 10 minutes.
6. Briefly dry matrices on sterile filter paper (allow enough time for liquid to be drawn
out, but do not allow matrices to dry completely, as they can become difficult to
remove from the filter paper).
7. Transfer matrices to warmed 12-well plates.
8. Pipette 25 gl onto one side of each matrix. After 10 min., flip matrices and pipette 25
gl onto the opposite sides.
9. Place matrices in incubator for 1 hour.
10. Add 0.5 ml medium (or enough to just cover matrices) to each well.
11. The following day, add another 1.0 ml medium to each well.
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Radiolabeling Protocol
Written by Cvndi Lee, adaptedfrom MIT Continuum Electromechanics Lab protocol
General Outline
1) Label disks during final 24 hrs of culture with 35-S and 3-H to measure GAG and
collagen synthesis, respectively
2) Wash unincorporated radiolabel
3) Lyophilize tissue and measure dry weights
4) Papain or Proteinase K digestion - use digest for GAG, DNA, and scintillation
counts
Materials needed
1) Latex gloves (double glove)
2) Tape for labcoat sleeves
3) Aluminum foil to line hood
4) Complete DMEM/F12 (10%FBS, 1% Antibiotic/Antimicotic, 25gg/ml Ascorbic
Acid)
5) Sterile 15ml or 50ml centrifuge tube
6) Pipetman - 20ul and/or 200ul
7) Sterile pipette tips - 200ul capacity
8) Vacuum flask and sterile pasteur pipettes
9) Radionuclide (35-S and 3-H)
10) PBS
11) Na 2SO 4 and proline
12) Clean spatula/forceps
13) 48 well culture plate (doesn't have to be sterile, can reuse)
14) Sterile pipets
Preparation of radioactive media (1.5 ml media/disk; V=1.5n+2ml):
1) Calculate volume of isotope needed:
For 35-S half-life is 87.4 days:
C(1uCi / ml ) = 10000 pCi / mlx2 4
volume 5S - V(ml )x10 UCi / ml
C(ApCi / ml)
where (x = #days past calibration date)
For 3-H half-life is 8-9 years:
Always at 1000 Ci/ml
volume 3H = V(ml)x20uCi / ml
I000pCi / ml
2) Wipe hood with 70% EtOH
3) Line with aluminum foil
4) Double glove and tape lab coat sleeves
5) Aliquot calculated volume of media into centrifuge tube
6) Place radionuclide in hood on aluminum foil and loosen cap
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7) Use sterile technique to aliquot calculated volume of 35-S
8) Save lml media for calibration
9) Add calculated volume of 3-H
10) Save 1 ml media for calibration
11) Remove pipette tips to original wrapper and dispose of in radioactive waste container
12) Return radionuclides to container and note amount used; return to refrigerator
13) Warm media in incubator
14) Rinse pipetman in cold water
15) Check pipetman and hood with geiger counter
Labeling disks:
1) Aspirate spent media
2) Feed disks with radiolabeled media
3) Return pipette to paper wrapper and dispose of in radioactive waste container
4) After 8-24 hours, radiolabel is complete
Washing disks:
1) Complete PBS with 0.8 mM Na2SO 4 and 1.0 mM proline
a. For 500ml PBS: 0.057 g Na 2SO 4 and 0.057 g proline
b. Recommended to make fresh wash solution each time; can make frozen
stock solutions of proline and sulfate and dilute in PBS
2) Aliquot Iml PBS/well in 24 well culture plate
3) Line hood with aluminum foil
4) Use clean spatula to transfer disk to top row of 48 well plate
5) Place in refrigerator for 15 minutes
6) Transfer disks to 2nd row and refrigerate for 15 minutes
7) Repeat for a total of four washes
8) Dispose of radiolabeled media in sink and note amount of radioactivity disposed
9) Place each sample in a labeled vial
10) Optional: Save PBS from last row (1 from each group) to make sure thoroughly
washed (radioactive counts ~ background)
11) Lyophilize, measure dry weight, digest... (for DNA, GAG, scintillation counting)
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Scintillation Counting of Radiolabeled Matrices
(Taken from T. Gordon M.S. thesis, modified by S. Vickers 1- 11-05)
Summary
Radioactive counts of matrix digests and calibrated medium are measured with the
Packard 1600 TR liquid scintillation counter and used to determine incorporation rates of
proline and sulfate as measures of protein and proteoglycan biosynthesis.
Protocol
Combine 100 pl of sample digest or calibrated medium with 4 ml of scintillation fluid
(CytoScint ES, ICN Biomedicals Inc., Irvine, CA). If the counts are too low or high, you
may have to add more or less than 100 pl of digest; make up the balance with dH20.
Counts per minute (cpm) are measured with the Packard 1600 TR liquid scintillation
counter on the 3rd floor of the Medical Research Building at the Jamaica Plain VA.
Channel 1 (also referred to as channel A) records activity from 0.5 - 18.6 keV, channel 2
(or, channel B) records activity from 18.7 - 156 keV, and the machine counts for 3
minutes/sample (or less if it determines accuracy to 2a before this period). After
determining the spillover percentage (discussed below), the cpmA and cpmB can be
converted to nanomoles of incorporated radiolabel.
Quenching effects were assumed to be constant throughout all measurements and are,
therefore, not directly treated in the calculations.
After samples are counted, the vials with scintillation fluid and radioactive digest should
be dumped into the barrel for liquid scintillation vials.
Theory
It is not possible to isolate all the counts for both radionuclides into separate channels
when counting a dual-labeled sample, since the energy vs. cpm curve for the
radionuclides will overlap (see figure below). However, it is possible to isolate tritium.
The maximum energy of 3H counts is 18.6 keV, so by setting the upper limit of channel 1
to this value, all 3H counts will occur in channel 1 and none will spill over into channel 2.
The lower limit of channel 1 is set at 0.5 keV to eliminate any low energy noise.
Unfortunately, 3S counts extend from 0 to 167 keV, so some of the counts in channel 1
will be due to 3S and some will be due to 3H. However, it can be assumed that the
spillover percentage (i.e. the percent of the total counts per minute of 35 S that occur in
channel 1) remains constant. This is the case because the shape of the energy vs. cpm
curve remains the same, regardless of the amount of 35S in the sample. This spillover
percentage can be determined by counting a sample that is labeled with 3S alone, and
then used to isolate the counts for each radionuclide.
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------------- 3H
35S
18.6 keV
Calculating Spillover, Total 3s S, and Total 3H Counts
When preparing the radiolabeled medium for cell culture, a sample of medium labeled
with 35S alone and a sample labeled with both 35S and 3H should have been saved (see
radiolabeling grotocol). The spillover percentage, aspill, can be determined from the
counts of the P5S labeled sample as follows:
asvill = cpmA3Ss/CpmB 35s
Since the shape of the 35S energy curve is assumed to be the same in both your samples
and your standard (regardless of the difference in total 35S content), aspill is a constant,
and can be used to determine how many of the counts in channel A of your sample
(cpmA) are from 35S and 3H respectively. The counts in channel A due to 35S are
cpmAS = aspill * cpmB
Once cpmA3Ss is found, the counts in channel A due to 3H can be found by simply
subtracting
CPMA3H = cpmA - cpmA3Ss
Since there are no counts in channel B coming from 3H, the total number of counts from
the 3H is
Cpm3H= pmA3H
The total counts from both channels due to 35S can also be computed by
CPM3Ss = cpmA35s + cpmB = (I + aspill ) * cpmB.
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The spillover percentage should also be used to determine the total counts for S and 3H
in the sample of double-labeled medium to use as a standard in the calculations for the
next section. These are then
cpm 35S, standard = (1 + aspill) * cpmB35S+ 3H
cpm3H, standard = CpmA35S+ 3H - (gspill * cpmB35S+ 3H)
Calculating the fractions of available proline and sulfate incorporated
into the ECM
The percentage of the total available radiolabeled proline incorporated into the protein
manufactured during the radiolabeling period uproline is given by the ratio of the
radioactive proline in the digested sample (as measured by cpm3H) to the radioactive
proline concentration of the culture medium (the known amount of radioactive proline
you added to the medium, measured as cpm3H, standard). The calculation for cqsufate is
analogous. The expressions for these fractions are
aproline = Cpm3H/Cpm3Hstandard
asulfate = Cpm 35S/Cpm
35Sstandard
Next, we assume that the percentage of available, unlabeled proline/sulfate incorporated
into the ECM by the cells is the same as the percentage of available, radiolabeled
proline/sulfate incorporated (i.e. the cells have no preference whether the molecule is
radiolabeled.) Furthermore, assume that the amount of proline/sulfate added in
radiolabeled form is insignificant compared to the concentrations of unlabeled
proline/sulfate in the medium. Strictly speaking, the total number of moles of
proline/sulfate incorporated into the ECM is the sum of the radiolabeled proline/sulfate
and the unlabeled proline/sulfate, but if you assume the labeled molecules are negligible,
you can ignore their contribution to the total number of moles of incorporation. Then the
proline/sulfate incorporation is due only to the unlabeled proline/sulfate taken out of the
medium by the cells in order to synthesize collagen and proteoglycans, respectively. The
following calculation demonstrates the validity of the assumption that the amount of
added radiolabeled proline/sulfate is insignificant compared to the concentrations of
unlabeled proline/sulfate present in the medium: one recent bottle of proline had 31
Ci/mmol and the concentration of radioactive proline in the culture medium was [3H]=
10 gCi/ml, so the molarity of radioactive proline in the medium is
l0xO-6 Ci /ml
= 3.2xl0-7 mmol / ml = 0.32nmol / ml.
31Ci /mmol
This molarity value is much lower than the 150 nmol/ml proline in DMEM/F12 medium
(this value is from the manufacturer's data sheet on the contents of DMEM/F 12). The
situation is similar for sulfate: there is 406 nmol/ml of unlabeled sulfate in DMEM/F 12
medium.
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IMPORTANT NOTE: if you use any medium other than DMEM/F 12 during the
radiolabeling period, you must look up the proline and sulfate molar concentrations for
all of the components of that medium and add them together (multiplying each
component by its volume fraction in the medium) to get the actual values for your
calculations. For example, the non-essential amino acids (NEAA) used in the Jakob
media has proline in it. You cannot use the values of 150 nmol/ml proline and 406
nmol/ml sulfate unless the only proline and sulfate containing ingredient in your media is
DMEM/F 12. Other media formulations will require different numbers. However in the
calculations below I have used those values as an example. I have also assumed that 88%
of the volume of the medium was due to the DMEM and 12% of the medium was due to
other ingredients which did not contain any proline of sulfate.
The amount of proline/sulfate incorporated into macromolecular form during the
radiolabel period is then determined as follows:
moles ofproline = V-aproine - (0.88) - (150 nmol/ml)
moles of sulfate = V -asugfate - (0.88) - (406 nmol/ml)
where V is the volume of radiolabeled media fed to the cultures, in milliliters.
Incorporation data can be normalized to the time of radiolabel and the amount of DNA in
the matrix to yield the rate of incorporation normalized to cell content (nmol/gg
DNA/hr).
For the Jakob serum-free media formulation the high-glucose DMEM (GIBCO cat. no.
10313021) contains 97.67 mg/L of magnesium sulfate (molec. wt. = 120.37 g/mol) =
8.11 x10 4 M. Approximately 95% of the differentiation medium is DMEM, so there is
7.71 x10-7 mol/L = 771 nanomoles of sulfate per ml of differentiation medium.
Similarly, the I00x NEAA (10mM solution, GIBCO cat. no. 11140 050) contains 1150
mg/L of proline (molec. wt. = 115.13 g/mol) = 0.01 M. But only 0.95% of the
differentiation medium is DMEM, so there are 0.95 x104 mol/liter = 9.5 x10-8 mol/L = 95
nanomoles of proline per liter of differentiation medium. Thus with the Jakob media
the amount of proline/sulfate incorporated into macromolecular form during the
radiolabel period is
moles ofproline = V -aprOline - (95 nmol/ml)
moles of sulfate = V -asute - (771 nmol/ml)
where V is the volume of radiolabeled media fed to the cultures, in milliliters. There is
no proline or sulfate in any other Jakob media components.
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NOTE: superscripts denote to samples of culture medium, while subscripts denote
samples of digested matrix.
Uspill
Cpm3H
Cpm35s
cpmA
cpmA3ss
cpmA3H
cpmB
cpmB3S+3H
cpmASs+
3H
cpmB 35S
cpmA 3 Ss
Cpm3S, standard
cpM3H, standard
spillover percentage (i.e. percentage of total counts from 35S that show up
in channel A)
total counts per minute, from both channel A and channel B, resulting
from 3H
total counts per minute, from both channel A and channel B, resulting
from 35S
total counts per minute in channel A, equal to cpmA3ss + cpmA3H
counts per minute from channel A that result from 35S
counts per minute from channel A that result from 3H. This is equal to the
total counts resulting from 3H in the sample (cpm3H) since the limits on
the channels should be set such that no 3H shows up in channel B.
total counts per minute in channel B. These should all be from 35S.
Counts in channel B from sample of culture medium containing both 3H
and 35S
Counts in channel A from sample of culture medium containing both 3H
and 35S
Counts in channel B from sample of culture medium containing 35S alone
Counts in channel A from sample of culture medium containing both 35S
alone
Total counts that are derived from 35S from sample of culture medium
containing both 35S and 3H.
Total counts that are derived from 3H from sample of culture medium
containing both 35S and 3H.
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Histology Protocols
Processing Samples for Histology
Fixation
Fix samples in 10% neutral buffered formalin (Fisher #SF 100-4) for a minimum of 3
days (longer for larger samples).
Decalcification
Samples containing bone require decalcification followingfixation.
Decalcification solution (15% EDTA, pH 7.4)
o Prepare 3000ml PBS (Sigma P3813)
* Add 96gm NaOH (Fisher S318-3) while stirring
* Add 600gm EDTA (Fisher S311-3)
* pH to 7.4 with HCL (-40-60mls)
* Bring volume to 4000mls with PBS
* Change decal 2X per week, keep in cold room
Dehydration and Paraffin Infiltration
" Place samples in labeled processing cassettes (Fisher Cat. # 15-197-700E)
" Process samples according to the following program:
Tissue Processor: ThermoShandon Hypercenter XP, Mode 1 Program 1
Reagent Temperature Vacuum Immersion Drain
70% Alcohol Ambient No 0:10:00 0:00:15
80% Alcohol Ambient No 1:30:00 0:00:15
95% Alcohol Ambient No 1:30:00 0:00:15
95% Alcohol Ambient No 1:30:00 0:00:15
100% Alcohol Ambient No 1:30:00 0:00:15
100% Alcohol Ambient No 1:30:00 0:00:15
100% Alcohol Ambient No 1:30:00 0:00:15
Xylene Ambient No 1:30:00 0:00:15
Xylene Ambient No 1:30:00 0:00:15
Xylene Ambient No 1:00:00 0:00:15
Paraffin 600C Yes 2:00:00 0:01:55
Paraffin 600C Yes 3:00:00 0:01:55
Paraffin Embedding
* Remove cassettes from tissue processor and place in paraffin bath on embedding
machine.
" Fill appropriate size metal embedding mold with paraffin and position sample
within mold. It is often advantageous to bisect the sample at this stage, and
embed both halves in the same mold, positioning one half in a planar orientation
and the other half in a cross-sectional orientation.
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Sectioning
" Cut 6 pm sections using with microtome (ThermoShandon Finesse)
" Float sections in 40'C water bath. Pick up sections with slides, 3-4 sections per
slide. Note, ifplanning to do immunostaining it is best to use pre-coated slides
(Fisher Superfrost Gold Plus) to improve adherence.
" Warm on slide warmer at 60'C for at least 2 hours prior to staining (or overnight
at a lower temperature.)
216
Embedding Collagen Matrices in Glycolmethacrylate (JB-4)
adaptedfrom H. Breinan
Materials
" JB-4 Solution A (monomer) Polysciences, Inc. Cat# 0226A-800
" JB-4 Solution B (accelerator) Polysciences, Inc. Cat# 0226B-30
" Benzoyl Peroxide (catalyst) Polysciences, Inc. Cat# 02618-12
" Plastic molds and labeled block holders (chocks).
Solutions
Infiltration Solution
e 0.90g benzoyl peroxide in 100ml JB-4 Solution A. Stir to mix.
Equilibration Solution
* 50:50 solution of Infiltration Solution and 100% EtOH.
Embedding Solution
0 lml JB-4 Solution B per 25 ml Infiltration Solution.
Procedures
Notes: Allprocedures using JB-4 solutions should be performed in fume hood.
Dispose of solutions as hazardous waste.
1. Dehydration
Collagen matrix samples should be dehydrated by hand. Water and alcohol solutions
can be pipetted in and out of 24-well plates as follows:
Solution
distilled H20
distilled H20
50% EtOH
70% EtOH
80% EtOH
95% EtOH
95% EtOH
100% EtOH
100% EtOH
100% EtOH
Time
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
30 min- 1 hour
Temperature
room temp
room temp
room temp
room temp
room temp
room temp
room temp
room temp
room temp
room temp
If only matrix samples are being processed (no cells or tissue), matrices can be
placed directly into 100% EtOH and incubated overnight.
2. Equilibrate scaffolds in the equilibration solution overnight at 4'C.
3. Incubate scaffolds in infiltration solution for 1-2 days at 4*C. It may be helpful to
rotate on a rocker in order to improve infiltration and remove trapped air bubbles.
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When infiltration is complete, tissue usually appears translucent and will sink to the
bottom of the container.
4. Embedding
" Label chocks with pencil.
* Prepare JB-4 embedding solution.
* Place samples in plastic molds in proper orientation.
" Quickly fill molds with embedding solution. Ensure proper orientation of
matrices is maintained.
" Solution begins to harden within approximately 30 minutes. After the JB-4
mixture becomes viscous enough that the samples do not float, place labeled
metal or plastic block holders onto each well and place the plastic mold tray in a
refrigerator (4*C) and wait overnight.
5. Sectioning
" Prepare 5 gm sections using a microtome.
Cut single sections very slowly while picking up with sharp-pointed forceps.
" Float individual sections in a water bath (room temperature) supplemented with a
few drops of ammonium hydroxide.
* Pick up sections with slides.
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Aniline Blue Staining
Materials
" Analine Blue (Fisher Cat. # A-967).
* Glacial acetic acid (Fisher Cat. A A507-500).
" Cytoseal 60 (Electron Microscopy Sciences Cat. # 18006).
Solutions
Aniline Blue, 2.5% (v/v)
* 2.5 g aniline blue
0 2 ml glacial acetic acid
0 100 ml distilled water
* Filter before use
Acetic Acid, 1 % (v/v)
* 1 mL acetic acid
* 99 mL distilled water
Procedure
1. Dip slides in aniline blue solution for 2 minutes.
2. Place in 1% acetic acid solution for 1 min.
3. Dip 5-lOX in 95% alcohol until most of background staining goes away.
Careful, excessive exposure to the alcohol can ruin the sections.
4. Dip 5-lOX in 100% alcohol.
5. Mount with Cytoseal 60 and coverslip. Try not to get air bubbles.
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Hematoxylin and Eosin (H & E) Staining
Summary
Formalin fixed, paraffin embedded sections are stained with H&E for visualization of
structure. Hematoxylin stains acidic portions deep blue (such as cell nuclei rich in DNA
and RNA). Eosin stains basic substances pink (the collagenous ECM).
Solutions
Harris Hematoxylin Solution (Sigma Cat# HHS-128).
Filter 200ml of stock solution into staining dish.
Eosin Y Solution Aqueous (Sigma Cat# HT110-2-128).
Acid Alcohol
0.5 % in 80% alcohol (99.5ml of 80% alcohol + 0.5 ml HCl)
Methods
6. Deparaffinize and Rehydrate
Xylene 2 x 5 min.
100% alcohol 2 x 3 min.
95% alcohol 2 x 2min.
80% alcohol 1 min.
Wash in tap water 5 min.
7. Hematoxylin, 3 min. Note: be sure to filter hematoxylin prior to use!
8. Wash in tap water for 5 min.
9. One quick dip in acid alcohol.
10. Wash in tap water for 5 min.
11. Eosin, 30 seconds.
12. Dehydrate
100% alcohol 2 x 3 min.
Xylene (or substitute) 2 x 3 min.
13. Coverslip with Cytoseal 60 (Electron Microscopy Sciences Cat. # 18006).
Note: This is not compatible with some xylene substitutes.
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Safranin-O Staining
Summary
Safranin-O is a cationic dye that binds to sulfated glycosaminoglycans (chondroitin 6-
sulfate or keratin sulfate) staining pink-red. Fast green acts as a light counterstain.
Hematoxylin stains cell nuclei dark purple.
References
Rosenburg, J Bone Joint Surg 1971; 53-A(1): 69-82.
Materials
Safranin-O Fisher Cat. # S-670
Fast Green
Glacial Acetic Acid (Fisher Cat. # A507-500)
Gill's Hematoxylin (Fisher Cat. # 23-245654)
Solutions
* Safranin-O (0.2% w/v).
o 0.2 g Saf-O + lml acetic acid + 100 ml dH20.
* Fast Green Stock Solution
o 0.2g Fast green + 1 ml acetic acid + 100 ml dH20
* Fast Green Working Solution
o 1:5 dilution of stock solution in dH20. Note that this may not be accurate.
Test to find an appropriate dilution.
* 0.5% Acetic Acid
o 1 ml acetic acid in 200 ml dH20.
Procedure
1. Deparaffinize and Rehydrate
Xylene 2 x 5 min.
100% EtOH 2 x 3 min.
95% EtOH 2 x 2min.
80% EtOH 1 min.
Wash in tap water 5 min.
2. Hematoxylin, 3 min. Note: be sure to filter hematoxylin!
3. Wash in tap water for 5 min.
4. Fast green - 3 quick dips.
5. 0.5% acetic acid - 3 quick dips.
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6. Safranin-O - 30 minutes
7. Dehydrate
95% EtOH
100% EtOH
Xylene (or substitute)
a few quick dips
2 x 3 min.
2 x 3 min.
8. Coverslip with Cytoseal 60 (Cat# 18006, Electron Microscopy Sciences.)
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Immunohistochemical Staining of Type II Collagen
Adaptedfrom protocols written by Tobias Gotterbarm, MD., 03/2006
Summary
Deparaffinized and rehydrated sections are incubated with protease to uncover
antigenic sites, followed by quenching of endogenous peroxidase with H202. After
blocking of nonspecific binding, primary antibody against the desired antigen (type II
collagen) is applied. A biotinylated secondary antibody binds to the primary antibody,
and is labeled with peroxidase via avidin/biotin complexation. The bound peroxidase is
then reacted with an AEC chromogen for detection.
Solutions
Tris-Buffered Saline (TBS)
0 1 package (Dako, S3001) to IL dH20
0 1 package (Dako, S1968) to 5L dH20
0 Used for diluting the antibody/horse serum/ and rinsing the
them onto the autostainer,
Stored at RT
slides before putting
Wash Buffer with Tween 20 Stored at 4 *C
(Dako Cytomation, S3006, 1000ml)
" 500ml of lOX in 4500ml dH20
" Used for washing the slides in the autostainer. If you don't use buffer with
Tween, slides won't get washed properly and will show a very high background
stain. If you don't have the wash buffer with tween already added, you can use
plain TBS and add 2.5ml Tween 20 to 5L TBS.
Protease XIV (0.1%, w/v)
* 10mg Protease (Sigma P5174)
" Add to 10 ml TBS
Peroxidase Blocking Reagent
9 Dako, S2001, ready-to-use 1lml/vial
5% Goat Serum
" 0.5ml goat serum (Sigma)
" Add to 9.5ml TBS
" Use 0.5ml aliquots stored at the lower
Stored at -200C
Stored at 4 *C
Stored at -20 0C
shelf of freezer
Primary Antibody
* Collagen II antibody
o (U. of Iowa Hybridoma Bank CIICI)
* Use a 1:20 dilution
o 375pl Primary Antibody
o 7.125ml Dako universal antibody diluent or TBS
Stored at 4 *C
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Stored at 4'CUniversal Negative Control
* Mouse IgG and IgM Cocktail
o Dako Cytomation N 1698
o Ready to use
Secondary Antibody Kit
* DakoCytomation LSAB2@ System-HRP (K0675)
o Biotinylated Link
- Yellow liquid, ready to use
o Streptavidin-HRP
- Red liquid, ready to use
Stored at 4 "C
Stored at 4*CSubstrate Chromogen
AEC Substrate Chromogen
o Dako, K3464
o Ready to use
o Red chromogen
Alternative Substrate Chromogen
* Diamenobenzadine (DAB, from Dako)
o Add 1 drop DAB to Iml buffered substrate
o Brown chromogen
Counter stain
* Mayer's Hematoxylin
o Sigma: MHS 16-500ML
o Filter before use
Stored at 4'C
Stored at RT
Procedure
1. Switch on computer.
2. On the Desktop click on "DAKO Autostainer".
3. Login: Dong; password: Dong.
4. Select "Program" on Main Menu.
5. Click on "File", in the pull down menu click on "Open" and choose "Coll2tem".
6. The template will show you two slides: #1 for the positive collagen type II staining
and #2 for the negative control stain.
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
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8. Copy and past the staining protocol by first clicking on "copy," then on the slide you
want to copy. Clicking on any slide will automatically "paste" the protocol to any
desired row.
Single steps performed by autostainer
* Rinse (TBS+Tween)
" Add 0.1% Protease - 40 min.
* Rinse (TBS+Tween)
" End. Enyme Block: H202 - Peroxidase blocking solution - 10 min.
" Rinse (TBS+Tween)
" Pretreatment Serum Block with 5% goat serum - 30 min.
" NO RINSE
* Anti-collagen II (Primary antibody or negative mouse control) - 30 min.
" Rinse (TBS+Tween)
" Secondary Reagent: Biotinylated secondary antibody - 10 min.
* Rinse ((TBS+Tween)
* Tertiary Reagent: Extravidin peroxidase - 10 min.
" Rinse (TBS+Tween)
* Switch
" Substrate: AEC 10 (or DAB) - 10 min.
9. Click on "Next". "Rinse Missing" window will appear, Click on "Yes".
It is important to make sure that there is no rinse after the Serum Block in order to
reduce unspecific background stain.
10. The Program will now show the "Program Slides" Screen. Standard setting will use
150l per treated section of each slide. The standard setup of the machine will treat
the lower 2/3 of the slide (marked yellow). If you want to change this:
* click on the slide while holding "shift", or click on the slide in the top left corner.
This will change all slides the same way.
11. Click on "Next." The Program will show you how much Washing Buffer is needed
to run the program. Check bottle in cupboard under autostainer. If necessary make
some new Wash Buffer, then click on "OK."
12. The "Load Reagents" Screen will show amount and the location in rack #1 of any
reagent used in the protocol. The Autostainer will calculate the amount of reagent
required according to the number of slides being stained. Prepare solutions and click
on "Next."
13. Load slides as shown on "Load Slides" Screen
Pretreatment of the slides
9 Xylene 2x5 min
* 100% alcohol 2x3 min
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0 95% alcohol 2x2 min
* 80% alcohol 1 min
0 TBS 2x2 min
0 Load slides on coverplate. Make sure to keep slides wet with TBS.
14. Click on "Next" After loading slides.
15. Click on Prime Pump (Buffer) and Prime Pump (Water) and check to be sure it is
really running!
16. Click on "Start Run." The program will take 3-5 hours depending on the number of
slides being stained.
17. When program is finished, remove slides and put into TBS to keep wet.
18. Counter-stain with Mayers Hematoxylin for 1.5 min.
19. Rinse in running tap water for 3 min.
20. Transfer "Slideholder" into a container with tap water.
21. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off!
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Immunohistochemical Staining of Superficial Zone Protein (SZP, a.k.a. PRG4)
Adapted from protocols written by Tobias Gotterbarm, MD., 03/2006.
Summary
Deparaffinized and rehydrated sections are incubated with protease to uncover
antigenic sites, followed by quenching of endogenous peroxidase with H202. After
blocking of nonspecific binding, primary antibody against the desired antigen (SZP) is
applied. A biotinylated secondary antibody binds to the primary antibody, and is labeled
with peroxidase via avidin/biotin complexation. The bound peroxidase is then reacted
with an AEC chromagen for detection.
Solutions
Tris-Buffered Saline (TBS) Stored at RT
0 1 package (Dako, S3001) to IL dH20
0 1 package (Dako, S1968) to 5L dH20
9 Used for diluting the antibody/horse serum/ and rinsing the slides before putting
them onto the autostainer,
Wash Buffer with Tween 20 Stored at 40C
(Dako Cytomation, S3006, 1000ml)
" 500ml of xlO in 4500ml dH20
" Used for washing the slides in the autostainer. If you don't use buffer with tween
your slides won't get washed properly and will show a very high background
stain. If you don't have the wash buffer with tween already added, you can use
plain TBS and add 2.5ml Tween 20 to 5L TBS.
Protease XIV (0.1%, w/v) Stored at -20'C
" 10mg Protease (Sigma P5174)
" Add to 10 ml TBS
Peroxidase Blocking Reagent Stored at 4*C
* Dako, S2001, ready-to-use 1lml/vial
5% Horse Serum Stored at -20'C
* 0.5ml Horse Serum (Sigma H-0146)
" Add to lOml TBS
" Use 0.5ml alliquots stored at the lower shelf of freezer
Primary Antibody (anti-SZP) Stored at 4"C
" Dr. T. Schmid, Rush University Medical Center
* Use a 1:1000 dilution
o 1 Opl Primary Antibody
o 10ml TBS
* Right drawer at 4'C. A 1.5ml tube in 50ml Falcon labeled as anti SZP AB
(1.Lmg/ml) Dr T. Schmid.
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Universal Negative Control
* Mouse IgG and IgM Cocktail
o Dako Cytomation N1698
o Ready to use
Stored at 4'C
Secondary Antibody Kit
* DakoCytomation LSAB2@ System-HRP (K0675)
o Biotinylated Link
N Yellow liquid, ready to use
o Streptavidin-HRP
= Red liquid, ready to use
Substrate Chromogen
* AEC Substrate Chromogen
o Dako, K3464
o Ready to use
Counter stain
* Mayer's Hematoxylin
o Sigma: MHS 16-500ML
o Filter before use
Stored at 4 *C
Stored at 40C
Stored at RT
Procedure
1. Switch on computer.
2. On the Desktop click on "DAKO Autostainer".
3. Login: Dong; password: Dong.
4. Select "Program" on Main Menu.
5. Click on "File", in the pull down menu click on "Open" and choose "SZP temp".
6. The template will show you two slides: #1 for the positive SZP- staining and #2 for
the negative control stain.
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
8. Copy and past the staining protocol by first clicking on "copy," then on the slide you
want to copy. Clicking on any slide will automatically "paste" the protocol to any
desired row.
Single steps performed by autostainer
" Rinse (TBS+Tween)
" Add 0.1% Protease - 45 min.
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* Rinse (TBS+Tween)
* End. Enyme Block: H202 - Peroxidase blocking solution - 10 min.
* Rinse (TBS+Tween)
* Pretreatment Serum Block with 5% horse serum - 30 min.
* NO RINSE
* Anit-SZP (Primary antibody or negative mouse control) - 30 min.
* Rinse (TBS+Tween)
* Secondary Reagent: Biotinylated link - 15 min.
* Rinse ((TBS+Tween)
" Tertiary Reagent: Streptavidin-HRP - 15 min.
* Rinse (TBS+Tween)
* Switch
* Substrate: AEC 10 - 10 min.
9. Click on "Next". "Rinse Missing" window will appear, Click on "Yes".
It is important to make sure that there is no rinse after the Serum Block in order to
reduce unspecific background stain.
10. The Program will now show the "Program Slides" Screen. Standard setting will use
150p per treated section of each slide. The standard setup of the machine will treat
the lower 2/3 of the slide (marked yellow). If you want to change this:
* click on the slide while holding "shift", or click on the slide in the top left corner.
This will change all slides the same way.
11. Click on "Next." The Program will show you how much Washing Buffer is needed
to run the program. Check bottle in cupboard under autostainer. If necessary make
some new Wash Buffer, then click on "OK."
12. The "Load Reagents" Screen will show amount and the location in rack #1 of any
reagent used in the protocol. The Autostainer will calculate the amount of reagent
required according to the number of slides being stained. Prepare solutions and click
on "Next."
13. Load slides as shown on "Load Slides" Screen
Pretreatment of the slides
* Xylene 2x5 min
* 100% EtOH 2x3 min
* 95% EtOH 2x2 min
* 80% EtOH 1 min
* TBS 2x2 min
* Load slides on coverplate. Make sure to keep slides wet with TBS.
14. Click on "Next" After loading slides.
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15. Click on Prime Pump (Buffer) and Prime Pump (Water) and check if it is really
running!
16. Click on "Start Run." The program will take 3-5 hours depending on the number of
slides being stained.
17. When program is finished, remove slides and put into TBS to keep wet.
18. Counter-stain with Mayers Hematoxylin for 1.5 min.
19. Rinse in running tap water for 3 min.
20. Transfer "Slideholder" into a container with tap water.
21. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off!
230
Using ImageJ to Determine Areas of Selected Regions in an Image
Open the desired image in ImageJ.
Measure the area of the original defect
" Select the PENCIL TOOL
o You can change the width of the line drawn with the pencil tool by double
clicking the PENCIL TOOL button. To change the color, double click the
COLOR PICKER (dropper) button.
" Draw the outline of the original defect
" Select the WAND (TRACING) TOOL
" Click on the line you just drew. The region of the original defect will be selected.
" Select Analyze, Measure
o The results box will list the number of pixels in the area selected
o Record this number
o You may wish to save the image at this point
Measure the area(s) of repair tissue coverage
* Change to a new color by double-clicking the COLOR PICKER button.
* Select PENCIL TOOL
* Draw the outline of the repair tissue. The line should be in the newly chosen
color.
" Select WAND (TRACING) TOOL
" Click on the line you just drew. The region of the new repair tissue will be
selected.
* Select Analyze, Measure
o The results box will list the number of pixels in the area selected
o Record this number
o You may wish to save the image at this point
* If the repair tissue comprises multiple, separate regions, repeat these steps to get a
measurement for each region.
Calculate % coverage
" Add the area measurements for all regions of reparative tissue
" Divide this number by the area measurement for original defect
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Quantitative Analysis of Safranin-O Staining
Summary
Analysis of the "red content" of Safranin-O stained samples as a measure of GAG
content, adapted from a method developed by Martin, et al. Digital images of Safranin-O
stained sections were acquired and normalized by subtracting a background image,
acquired with the same light intensity inverting the resulting negative image. The image
is split into red, green, and blue (RGB) image planes in a scale of 255 values (black=0).
RGB values for each pixel were imported into MatLab (Mathworks, Natick MA).
The tissue sections are defined as areas significantly darker than background
(R+G+B < 675). The red content of each tissue section (Ravg), a parameter defined by
Martin as a measure of the intensity of red color in the section, is calculated as the
average of the red content of each pixel (Rc) as follows. For each pixel, the red fraction
(RF) is defined as the ratio of the R component to the sum of the R, G, and B
components: RF = R/(R+G+B). In order to reduce Rc values in non-red bright regions in
which each component (R, G, B) is high, RF is normalized according to the equation RF,N
= 1.5*RF -0.5 for all pixels in which R is the dominant fraction (i.e. RF ;> 1/3), and set to
0 otherwise (i.e. RF < 1/3). Rc is then defined as Rc = R*RF,N such that it is proportional
to both the original R component of the image and the normalized fraction of red color.
In the work by Martin, Ravg was shown to be linearly correlated to the wet weight
fraction of GAG determined biochemically in engineered and natural samples of bovine
cartilage (r2=0.952).
References
Martin, et al., Ann Biomed Eng 1999; 27: 656-662
Procedure
1. Stain slides with Safranin-O. All slides to be compared should be stained in the same
batch.
2. Image acquisition.
" Photograph samples using 1.25X objective.
* Set microscope and software so that the settings do not change from one slide to
the next (i.e., do not use "find exposure" settings, etc...).
" Acquire a background image at the same settings by snapping a photograph
without any slides.
* It is preferable to save images in TIFF format to avoid loss of color data due to
image compression.
3. Open sample image in Image J (free image analysis software from NIH).
4. Open background image.
5. Subtract the background image from the sample image to remove artifacts.
* Select Image Calculator from the Process menu.
" Select the 2 images, and set the operation to "Difference".
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. Select Invert from the Edit menu.
6. Crop the image
* Draw a rectangle around the sample.
* Select Crop from the Image menu.
7. Split in to Red, Green, and Blue (RGB) color planes.
0 Select Color - RGB Split from the Image menu.
8. Save RGB image data as text files.
" Select Save As - Text Image from the File menu.
" Name the files so that you will recognize which is the Red, Blue, and Green data
(for example, "samplenumber-red txt", and "samplenumber-blue. txt").
" Be sure to save all 3 images.
9. Run the Saf-O analysis program in MatLab.
" Open MatLab
" Type "run safO". You may need to be sure you are in the directory to which the
RGB text files were saved.
* Enter the R,G,B filenames when prompted.
* The program will output Ravg ("avgredconc") for the sample, as well as a
grayscale image of the Rc values (Black, Rc = 0; White = highest Rc). This
image can be saved, imported into Image J, and inverted to compare with the
original color image of the sample.
Following is the MatLab code (safO.m), originally written by Lee Squitieri (B.S. 2005),
and modified by Kristy Shine.
% image processing saf-o:
% Lee's Program modified by K. Shine 01/06 to have user input
% user inputs red, green, and blue text file names (text files only)
redfile = input('Enter the red file name: ', 's');
greenfile = input('Enter the green file name: ', 's');
bluefile = input('Enter the blue file name: ', 's');
filer = strcat(redfile,'.txt');
fileg = strcat(greenfile,'.txt');
fileb = strcat(bluefile,'.txt');
r = load(filer);
g = load(fileg);
b = load(fileb);
[WIDTH LENGTH] = size(r);
sum=r+g+b; % adds red, green, and blue components
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redfrac=r./sum; % calc. the red fraction
%If you want the user to enter the dimensions manually you would do
%WIDTH = input('Enter length in pixels (larger dimension): ');
%LENGTH:= input('Enter width in pixels (smaller dimension): ');
i=1; % set up loop to calc "red content" for each pixel of image
safneg = 0;
while(i<=WIDTH)
j=l;
while(j<=LENGTH)
% only include non-white pixels in which red is dominant
if ((redfrac(ij) >= .3333) & (sum(ij) < 675))
rednorm(i,j)=1.5.*redfrac(i,j)-0.5; % normalized red fraction
redconc(i,j)=rednorm(i,j).*r(ij); % calc. "red content" of each pixel
% set "red content" of pixel to zero if red not dominant or if white
else
redconc(ij)=0;
end
if ((redfrac(ij) <= .3333) & (sum(ij) < 675))
safneg = safneg+l;
else
safneg = safneg;
end
j=j+l;
end
i=i+ 1;
end % close loop
i=1; % set up loop to calc. total "red content" of image (i.e. add all pixel values)
totalredconc=0;
while (i<=WIDTH)
j=1;
while (j<=LENGTH)
% tally up "red content" of each pixel
totalredconc=redconc(i,j)+totalredconc;
j=j+1;
end
i=i+ 1;
end % close loop
totalredconc /0 output total "red content" of entire image
zerofind=find(redconc==O); % finds # of pixels in which "red content" equals zero
[rows, columns]=size(zerofind);
numzeros=rows* columns;
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numzeros % output # of pixels in which "red content" equals zero
totalnum=WIDTH*LENGTH-numzeros; % calc. total # of red dominant pixels
totalnum % output # of red dominant pixels
avgredconc=totalredconc/totalnum; % calc. avg. "red content" per red dominant pixel
avgredconc % output avg. "red content" per red dominant pixel
safneg
image(redconc)
colormap(gray)
axis equal
%save redconc -ASCII -DOUBLE -TABS;
%dlmwrite(redconcfile,redconc,'\t')
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Biochemical Assays
Digesting Scaffolds and Pellets for Biochemical Analyses (Proteinase K Digestion)
Materials
" UltraPure Tris (Invitrogen, Cat #15504-020, Mw=121.14g/mol).
* CaCl2 Dihydrate (Sigma (Fluka), Cat #21097, Mw=147.02g/mol).
" Proteinase K (Sigma, Cat# P-6556, keep at -20C).
Solutions
Tris-HCl buffer ( L), store at room temperature
" Dissolve the following in 900 ml distilled water:
o 6.ig UltraPure Tris (makes 0.05M)
o 0. 147g CaCl 2 Dihydrate (makes 1mM)
" Adjust pH to 8.0 with IN NaOH.
" Bring to 1 L with distilled water
Procedure
1. Lyophilize samples and record dry masses.
2. Add Iml per sample of the following solutions:
o For 8mm scaffolds, use 500pg/ml proteinase K solution.
- 100ml Tris-HCl buffer
- 50mg proteinase K
- Use Iml solution per sample (important to be exact for future calculations).
o For cell pellets, use 1 OOgg/ml proteinase K solution.
- 100ml Tris-HCl buffer
- 10mg proteinase K
- Use I ml solution per sample (important to be exact for future calculations).
3. Vortex samples.
4. Place in 600C water bath.
5. Vortex again before leaving overnight (12-24 hours).
6. Store digested samples at -20'C until used for biochemical analyses.
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Digesting Scaffolds and Pellets for Biochemical Analyses (Papain Digestion)
Materials
" Sodium Phosphate, monobasic (Fisher # S369).
" Sodium Phosphate, dibasic (Fisher # S373).
" Disodium EDTA (Fisher # S311).
" L-Cystein HCL (Sigma #C1276)
" Papain (Sigma #P3125).
Solutions
0.5 M Monobasic stock
NaH2PO4*H 20 6.9 g
dH20 100 ml
0.5 M Dibasic stock
Na2HPO4*7H 20 13.4 g
dH 20 100 ml
Papain buffer
Dibasic stock 2.46 ml
Monobasic stock 17.54 ml
L-Cysteine HCL 87.82 mg
Disodium EDTA 186.12 mg
Papain 0.5 ml (stock is 25 mg/ml)
dH 20 80 ml
Procedure
1. Place lyophylized matrices in microcentrifuge tubes and add 1 ml papain buffer per
tube (important to be exact for future calculations).
2. Vortex samples and place in 65'C waterbath overnight.
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PicoGreen dsDNA Quantitation Assay
Adapted from protocol written by Ramille Capito
Materials
Quant-iTPicoGreen dsDNA Assay Kit (Molecular Probes, Cat# P7589) contains:
" PicoGreen dye reagent (lmL solution in DMSO, light sensitive, keep covered).
" 20X TE (25mL of 200mM Tris-HCl, 20mM EDTA, pH 7.5)
" Lambda DNA standard (lmL of 100 mg/mL in TE)
TE buffer for diluting samples:
0 1ml lM Tris (pH=8) (UltraPure Tris, Invitrogen, Cat# 15504-020, FW=121.1; or
use IM Tris (pH=8.0), Ambion, Cat# 9855G)
0 0.2 ml 0.5M EDTA (pH=8) (Disodium Ethenediamine Tetraacetate, Fisher,
Cat#S31 1, FW=372.24; or use 0.5M EDTA (pH=8.0), Invitrogen, Cat# 15575-
038)
* 98.8 ml dH20
96-wellplate-Black Isoplate (Clear bottom plates, Wallac, Cat# 1450-571)
Procedure:
1. Assay Buffer Preparation: Add 25ml (20X TE) + 500 ml sterile, distilled, DNase-free
water.
2. DNA std working solution (2mg/ml): Add 294ml of TE buffer + 6ml DNA stock
(100 mg/mL).
3. Dilute all digested samples 1:10 with TE buffer (not from kit): 180ul TE + 20ul
digest (can be diluted in microcentrifuge tubes or 96-well plate).
4. Prepare the DNA standards as follows in the first 8 wells of Picogreen 96-well plate:
Standard No. Standards TE buffer ( i1) DNA std-2mg/ml
Blank 0 100 0
1 10 99 1
2 50 95 5
3 100 90 10
4 250 75 25
5 500 50 50
6 750 25 75
7 1000 0 100
5. Add 20g1 of diluted digested sample to each well-vortex samples before adding.
6. Add 80g1 TE buffer (from kit) to each well (for total of I00 l solution per well).
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7. Dilute PicoGreen dye stock with TE buffer (from kit), 200X, Prepare just before use
-- 100 gi of working dye solution needs to be added to well used
--Make more working dye than needed (i.e. add solution for 5 additional wells)
For example, if there are 96 wells to fill, make enough dye for 110 wells:
110 x 100ul = 11000ul (or 11ml); 11000/200 = 551d of PicoGreen stock + 11ml TE
8. Dispense 100 gi PicoGreen working dye solution to each well being used.
9. Take fluorescence reading on microplate reader (WALLAC VICTOR2 1420
Multilabel Counter, Perkin Elmer Life Sciences): Protocol assigned in computer
program under DNA Assay--"Fluorescein (485nm/535nm, 1.0s)" (includes a 5 min
incubation period & shake)
* If samples end up having
be diluted more and re-run
a reading greater than the highest standard, samples need to
PicoGreen Microplate Template
Plate # Date:
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1 2 3 4 5 6 7 8 9 10 11 12
A Blank Std I Std 2 Std 3 Std 4 Std 5 Std 6 Std 7
B
C
D
E
F
G
H
Quantitative Analysis of Sulfated Glycosaminoglycan with DMMB
Adapted from protocol written by Ramille Capito
Summary
Spectrophotometric procedure for quantification of sulfated glycosaminoglycans in
solution, based on the metachromatic shift in the absorbance maximum that occurs upon
complexation of dimethylmethylene blue (DMMB) dye with sulfated GAGs.
References
Famdale, et al., Conn Tiss Res 1982; 9: 247-248.
Solutions Needed:
Color Reagent
For 500ml of DMMB dye solution, mix the following:
* 425 ml dH20
* 1.52 g glycine (Sigma, Cat# G-8898)
* 1.19 g NaCl (Fisher, Cat# S642)
a. Adjust pH to 3.0 with concentrated HCl and NaOH
b. Add more dH20 to bring volume up to 500ml
* Add 8mg of DMMB dye
* Solution good for 3 months and should be kept in a light-protected bottle (stir 30
min prior to use)
TE buffer for diluting samples:
I lml IM Tris (pH=8) (UltraPure Tris, Invitrogen, Cat# 15504-020, FW=121.1
* or use IM Tris (pH=8.0), Ambion, Cat# 9855G)
* 0.2 ml 0.5M EDTA (pH=8) (Disodium Ethylenediamine Tetraacetate, Fisher,
Cat#S311, FW=372.24)
* or use 0.5M EDTA (pH=8.0) (Invitrogen, Cat# 15575-038)
* 98.8 ml dH2 0
Procedure:
1. Stir DMMB dye working solution at least 30min before use.
2. Prepare the Chondroitin Sulfate (CS) stock solution at 2 mg/mL (keep in -20C
freezer).
3. CS working solution (200gg/ml): Add 100 gl of CS stock + 900 gl dH 20
4. Prepare the CS standards as follows: (Start w/ 7 labeled tubes filled w/ 200ul TE
buffer, then serially dilute)
200g1 200g1 200g1 200g1 200g1 200g1 200g1
Tube# 8 7 6 5 4 3 2 1
TE buffer (gl) - 200 200 200 200 200 200 200
CS (gg/ml) 200 100 50 25 12.5 6.25 3.125 1.563
240
5. Dilute all digested samples 1:10 with TE buffer: 180pl TE + 20pl digest
(can be diluted in microcentrifuge tubes or 96-well plate)
6. Add 20g1 of each standard and sample to the 96-well plate (Clear plates, Packard
Bioscience Spectraplate-96, Cat# P12-106-043)-good to do this in duplicate, at least
for the standard (Use 2 0pl aliquot of TE buffer as blank)
7. Dispense 200 gL of DMMB dye solution to each well used
8. Take reading at 530 nm on microplate reader (WALLAC VICTOR2 1420 Multilabel
Counter, Perkin Elmer Life Sciences): Protocol assigned on computer program for
the microplate reader is under GAG Assay-"GAG-DMMB Assay protocol (530nm-
is)"
* If sample reading is outside the standard curve range (or at the extremes of the
standard curve), it is recommended that another dilution and reading of the sample be
performed-the ideal is to have the reading land on the mid-range of the standard
curve (usually a 2 nd order polynomial is the best fit curve for this standard)
DMMB-GAG Microplate Template
Plate # Date:
1 2 3 4 5 6 7 8 9 10 11 12
A Blank Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8
B
C
D
E
F
G
H
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